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The important thing is not to stop questioning.
Albert Einstein (1879 - 1955)











Scope of the thesis
Human papillomavirus (HPV) upregulates the cellular deubi-
quitinase UCHL1 to suppress the keratinocyte’s innate immune 
response
CD40-mediated amplification of local immunity by epithelial cells 
in impaired by HPV 
The interferon-related developmental regulator 1 (IFRD1) is used 
by Human papillomavirus (HPV) to suppress NFκB activation
Human papillomavirus (HPV) downregulates the expression of 
IFITM1 to resist the anti-proliferative effects of IFNγ and TNFα
General discussion
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Human papillomaviruses (HPV) are small, non-enveloped viruses belonging 
to the Papillomaviridae family. The icosahedral virion encapsulates a double-
stranded episomal DNA genome of 7 – 8 kb, comprising an early open reading 
frame (ORF), containing 6 non-structural early genes (E6, E7, E1, E2, E4 and 
E5), and a late ORF, containing 2 late genes (L2 and L1) that encode the 
capsid proteins. A non-coding long control region (LCR), between the L1 and 
E6 genes, contains regulatory elements that control replication and viral gene 
expression [1]. Over 180 HPV types have currently been identified. They are 
divided into genera α, β, γ, μ and ν, based on the nucleotide sequence of the 
L1 gene [2]. 
1.2 Clinical implications
HPV is widespread within all human populations and transmitted via the 
skin, including the genitalia. Diseases associated with HPV infection range 
from warts to cancers [3]. HPV types of the α genus (~40) infect cutaneous 
and mucosal epithelia. Based on their oncogenic potential, mucosal HPVs are 
classified as low-risk, associated with benign warts or epithelial lesions, or 
high-risk, that can cause oropharyngeal and anogenital malignancies, including 
cancers of the cervix, vulva, vagina, penis and anus. HPV types of the other 
genera infect cutaneous epithelium and are associated with non-melanoma 
skin cancer (β genus) or cutaneous papillomas and warts. Most HPV infections 
resolve spontaneously within one (70%) to two (90%) years [4], and in only 
<1% of cases malignancies develop. Still, HPV causes ~530,000 new cancer 
cases and ~275,000 deaths each year [5]. High-risk HPV (hrHPV) types are 
responsible for ~5% of all human cancers and 33% of all tumors induced by 
viruses. They are detected in 99.7% of cervical cancer cases, the second most 
common cancer in women, accounting for 20% of all cancer-associated deaths 
in women worldwide per year [6, 7]. HPV types 16, 18, 31, 33, 35, 39, 45, 
51, 52, 56, 59, 69, 73 and 82 have been detected in cervical carcinomas, but 
HPV16 and 18 are by far the most prevalent types responsible for ~50% and 










































1.3 The viral life cycle 
HPVs exclusively infect keratinocytes (KCs) of the basal layer of the 
epidermis and mucosal epithelia, which they reach via micro-wounds and 
abrasions. Binding of the L1 protein of HPV to heparan sulfate proteoglycans 
at the surface of KCs induces endocytosis of the virion. Subsequently, the 
capsid disassembles following acidification of the endosome and then the viral 
episome, still associated with L2, travels via the Golgi apparatus and ER to the 
nucleus [10] where low levels of viral early proteins are produced that reside 
mainly in the nucleus [11]. E1 and E2 initiate episome replication and, together 
with the host DNA replication machinery, maintain a low episome copy-number 
of 50 – 100 per cell [12]. Furthermore, E6 and E7 are produced to prevent 
cell growth arrest and apoptosis and delay differentiation, by inactivating 
p53 and the retinoblastoma protein (pRB). This induces a proliferative, non-
differentiating state of the infected KC, resulting in lateral cell division. As the 
infected KC differentiates and migrates through the suprabasal layers of the 
epithelium, the expression of all viral genes is induced to enhance viral episome 
replication, which reaches high copy-numbers of hundreds to thousands per 
cell. In the higher layers of the epithelium the production of the late proteins L1 
and L2, together forming the viral capsid, is induced and virion assembly takes 
place. With the rupture and shedding of the matured KC the viral particles are 
released [13]. 
1.4 Malignant transformation
Sometimes, for yet unknown reasons, hrHPV genomes can spontaneously 
integrate into the host genome. When this happens, the E6 and E7 oncogenes 
are fully integrated whereas the E2 gene is not. Abrogation of E2 expression 
releases the tight regulation of E6 and E7 expression. The newly transformed 
cells stably express E6, which binds to p53 and recruits the E3 ligase E6AP 
to target p53 for proteasomal degradation, as well as E7, which recruits the 
E3 ligase cullin 2 to target pRb for proteasomal degradation. The loss of 
these tumor suppressors results in uncontrollable cell growth, host genome 
mutations and inhibition of apoptosis, ultimately leading to cancer formation 










































12. HPV immune evasion strategies
High-risk HPV infections can last up to two years despite viral activity in 
keratinocytes, indicating that hrHPV has developed mechanisms to effectively 
evade or suppress the hosts innate and/or adaptive immune response. Indeed, 
several studies on the spontaneous immune response to HPV have shown 
that HPV-specific cellular immunity develops quite late during persistent HPV 
infections and often is of dubious quality in people with progressive infections 
[15]. 
Viral persistence may be linked to the life cycle of HPV since HPV does 
not cause viremia, cell death, or cell lysis, and the life-cycle takes place within 
the boundary of the lamina basalis, away from dermal immune cells. Thus, 
spontaneous contact between the immune system and the virus is minimal 
and inflammatory responses are not readily elicited. Langerhans cells residing 
within the epidermis can sense viral presence, but HPV counteracts their 
recruitment by interfering with the production of immune attractants. After 
the infection is established, the virus produces only low quantities of viral 
proteins that mainly reside in the nucleus of the cells. Besides these passive 
mechanisms to evade the immune system, hrHPV also actively interferes with 
innate and adaptive immune mechanisms. 
2.1 Viral recognition by keratinocytes
Keratinocytes are well equipped to sense pathogens. Basal KCs express 
pattern-recognition receptors (PRRs), such as Toll-like receptors (TLRs), NOD-
like receptors (NLRs), and RNA helicases, to recognize pathogen-associated 
molecular patterns (PAMPs) on viruses and microbes. PRR ligation leads to 
activation of inflammatory and proliferative signaling cascades and subsequent 
production of pro-inflammatory cytokines that can induce innate and adaptive 
immune responses. KCs express TLR 1, 2, 3, 5 and 6 on the cell-surface 
and the nucleic acid-sensing TLR3 in endosomes. TLR7 and TLR8 are not 
expressed, but TLR7 expression can be induced upon TLR3 ligation [16]. The 
expression of TLR4 and TLR9 in basal KCs is still under debate, but TLR9 
expression can be induced after terminal differentiation [17]. Cytosolically, 
KCs express the RNA helicases retinoic acid-inducible gene I (RIG-I; DDX58) 
and melanoma differentiation-associated protein 5 (MDA5; IFIH1) [18], and 










































melanoma 2 (AIM2) [19]. 
Although the vesicle-mediated entry mechanism used by HPV may hide 
the virus from recognition by cytoplasmic DNA sensors, KCs can produce 
type I interferon (IFN) and pro-inflammatory cytokines upon viral entry and, 
therefore, do recognize HPV [17]. Indeed, the episome contains CpG motifs 
that can be recognized by TLR9 [20] and the viral capsid itself is a potential 
PAMP. Whether HPV interferes with the expression of TLRs, RIG-I or MDA5 in 
HPV episome-containing KCs is still under debate [17, 18, 21], and while TLR9 
expression and function was shown to be abolished in KCs that overexpressed 
HPV16 E6 and E7 [20], by an E7-induced recruitment of a NFκB1, ERα and 
HDAC1 inhibitory complex to the TLR9 promotor [22], others concluded that E6 
nor E7 influenced TLR9 expression or function [23]. The DNA sensor AIM2 is 
strongly expressed in HPV16-infected skin lesions, whereas IFI16 expression 
is not elevated [19]. Hence, it is not yet clear if HPV affects the expression of 
virus sensory molecules on KCs. 
2.2 HPV influences innate immune signaling
Keratinocytes produce type I IFNs and pro-inflammatory cytokines upon 
PRR ligation through signaling via interferon regulatory factor (IRF) and nuclear 
factor of kappa-light-chain-enhancer of activated B cells (NFκB) activating 
pathways. Type I IFNs (mainly IFNα (13 subtypes) and IFNβ, but also IFNε, 
IFNτ, IFNκ, IFNω, IFNδ and IFNζ) stimulate cells to express genes inducing 
an anti-viral state. They can also stimulate dendritic cells and as such act as 
a bridge between innate and adaptive immunity [24-26]. Pro-inflammatory 
cytokines are chemoattractants for immune cells and regulate cell migration, 
activation, polarization and proliferation. Several genome-wide transcription 
studies reported that hrHPV types 16, 18 and 31 influence – mainly reduce 
– basal, TLR3-induced cytokine expression, and type I IFN-induced interferon-
stimulated gene (ISG) expression [18, 27-29], indicating that hrHPV affects 
PRR- and type I IFN-induced signaling pathways. 
2.2.1 The effect of HPV on the IrF signaling pathway
All TLRs, except TLR3, convey their signals via the adapter molecule 
MyD88. This induces the IRAK complex (consisting of IRAK1, 2 and 4) to recruit 










































1TRIF, cytosolic RNA sensors via MAVS, and cytosolic DNA sensors signal via 
the adaptor molecule STING to activate TRAF3, which then induces the TBK1-
IKKε complex to phosphorylate IRF3. Phosphorylated IRF3 and IRF7 homo-
dimerize and translocate to the nucleus where production of type I IFNs is 
initiated. Furthermore, PRR ligation can result in IRF1 activation (Figure 1).
HrHPV influences type I IFN production by interfering at several points in 
the signaling cascade. Its E2 proteins reduce the expression of STING and 
IFNκ [30], the latter of which its expression is also reduced by E6 [21, 31]. 
HPV16, but not HPV18, E6 protein binds to IRF3 and, thereby, may prevent 
its transcriptional activity [32]. E7 blocks IFNβ transcription by binding to IRF1 
and recruiting histone deacetylases (HDACs) to the IFNβ promotor site [33, 
34]. In contrast, E5 enhances IFNβ and IRF1 expression [35].
Figure 1: The effects of hrHPV on IrF signaling
Schematic representation of the effects of hrHPV on IRF signaling. All TLRs, except TLR3, 
activate IRF7 via signaling through MyD88, the IRAK complex, TRAF3 and IKKα. TLR3 and 4 
signal via TRIF, cytosolic RNA sensors through MAVS and cytosolic DNA sensors via STING 
activate IRF3 through TRAF3, TBK1 and IKKε. Activated IRFs dimerize, translocate to the nucleus 



















































































2.2.2 The effects of HPV on IFNAr signaling
The PRR-induced type I IFNs IFNα and IFNβ are secreted and can induce 
IFN-stimulated gene (ISG) expression in the infected cell itself but also in their 
uninfected neighbors. IFNα and IFNβ bind to the heterodimeric transmem brane 
IFNα/β receptor (IFNAR), composed of the IFNAR1 and IFNAR2 subunits. 
The IFNAR activates the receptor-associated protein tyros ine kinases Janus 
kinase 1 (JAK1) and tyrosine kinase 2 (TYK2), which recruit and phosphorylate 
STAT1 and STAT2, causing them to hetero-dimerize, bind IRF9, thereby 
forming the IFN-stimulated gene factor 3 (ISGF3) complex, and translocate to 
the nucleus. ISGF3 binds to IFN-stimulated response elements (ISREs) on the 
DNA and activates ISG transcription. IFNAR ligation can also lead to STAT1 
homo-dimerization. STAT1 homo-dimers translocate to the nucleus and bind to 
γ-activated sequences (GAS) on the DNA, thereby activating ISG transcription 
more associated with IFNγ signaling (Figure 2) [25, 36]. 
HrHPV also interferes with IFNAR signaling. HPV18 E6 can bind to TYK2 
in order to hamper phosphorylation of STAT1 and STAT2 [37]. E6, and to a 
lesser extend E7, of the hrHPV types 16 and 31 were shown to impair STAT1 
transcription and translation, and binding of STAT1 to the ISRE [27, 29, 38]. 
However, although hrHPV represses STAT1 protein levels, the IFNβ-induced 
STAT1 signal cascade is not affected by hrHPV, as phosphorylation of STAT1 
still occurs [38]. Expression of STAT2 and IRF9 are not affected, but E7 can 
interact with cytosolic IRF9, preventing IRF9 to translocate to the nucleus with 
as a consequence impairment of ISGF3 complex formation [39, 40]. 
2.2.3 The effect of HPV on the NFκB signaling pathway
PRRs also induce cytokine production through signaling via TRIF, MAVS, 
STING and the IRAK complex, which leads to the K63-linked poly-ubiquitination 
of TRAF6. The TAB1-TAB2-TAK1 complex and the IKK complex (consisting of 
NEMO, IKKα and IKKβ) bind to the poly-ubiquitin chain on TRAF6, resulting 
in the phosphorylation of IKKβ by TAK1. Activated IKKβ then phosphorylates 
IκBα, leading to the SCF-βTrCP-mediated K48-linked poly-ubiquitination 
of IκBα and its subsequent degradation. This releases the NFκB1 complex 
(consisting of RelA and p50) and allows it to translocate to the nucleus where it 


























































































Figure 2: The effects of hrHPV on IFNAR and IFNγR signaling
Schematic representation of the effects of hrHPV on IFNAR and IFNγR signaling. Type I IFN 
binding to the IFNAR leads to signaling via JAK1 and TYK2 to activate STAT1 and STAT2. STAT1 
and STAT2 heterodimerize and recruit IRF9, forming the ISGF3 complex, which translocates to the 
nucleus, binds to ISREs and initiates ISG transcription. Activated STAT1 can also homodimerize, 
translocate to the nucleus, bind to GAS and initiate ISG transcription. Type II IFN binding to the 
IFNγR results in the activation of JAK1 and JAK2 and recruitment and phosphorylation of STAT1, 
which homo-dimerizes, translocates to the nucleus, binds to GAS on the DNA and initiates ISG 
transcription. HPV proteins (red) interfere with both IFNAR and IFNγR signaling by decreasing 










































By the use of several different model systems hrHPV or its individual 
proteins have been shown to affect the PRR-induced signaling cascade that 
leads to NFκB nuclear translocation and to impair the function of NFκB within 
the nucleus. HrHPV upregulates the NFκB family members RelA, c-Rel, and 
the precursor proteins p105 and p100, which are processed into p50 and p52, 
respectively, and sequesters these proteins in the cytoplasm [29, 42-45]. The 
last NFκB family member, RelB, is not reported to be regulated by HPV. 
Within the nucleus, E6 reduces NFκB RelA-dependent transcriptional 
activity [46], by binding to the C/H1, C/H3 and C terminal domains of CBP/
p300 [47, 48], thereby competing with RelA and SRC1, which bind the C/H1 
and C terminal domain of CBP/p300, respectively [49]. P/CAF can still bind to 
the C/H3 domain of CBP/p300 in presence of E6, but P/CAF cannot acetylate 
NFκB since E7 binds to, and thereby blocks, the HAT domain of P/CAF [49]. 
E7 blocks NFκB DNA binding activity [34] and competes with E2 for binding 
the C/H1 domain of p300/CBP, thereby hampering E2 transactivation [50]. 
In contrast, E2 binds to p300/CBP [51, 52] and increases NFκB signaling by 
enhancing RelA expression and transcriptional activation upon TNFα treatment 
[44]. 
2.2.4 The effect on the inflammasome pathway
It is not clear whether the inflammasome pathway is important in the 
protection against HPV. However, recently it was reported that the production of 
IL1β, a cytokine that is secreted upon cleavage of pro-IL1β by inflammasome-
activated caspase1, is impaired. HPV E6 binds to E6-AP and p53 and this 
complex induces the inflammasome-independent proteasome-mediated 
degradation of pro-IL1β and as such hampers IL1β formation [53], indicating 
that hrHPV may suppress immunity by interference with post-translational 
processes. 
2.3 HPV suppresses the action of KCs to secondary immune signals
Cells of the adaptive immune system, in particular T cells, are activated by 
antigen-presenting cells (APCs) in the lymph nodes and migrate to infected 
sites. They produce cytokines and express ligands that can activate signaling 
cascades in the KC involved in survival and pro-inflammatory cytokine 










































1adaptive immunity. Despite the infiltration of adaptive immune effector cells 
the persistence of hrHPV-infected sites suggests that hrHPV has evolved 
mechanisms to resist this attack. Especially CD4+ T helper 1 (Th1) cells are 
important in controlling hrHPV infections. However, even vaccines that boost 
viral Th1 immunity during chronic infection are only partially successful [54]. 
Th1 cells produce IFNγ and TNFα, and express CD40L, which induce cytokine 
production and proliferative changes in KCs. 
2.3.1 The effect of HPV on the TNFα-activated NFκB signaling pathway
TNFα is the ligand for both the TNFα receptor 1 (TNFR1) and TNFR2. 
TNFR1 activates canonical NFκB1 by recruiting and activating TRADD, leading 
to the formation of a complex consisting of RIP1,    
TRAF2 or 5, and cIAP1 or 2. cIAP1/2 is ubiquitinated with a K63-linked 
poly-ubiquitin chain to which the LUBAC complex (consisting of Sharpin, HOIP 
and HOIL1) binds. RIP1 is ubiquitinated with both K63-linked and linear poly-
ubiquitin chains. The TAB1-TAB2-TAK1 complex binds to the K63-linked poly-
ubiquitin chain and phosphorylates the IKK complex that binds to the linear 
poly-ubiquitin chain of RIP1, leading to NFκB1 release through IKKβ-induced 
SCF-βTrCP-mediated degradation of IκBα. TNFR2 activates the non-canonical 
NFκB2 pathway by recruiting TRAF2/5, cIAP1/2 and TRAF3, resulting in TRAF3 
degradation. This abrogates TRAF3-induced NIK degradation, causing NIK to 
accumulate and activate IKKα. IKKα phosphorylates the p100 NFκB precursor 
protein of the NFκB2 complex, which further consists of RelB. This induces 
SCF-βTrCP to ubiquitinate p100 with a K48-linked poly-ubiquitin chain, leading 
to the proteosomal processing of p100 into p52, and the subsequent nuclear 
translocation of the p52-RelB dimer (Figure 3). 
HPV interferes with these cascades in a similar way as it attenuates PRR-
induced NFκB. Additionally, E6 binds to the C terminus of TNFR1 [55], and the 
N terminus of the death effector domains (DEDs) of FADD, which accelerates 
the degradation of FADD [56], thereby hampering the induction of apoptosis. 
E6 does not bind to the TRADD adaptor molecule [56]. Furthermore, E7 binds 
to the IKK complex and attenuates TNFα-induced kinase activity of IKKα and 
IKKβ, which hampers IκBα phosphorylation and degradation, and subsequent 
NFκB nuclear translocation [46]. In contrast to E6 and E7, E2 stimulates TNFα-










































Figure 3: The effects of hrHPV on NFκB signaling
Schematic representation of the effects of hrHPV on NFκB signaling. The canonical NFκB1 
pathway is activated by PRRs and CD40 through TRAF6 and TNFR1 through RIP1. Poly-
ubiquitination of TRAF6 and RIP1 recruits the TAB1-TAB2-TAK1 and IKK complexes resulting in 
the phosphorylation of IKKβ by TAK1. IKKβ phosphorylates IκBα, which is then ubiquitinated by 
SCF-βTrCP and subsequently degraded, and thereby releases the NFκB1 complex to translocate 
to the nucleus. CD40 and TNFR2 initiate non-canonical NFκB2 signaling by recruitment of 
TRAF2/5, cIAP1/2 and TRAF3 to the respective receptor, leading to TRAF3 degradation. This 
causes NIK to accumulate and activate IKKα to phosphorylate p100. This induces SCF-βTrCP to 
ubiquitinate p100, leading to the proteosomal processing of p100 into p52, and the subsequent 
nuclear translocation of NFκB2. In the nucleus NFκB binds to the DNA and is aided by coactivators 
to initiate gene transcription. HPV utilizes its encoded E proteins (red) to interfere with NFκB1 
signaling at multiple positions in the pathway. Green circles indicate K63-linked poly-ubiquitin 













































































































1with TRAF5 and TRAF6, but not TRAF2, thereby stimulating K63-linked 
ubiquitination of TRAF5 [57]. 
2.3.2 The effects of HPV on IFNγR signaling
Ligation of the IFNγR with type II IFN results in the activation of JAK1 and 
JAK2 and recruitment and phosphorylation of STAT1, which homo-dimerizes, 
translocates to the nucleus, binds to GAS on the DNA and initiates ISG 
transcription (Figure 2). The effects of  hrHPV on the IFNγ-signaling pathway 
might be explained by the repressed STAT1 expression and protein levels in 
HPV infected cells, albeit that STAT1 phosphorylation still is intact [38]. 
2.4 HrHPV influences MHC surface expression and peptide presentation
The attack of virus-infected cells by T cells is a highly effective and 
specific mechanism to prevent the production and spread of virus particles. 
T cells recognize cells when viral protein-derived peptides are presented in 
the context of MHC molecules. Literature shows that primary KCs constitute 
excellent targets for antigen-specific cytotoxic T lymphocytes (CTLs) if their 
cognate peptide is presented on the KCs cell surface [58]. The overexpression 
of E5 [59] or E7 [60], however, makes cells more resistant to CTL-mediated 
lysis. E5 and E7 both reduce MHC-I surface expression, but act on different 
levels (Figure 4). E7 reduces MHC-I gene expression by physically associating 
with a putative RXRbeta binding motif (GGTCA) of the proximal promoter of 
MHC-I genes and recruiting HDAC1, 2 and 8 to this promoter site, leading 
to repressed chromatin activation. Indeed, E7 knock-down in Caski cells 
released HDAC1 and 2 from the MHC class-I promoter, and increased histone 
acetylation and MHC-I expression [60-64]. Furthermore, E7 represses the 
LMP2 and TAP1 promotors [61, 62], two important proteins involved in peptide 
production and transportation, respectively. E7 also reduces IRF1 expression 
by suppression of IFNγ-induced STAT1-Tyr701 phosphorylation, repressing 
IFNγ-mediated upregulation of MHC-I expression via the JAK1/JAK2/STAT1/
IRF-1 signal transduction pathway [65, 66]. E5 does not influence MHC-I 
synthesis, but reduces MHC-I surface expression [65] by retaining MHC-I in 
the Golgi complex via interaction of di-leucine motifs (LL1 and LL3) localized in 
the N-terminal helical transmembrane (TM1) region of the protein [67]. This E5 










































Figure 4: The effects of hrHPV on antigen presentation
Schematic representation of the effects of hrHPV on antigen presentation. The proteasome 
processes proteins into peptides, which are transported into the ER via TAP1. Aided by several 
chaperone proteins, MHC-I is folded and loaded with peptide after which it exits the ER to travel 
via the Golgi apparatus to the plasma membrane were the peptides are presented to T cells. 
HPV proteins (red) attenuate gene expression of critical components of this pathway as well as 
actively retains MHC-I in the ER and Golgi apparatus. MHC-II forms in the ER and complexes 
with the invariant chain. The complex travels via the ER and Golgi apparatus to lysosomes where 
the invariant chain is degraded and MHC-II is loaded with processed peptides from endocytosed 
proteins. Loaded MHC-II then travels to the plasma membrane to present the peptides. Upon 
IFNγ stimulation, HPV E5 (red) blocks invariant chain degradation and peptide loading, as well as 
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1all MHC-I-dependent antigen presentation [68]. Moreover, binding of the TM1 
domain of E5 to the ER chaperone Calnexin retains MHC-I in the ER [69], 
and down-regulates surface expression of CD1d, a sentinel protein in bridging 
innate and adaptive immunity [70]. Furthermore, via its C-terminus E5 can 
bind the B-cell-associated protein 31 (BAP31) [71], a protein involved in the 
exit of peptide-loaded MHC-I from the ER [72]. Interestingly, E5 selectively 
downregulates the surface expression of HLA-A and -B, but not that of HLA-C 
and HLA-E [65]. Under normal conditions expression of HLA class II is not 
affected but upon IFNγ stimulation E5 does abrogate MHC-II surface expression 
and blocks peptide-loading of MHC-II and invariant chain degradation [73], by 
inhibiting endosome acidification [74] or perturbing trafficking from early to late 
endocytic structures [75].
SCoPE oF THIS THESIS
In this thesis we examined how hrHPV interferes with innate and adaptive 
immune signaling in keratinocytes. It is clear that hrHPV invests heavily in 
1) preventing infected cells to adapt an anti-viral state, 2) suppressing the 
production of cytokines that can induce the attraction of adaptive immune 
cells which may control HPV infection, and 3) perturbating the expression 
of HLA class I and II molecules making the infected cells less visible to the 
adaptive immune system. Until now, studies focused specifically on the 
effects of hrHPVs’ early proteins. In the present studies, we show that hrHPV 
also exploits cellular proteins to intervene with innate and adaptive immune 
signaling. We used a cell culture system that resembles the natural infection 
of KCs with hrHPV as close as possible. Primary basal layer KCs of foreskin, 
vaginal and cervical origin stably expressing full HPV16 or HPV18 episomes 
following electroporation were studied. These HPV-positive KCs mimic HPV 
infection in vivo as they undergo the entire differentiation-dependent HPV 
life cycle, documented by episome amplification, late gene expression and 
virus production, when cultured in organotypic raft cultures [76-78]. These raft 
cultures produce infectious authentic HPV virions, which we used to infect 










































In chapter 2, the impact of hrHPV presence in KCs on the production of 
type I IFNs and pro-inflammatory cytokines after PRR ligation was assessed. 
HrHPV presence attenuated pro-inflammatory cytokine production, hampered 
RelA and IRF3 phosphorylation, and decreased NEMO protein levels. HrHPV 
upregulated the expression of UCHL1, which impaired IRF3 phosphorylation 
by removing K63-linked polyubiquitin chains from TRAF3, thereby impairing 
TBK1 binding to TRAF3. Furthermore, UCHL1 hampered RelA phosphorylation 
by affecting TRAF6 ubiquitination and inducing degradation of NEMO. 
Chapter 3 focused on the reaction of keratinocytes to CD40 ligation and 
the impact of hrHPV herein. Keratinocytes reacted very coordinately to CD40 
ligation, predominantly expressing genes involved in leukocyte migration, cell-
to-cell signaling and interaction, as well as cell death and survival. HrHPV 
presence did not affect the gene expression profile of CD40 stimulated KCs, 
but attenuated the extent of the response, resulting in the impairment of the 
attraction of PBMCs. 
In chapter 4, the impact of hrHPV presence in KCs on pro-inflammatory 
cytokine production after IFNγR and TNFR ligation was studied. Pro-
inflammatory cytokine production induced by IFNγ, TNFα or their combination 
was impaired when hrHPV was present in the KCs. HrHPV attenuated RelA 
acetylation by upregulating the expression of IFRD1 in an EGFR-dependent 
way. The effects of hrHPV on the cytokine expression in KCs could partially be 
overcome by treatment with the EGFR antibody cetuximab and the HDAC1/3-
specific inhibitor entinostat. Notably, these treatments also enhanced Poly(I:C)-
induced cytokine expression. 
In chapter 5, the impact of hrHPV on the effects of IFNγ, TNFα and 
their combination on the proliferation of keratinocytes was studied, as these 
cytokines were shown to have growth inhibitory effects on KCs. HrHPV 
rendered KCs resistant to the growth inhibitory effects of these cytokines by 
counteracting the IFNγ-induced arrest in cell proliferation via downregulation 
of the anti-proliferative gene IFITM1.
Finally, chapter 6 presents a general discussion and the conclusions of the 
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Persistent infection of basal keratinocytes with high-risk human 
papillomavirus (hrHPV) may cause cancer. Keratinocytes are equipped with 
different pattern recognition receptors (PRRs) but hrHPV has developed ways 
to dampen their signals resulting in minimal inflammation and evasion of 
host immunity for sustained periods of time. To understand the mechanisms 
underlying hrHPV’s capacity to evade immunity, we studied PRR signaling 
in non, newly, and persistently hrHPV-infected keratinocytes. We found that 
active infection with hrHPV hampered the relay of signals downstream of the 
PRRs to the nucleus, thereby affecting the production of type-I interferon and 
pro-inflammatory cytokines and chemokines. This suppression was shown to 
depend on hrHPV-induced expression of the cellular protein ubiquitin carboxyl-
terminal hydrolase L1 (UCHL1) in keratinocytes. UCHL1 accomplished this 
by inhibiting tumor necrosis factor receptor-associated factor 3 (TRAF3) 
K63 poly-ubiquitination which lead to lower levels of TRAF3 bound to TANK-
binding kinase 1 and a reduced phosphorylation of interferon regulatory factor 
3. Furthermore, UCHL1 mediated the degradation of the NF-κB essential 
modulator with as result the suppression of p65 phosphorylation and canonical 
NF-κB signaling. We conclude that hrHPV exploits the cellular protein UCHL1 
to evade host innate immunity by suppressing PRR-induced keratinocyte-
mediated production of interferons, cytokines and chemokines, which normally 
results in the attraction and activation of an adaptive immune response. This 
identifies UCHL1 as a negative regulator of PRR-induced immune responses 
and consequently its virus-increased expression as a strategy for hrHPV to 
persist. 
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A persistent infection with high-risk human papillomavirus (hrHPV) may 
cause cancer. Whereas keratinocytes – the cells infected by hrHPV – are 
equipped with different receptors allowing them to recognize invading pathogens 
and to activate the immune system, hrHPV has developed ways to evade the 
host’s immune response for sustained periods of time. We showed that hrHPV 
accomplishes this by interfering with the signaling of the pathogen receptors, 
thereby hampering the production of cytokines that are known to attract and 
activate the immune system. HrHPV accomplishes this by upregulating the 
expression of a cellular protein called ubiquitin carboxyl-terminal hydrolase 
L1 (UCHL1). This protein suppresses the activation of signals downstream of 
the pathogen receptor leading to reduced transcription factor activation and 
downstream gene expression, in particular that of type I interferon and pro-
inflammatory cytokines. This lowers the attraction of immune cells and thereby 
the chance of hrHPV-infected cells to be recognized and eliminated and as 











































Human papillomaviruses (HPVs) are absolutely species-specific small 
double-stranded DNA viruses. Persistent infections with a number of HPVs, 
predominantly types 16 and 18, can induce cancers of the anogenitalia as well 
as of the head and neck region. These so-called high-risk HPVs (hrHPVs) are 
widespread within all human populations where they are commonly transmitted 
by sexual contact [1]. The undifferentiated keratinocytes of the squamous 
epithelia are the primary target for hrHPV [2] where it establishes an infection 
that can last for up to 2 years, indicating that hrHPV has evolved mechanisms 
to effectively evade the innate and adaptive immune mechanisms protecting 
the majority of immunocompetent hosts [3,4].
Viruses and microbes contain pathogen-associated molecular patterns that 
are recognized by the host’s pattern recognition receptors (PRRs), comprising 
the Toll-like receptors (TLRs), nucleotide oligomerization domain-like receptors 
and retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs) [5]. While all of 
these receptors activate signaling cascades that lead to activation of NF-κB via 
the canonical route, only RLRs and some TLRs activate interferon regulatory 
factors (IRFs) which induce the production of type I interferons (IFN) and 
other effector molecules [6]. The signals from the PRR to the cell nucleus 
are coordinated via ubiquitination, including that of the different tumor-necrosis 
factor receptor-associated factors (TRAFs) and the NF-κB essential modulator 
(NEMO). Poly-ubiquitination of TRAF and NEMO allows downstream signaling 
whereas disassembly of the formed poly-ubiquitin chains by deubiquitinating 
enzymes provides a mechanism for downregulating immune responses [6,7]. 
Keratinocytes (KCs) express TLRs 1-3, TLR5, TLR6, TLR10, RIG-I, protein 
kinase R (PKR), and MDA5 independent of their differentiation status and gain 
the expression of TLR9 upon full differentiation indicating that these cells may 
respond to pathogenic challenges [8,9,10]. Thus, KCs should be able to sense 
the presence of hrHPV genomic DNA directly via TLR9 or indirectly via RIG-I 
[5,11,12]. The expression levels of these PRR were not altered in hrHPV+ KCs 
[10]. However, via genome-wide expression profiling of keratinocytes activated 
through TLR3, PKR, RIG-I and MDA-5 we found that the presence of hrHPV 
dampens a network of genes encoding chemotactic, pro-inflammatory and 
antimicrobial cytokines suggesting that HPV’s immune evasion strategy may 
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rely on countering PRR-mediated cell signaling [10]. 
To understand the mechanisms underlying hrHPV’s capacity to dampen PRR 
signaling we utilized a system that resembles the natural infection with HPV as 
closely as possible. It comprises the use of primary KCs that stably maintain 
the hrHPV genome as episomes following transfection. These hrHPV+ KCs 
grow at similar rates as non-transfected KC and have been shown to mimic 
HPV infection in vivo as they undergo the entire differentiation-dependent HPV 
life cycle documented by genome amplification, late gene expression, and virus 
production, upon culture of hrHPV+ KCs in organotypic raft cultures [13,14,15]. 
In addition, we used non-infected primary KC cultures and primary KCs newly 
infected with authentic HPV16 virions. These primary KCs were compared 
with respect to PRR signaling under different conditions and resulted in the 
identification of the cellular enzyme ubiquitin carboxyl-terminal hydrolase L1 
(UCHL1) that was specifically upregulated by hrHPV in primary keratinocytes 
to dampen innate immunity. UCHL1 acted on the PRR-signaling pathway 
adaptor molecules TRAF3 and NEMO and its inhibition restored PRR-induced 











































High risk HPV is associated with a decreased induction of type I IFN and 
pro-inflammatory cytokines following stimulation of keratinocytes via 
different pattern-recognition receptors.
Undifferentiated uninfected primary KCs and hrHPV+ KCs were tested 
for their capacity to respond to triggers of innate immunity by incubation 
with Pam3CSK4 (TLR1/2), poly(I:C) (TLR3, RIG-I, PKR and MDA-5)[9], 
lipopolysaccharide (LPS, TLR4), flagellin (TLR5), R848 (TLR7/8), or CpG 
(TLR9). The supernatant of non-infected keratinocytes contained higher 
levels of MIP3α and IL-8 but not MIP1α than hrHPV+ KCs at the basal level. 
Activation with poly(I:C) induced the production of high amounts of MIP3α, 
IL-8 and MIP1α in KCs but not in hrHPV+ KCs. Flagellin especially triggered 
the production of MIP3a by KCs but not in hrHPV+ KCs, although IL-8 was still 
produced (Figure 1A). The function of TLR9, expressed only at high protein 
levels in differentiated keratinocytes as measured by immunohistochemistry 
[10] and by RT-qPCR (Figure 1B), was tested by the capacity of CpG 
oligodeoxynucleotides (CpG ODN) to trigger the expression of mRNAs of 
pro-inflammatory cytokines and chemokines. Because suspension in methyl 
cellulose – to differentiate keratinocytes – does not allow the harvest of 
supernatant, secreted protein levels could not be measured. However, the 
experiments clearly showed that CpG ODN-stimulation resulted in the gene 
expression of IFNB1 (IFNβ), IL-8 and CCL20 (MIP3α) in differentiated KCs but 
not in undifferentiated KC cultures (Figure 1C). As a control, KCs were also 
stimulated with poly(I:C) as TLR3, RIG-I and MDA-5 expression is independent 
of KC differentiation [10] and this resulted in the induction of pro-inflammatory 
cytokine expression in both undifferentiated and differentiated KCs (Figure S1). 
In contrast to differentiated uninfected KCs, the hrHPV+ KCs that expressed 
TLR9 after differentiation, failed to induce the expression of IFNβ, IL-8 and 
MIP3α upon incubation with CpG (Figure 1C), indicating that PRR-signaling 
can be suppressed in undifferentiated and differentiated hrHPV+ KCs.
As the basal KCs are the target for hrHPV and TLR9 is not functionally 
expressed in basal KCs and hrHPV+ KCs displayed an impaired production of 
cytokines in response to poly(I:C),  subsequent studies were performed in the 
context of poly(I:C) stimulation. In addition to the secretion of cytokines, also 
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Figure 1: The presence of high risk human papillomavirus interferes with pattern recognition 
receptor (Prr) signaling of keratinocytes. 
(A) Cytokine production of non-differentiated uninfected or HPV16+ keratinocytes after stimulation 
with different indicated PRR stimuli as measured by ELISA.
(B) TLR9 expression as measured by qRT-PCR on total RNA samples from undifferentiated (und) 
and terminally differentiated (terminal dif) uninfected KCs, and HPV16 and HPV18 positive KC 
cultures. 
(C) IFNβ, IL-8 and MIP3α expression levels in unstimulated or CpG ODN-stimulated uninfected 
KCs, and two different HPV (16 or 18) positive KC cultures as examined by qRT-PCR. KCs were 
either left undifferentiated (und) or terminally differentiated (terminal dif) after which they were 











































the gene expression levels of MIP3α, CCL5 (RANTES) and IFNβ in hrHPV+ 
KCs were lower when compared to uninfected KCs upon 3 or 24 hours of 
poly(I:C) stimulation (Figure 2A). 
The production of pro-inflammatory cytokines and chemokines upon 
activation of the NF-κB pathway requires the phosphorylation and nuclear 
translocation of the subunit p65 [6]. The levels of phosphorylated p65 were 
lower in poly(I:C) stimulated hrHPV+ KCs than in non-infected KCs (Figure 2B), 
suggesting that the functional impairment of PRR signaling occurs upstream of 
this molecule. The IKK complex is a key component of the poly(I:C)-induced 
NF-κB pathway, with NEMO (IKKγ) functioning as a scaffold. The degradation 
of NEMO may form a mechanism for viruses to avoid innate immune signaling 
[16,17]. Therefore, the effect of hrHPV on the protein levels of NEMO was 
analyzed. Following treatment of non-infected KCs and hrHPV+ KCs with 
cycloheximide (CHX) – to prevent new protein synthesis – it became clear that 
NEMO degradation was enhanced in hrHPV+ KCs (Figure 2C and Figure S2), 
thereby explaining the decreased phosphorylation of p65 observed.
The production of type I IFN (e.g. IFNb) requires the activation of cytosolic 
IRF3 by phosphorylation and subsequent translocation to the nucleus. Analysis 
of poly(I:C) stimulated KCs and hrHPV+ KCs suggested that also the levels of 
phosphorylated IFR3 levels were decreased in HPV+ KCs (Figure 2D). 
The high risk HPV viral transcript is needed to impair Prr signaling. 
To confirm that the impairment in the production of IFNb and pro-
inflammatory cytokines did not simply reflect biological differences between 
the different primary KCs used but indeed was caused by hrHPV, we infected 
primary keratinocytes with infectious HPV16 virions (Figure 3A) for 24 hours 
and then stimulated the non-infected and newly infected KCs with poly(I:C) 
for another 24 hours after which the levels of IFNb, RANTES and MIP3a 
transcripts were measured (Figure 3B). After 24 hours of infection there was a 
small but discernible increase in the levels of these genes indicating that the 
keratinocytes initially react to the presence of the virus. However, the levels 
already dropped at 48 hours post-infection indicating that the virus rapidly 
exerted its PRR-signaling inhibitory effects. In addition, at the same time point 
these newly hrHPV-infected keratinocytes displayed a hampered activation 
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Figure 2: Canonical NF-κB signaling is impaired upstream of the 
transcription factor p65. 
(A) Poly(I:C) induced cytokine expression in HPV16+ KCs compared to non-infected KCs. 
MIP3a, RANTES and IFNβ expression was measured by qRT-PCR. Gene expression was 
normalized using GAPDH mRNA levels and standardized against 0h of stimulation with poly(I:C).
(B) Poly(I:C) stimulated phosphorylation levels of p65 in HPV16+ KCs compared to non-infected 
KCs. Total p65 levels and p65 phosphorylation status were determined in whole cell extracts by 
western blotting. β-actin served as loading control.
(C) NEMO degradation in HPV16+ KCs compared to non-infected KCs. Monolayer cultures 
were treated with 100 μM cycloheximide (CHX) and harvested after 0, 3, 6, 9, 12, 18 and 24 
hours. Whole cell extracts were analyzed by western blotting using antibodies against NEMO 
and β-actin (control for protein degradation).
(D) Poly(I:C) stimulation-induced phosphorylation levels of IRF3 in hrHPV+ KCs compared to 
KCs. Total IRF3 levels and IRF3 phosphorylation status were determined in whole cell extracts 










































of IFNb, RANTES and MIP3a following 24 hours of stimulation with poly(I:C) 
(Figure 3B). Moreover, we repressed the polycistronic viral mRNA transcript 
[18,19] in hrHPV+ KCs by the use of siRNA targeting HPV16 E2 as this allows 
the destruction of the whole RNA chain. Indeed the suppression of HPV early 
gene E2 expression translated into an overall decrease in viral early gene 
expression (Figure 3C) and an increase in the transcription of IFNb, RANTES 
and MIP3a following poly(I:C) stimulation (Figure 3D). 
Together these data demonstrate that the innate immune response to viral 
and bacterial-derived PRR stimuli of both undifferentiated and differentiated 
hrHPV+ keratinocytes is suppressed by HPV at a point downstream of the 
PRR receptors but upstream of the transcription factors that relay the PRR 
signals to the nucleus.  
The ubiquitin-modifying enzyme UCHL1 is over-expressed in hrHPV-
positive keratinocytes and responsible for suppressing the production 
of type I IFN as well as  pro-inflammatory and chemotactic cytokines.
Our data suggest that hrHPV+ keratinocytes manifest a generalized 
inability to respond to stimulation through interference at, or downstream of 
the cytosolic part of the PRR signaling pathways. We therefore re-analyzed 
the genome-wide expression profiles (Gene Expression Omnibus accession 
number GSE21260) of several different uninfected KC cultures and hrHPV+ 
KC cultures reported previously [10] by Ingenuity Pathways Analysis (IPA) 
and found a highly significant enrichment of genes belonging to the protein 
ubiquitination pathway (Table S1; p=6.69 x 10-5). In this pathway, the gene for 
the enzyme ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) was the most 
upregulated gene in hrHPV+ KCs compared to uninfected KCs (Figure 4A and 
B). The upregulation of UCHL1 in hrHPV+ KCs was confirmed by RT-qPCR in 
both foreskin and vaginal epithelial hrHPV+ KC cultures and expression was not 
influenced by poly(I:C) activation (Figure 4C). Furthermore, UCHL1 upregulation 
at the protein level was tested and shown for three different hrHPV+ KCs by 
western blotting (Figure 4D). Moreover, expression of UCHL1 was upregulated 
2 days post-infection of HPV16 in primary keratinocytes when compared to 
mock-infected primary keratinocytes (Figure 4E), whereas knock-down of 
the polycistronic viral mRNA transcript in hrHPV+ KCs by siRNA for HPV16 
E2 resulted in a decreased UCHL1 expression (Figure 4F). Thus, the 
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Figure 3. Expression of human papillomaviral transcripts are required to impair cytokine 
expression of poly(I:C) stimulated keratinocytes. 
(A, B) Cytokine expression at the initial stage of HPV16 infection. Primary basal layer human 
foreskin keratinocytes were infected with native HPV16. (A) Viral early gene E6 expression 
was analyzed 1 and 2 (24h poly(I:C)) days after infection by PCR. NC: negative control, PC: 
positive control, HPV16+ KCs. (B) MIP3a, RANTES and IFNβ expression was measured by 
qRT-PCR. Gene expression was normalized against GAPDH mRNA levels and standardized 
against the 0h poly(I:C) stimulated non-infected cells. Similar results were observed in two 
independent experiments. 
(C, D) Poly(I:C)-induced cytokine expression in HPV+ KCs transfected with control siRNA 
(siControl) or siRNA targeting HPV16 E2 (siHPV16 E2). E1, E2, E6, E7 (C) as well as MIP3a, 
RANTES, and IFNβ (D) expression was analyzed by qRT-PCR. Gene expression was 
normalized against GAPDH mRNA levels and standardized against no poly(I:C) siControl. 
For all three genes the response to poly(I:C) was significantly higher when HPV16 E2 was 










































Figure 4. HPV induces expression of UCHL1 in keratinocytes. 
(A) Summary of all differentially expressed genes within the Protein Ubiquitination Pathway. 
Differentially expressed genes between four uninfected KC and four hrHPV+ KC cultures with 
adjusted p-value ≤ 0.05 identified 24 hours after poly(I:C) stimulation by microarray analysis (log2 
ratios) are shown.  
(B) UCHL1 microarray gene expression values (log2 intensities) after 0, 4, and 24 hours of 
poly(I:C) stimulation in four primary KCs and four hrHPV+ KCs (circles). The box represents the 
25th and 75th percentiles, the median is indicated with a horizontal line within the box, and the 
whiskers represent the minimum and maximum. 
(C) UCHL1 expression in HPV16+ human foreskin keratinocytes (HFK; left panel) and HPV16+ 
human vaginal keratinocytes (HVK; right panel) when compared to uninfected KCs. KCs were 
either left unstimulated or stimulated with poly(I:C) for 24 hrs. UCHL1 expression was normalized 
 Protein Ubiquitination Pathway genes in 













































































































































































































































































































(D) UCHL1 protein levels in HPV16+ human foreskin keratinocytes (HPV16) and HPV16+ or 
HPV18+ human vaginal keratinocytes (HVK16 or HVK18, respectively) when compared to non-
infected KCs (HFK) as detected by western blotting (WB) in whole cell extracts. β-actin served as 
loading control. 
(E) UCHL1 expression at the initial stage of HPV16 infection. Primary basal layer human foreskin 
keratinocytes were infected with native HPV16 (HPV16 infected keratinocytes) or not (Mock). 
UCHL1 mRNA expression was analyzed by qRT-PCR 2 days after infection. Gene expression was 
normalized against GAPDH mRNA levels and standardized against the non-infected cells. Similar 
results were observed in two independent experiments. 
(F) UCHL1 expression in HPV+ KCs transfected with control siRNA (siControl) or siRNA targeting 
HPV16 E2 (siHPV16 E2). UCHL1 expression was analyzed by qRT-PCR. Gene expression was 
normalized against GAPDH mRNA levels and standardized against siControl. Similar results were 
observed in more than 3 independent experiments. 
cellular deubiquitinase UCHL1 is upregulated by hrHPV. 
Although UCHL1 had not been associated with the inhibition of PRR 
signaling, its enhanced expression in hrHPV+ KCs fits well with the general 
role of deubiquitinases in controlling PRR signaling [6]. To test whether hrHPV-
induced UCHL1 inhibits PRR signaling, we used lentiviral vectors expressing 
short-hairpin RNA (shRNA) against UCHL1 and this resulted in a downregulated 
expression of UCHL1 transcripts and protein levels in hrHPV+ KCs (Figure 
5A and B). Upon stimulation with poly(I:C), hrHPV+ KCs expressing shRNA 
against UCHL1 (shUCHL1) but not hrHPV+ KCs expressing a control shRNA 
(shControl) restored poly(I:C)-mediated induction of type I interferon and 
proinflammatory cytokines (Figure 5C). Similar results were obtained using 
transiently transfected RNA interference (RNAi) oligos targeting UCHL1 but not 
with control RNAi oligos (Figure S3). An increase in the expression levels of IL8 
and MIP3a was detected in hrHPV+ KCs in which UCHL1 was downregulated. 
Gene expression increased to the same levels found in UCHL1-non silenced 
hrHPV+ KCs cells stimulated with poly(I:C) (Supplemental Figure 3). This 
suggests that downregulation of UCHL1 increases the gene expression of 
IL-8 and MIP3a in hrHPV+ KCs. Conversely, transfection of uninfected KCs to 
overexpress UCHL1 resulted in a decreased expression of MIP3a, RANTES 
and IFNb upon poly(I:C) stimulation (Figure 5D and E). Based on control 
experiments in which KCs were transfected with green fluorescent protein 
expressing plasmids, the transfection efficiency of keratinocytes was 30-40% 
(not shown), indicating that in a large part of the keratinocytes the activation of 
cytokine-encoding genes is not impaired and explaining the expression levels 










































Figure 5. uCHL1 is responsible for suppressing poly(I:C) mediated gene activation of IFN-I 
and proinflammatory cytokines in hrHPV-infected KC. 
(A – C) UCHL1 knock-down effect of poly(I:C) mediated gene expression of IFN-I and 
proinflammatory cytokines. HPV16+ keratinocytes were transduced with lentiviral vectors 
expressing shRNA against control mRNA (TurboGFP; shControl) or targeting mRNA of UCHL1 
(shUCHL1). Cells were either left unstimulated, or were stimulated with poly(I:C) for 3 or 24 hrs. (A) 
UCHL1 mRNA expression was analyzed by qRT-PCR and (B) UCHL1 protein levels were analyzed 
by western blotting in whole cell extracts, β-actin served as loading control. (C) MIP3α, RANTES 
and IFNβ mRNA expression was analyzed by qRT-PCR. Gene expression was normalized against 
GAPDH mRNA levels and standardized against 0h of stimulation with poly(I:C). 
(D, E) UCHL1 overexpression effect on the activation of poly(I:C) mediated gene expression 
of IFNβ and proinflammatory cytokines. Uninfected keratinocytes were transfected with a vector 
harboring the UCHL1 gene, an empty control or only received the transfection agent (TFRO). 
Cells were either left unstimulated, or were stimulated with poly(I:C) for 24 hrs. (D) UCHL1 protein 
levels were upregulated in the UCHL1-transfected cells as detected by western blotting in whole 




































































































































































cell extracts, β-actin served as loading control. (E) MIP3α and RANTES mRNA expression was 
analyzed by qRT-PCR. Gene expression was normalized against GAPDH mRNA levels and 
standardized against the TFRO at 0h of stimulation with poly(I:C).
All together, these data clearly demonstrate that UCHL1 can downregulate 
the PRR-mediated activation of both the type I IFN and proinflammatory 
cytokine  and chemokine pathways. 
Knock down of UCHL1 increases the phosphorylation of IRF3 and NFκB 
p65 and alleviates NEMo degradation.
We then asked whether the restoration of PRR signaling, as indicated by 
an increased induction of type I interferon and proinflammatory cytokines by 
the knock down of UCHL1 in hrHPV+ KCs would also be reflected in the levels 
of phosphorylated p65 (p65-p) and IRF3 (IRF3-p) upon poly(I:C) stimulation. 
Therefore, the p65-p and IRF3-p levels were analyzed in whole cell extracts 
of HPV16+ KCs stably expressing shRNA against UCHL1 or control shRNA 
and following 3h or 24h of stimulation with poly(I:C). Knock down of UCHL1 in 
hrHPV+ KCs resulted in increased p65 phosphorylation at 3 and 24 hours after 
poly(I:C) stimulation (Figure 6A) coinciding with enhanced cyto- and chemokine 
production (Figure 5C). In addition, analysis of hrHPV+ KCs treated with 
cycloheximide revealed that NEMO degradation was alleviated when UCHL1 
was knocked down by shUCHL1 as compared to the shControl hrHPV+ KCs 
(Figure 6B). Furthermore, higher levels of phosphorylated IRF3 were detected 
in hrHPV+ KCs in which UCHL1 was knocked down as compared to hrHPV+ 
KCs expressing the shControl after 3 hours of poly(I:C) stimulation (Figure 
6C). 
uCHL1 alters the poly-ubiquitination of TrAF3 and NEMo. 
TRAF3 ubiquitination is critical for type I IFN production and is a likely 
target for ubiquitin-modifying enzymes such as UCHL1. As the biochemical 
experiments to understand the nature of this interaction would require 
substantial amounts of primary KCs, which can only grow for a few passages 
thereby restricting their use in biochemical studies, we switched to the 
HEK293T cell system that is widely used for these purposes. To investigate 
the interaction between UCHL1 and TRAF3 we overexpressed UCHL1 and 










































Figure 6. uCHL1 reduces phosphorylation levels of IrF3 and p65 and degrades NEMo in 
hrHPV-positive KC. 
(A) UCHL1 knock down effect on poly(I:C) stimulated p65 phosphorylation in HPV16+ keratinocytes. 
Monolayer cultures of shControl or shUCHL1-expressing HPV16+ KCs were stimulated for 0, 3 
or 24 hours with Poly(I:C). Whole cell extracts were analyzed by western blotting for p65, p65-p 
and β-Actin (as loading control). The relative expression of p65-p was quantified by measuring its 
density and by normalizing it to that of β-Actin. The expression levels of p65-p in the 0h Poly(I:C) 
cells were set to 100% for both shControl and shUCHL1 cells. The p65-p levels in the 3h and 24h 
Poly(I:C) cells were calculated against the levels measured at 0h Poly(I:C) (right panel). 
(B) NEMO protein levels after knock down of UCHL1 in HPV16+ KCs. Monolayer cultures of 
shControl or shUCHL1-expressing HPV16+ KCs were treated with 100 μM cycloheximide (CHX) 
for 16 hours. Whole cell extracts were analyzed by western blot using antibodies against NEMO 
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measuring its density and by normalizing it to that of β-Actin. The expression of NEMO in the 
DMSO control was set to 100% (right panel). 
(C) UCHL1 knock down effect on poly(I:C) stimulated IRF3 phosphorylation in HPV16+ 
keratinocytes. Similar to A, however cell extracts were analyzed by western blotting using 
antibodies against IRF3, IRF3-p and β-Actin (as loading control). The relative expression of IRF3-p 
was quantified by measuring its density and by normalizing it to that of β-Actin. The expression of 
IRF3-p in the 3h Poly(I:C) control cells (no knock down of UCHL1) was set to 100% (right panel). 
confirmed that UCHL1 co-immunoprecipitated with TRAF3 (Figure 7A). 
TRAFs are activated by oligomerization and auto-ubiquitination, a process that 
resultsin lysine 63 (K63)-linked poly-ubiquination of TRAF, and this event can 
be induced by either their overexpression or by receptor activation. In contrast 
K48-linked poly-ubiquitination results in proteasome-mediated degradation of 
ubiquitinated TRAFs [6]. To test whether UCHL1 modified TRAF3 ubiquitination 
status, Flag-tagged TRAF3 and haemagglutinin A (HA)-tagged ubiquitin 
were overexpressed in control or UCHL1 overexpressing HEK293T cells. 
Poly-ubiquitination of TRAF3 was clearly visible by immunoblot analysis but 
strongly reduced when UCHL1 was also overexpressed (Figure 7B, Figure 
S4). No reduction in poly-ubiquitination was detected when as a control 
the growth regulated ubiquitin-specific protease 8 (USP8), which similar to 
UCHL1 displays carboxyl-terminal hydrolase activity, was overexpressed 
(Figure 7B). The UCHL1-associated decreased detection of poly-ubiquitinated 
TRAF3 was not the result of increased TRAF3 degradation as blocking the 
proteasomal degradation pathway by the inhibitor MG132 did not result in a 
reappearance of poly-ubiquitinated TRAF3 (Figure 7C). Instead, experiments 
in which HA-tagged ubiquitin mutants ‘K63 Only’ and ‘K48 Only’ (where all 
lysine residues, except at position K63 and K48, respectively, were mutated to 
arginine) showed that UCHL1 removed K63-linked poly-ubiquitins but not K48-
linked poly-ubiquitins (Figure 7D), consistent with the known deubiquitinating 
capacity of UCHL1 [20]. K63-linked ubiquitination is required for TRAF3 to bind 
its partner TBK1 to activate the downstream type I IFN-signaling pathway. As 
expected, UCHL1-mediated deubiquitination of TRAF3 resulted in less TRAF3 
bound to TBK1 in UCHL1 overexpressing cells when compared to control cells 
(Figure 7E).  These data clearly show that UCHL1 binds and deubiquitinates 
TRAF3 resulting in a decreased TRAF3-TBK1 complex formation. 
Poly-ubiquitination of TRAF6 and its downstream partner NEMO is critical 
for the PRR-induced activation of proinflammatory cytokine genes [6]. Since 
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Figure 7. Interaction of uCHL1 with the Prr downstream signaling molecule TrAF3. 
(A) UCHL1 directly interacts with TRAF3 and TRAF6 but not NEMO. HEK293T cells were 
co-transfected as indicated and the respective TRAF3, TRAF6 or NEMO proteins were 
immunoprecipitated using Flag antibody, and co-precipitating UCHL1 was detected by WB. As a 
control a WB analysis for Flag was performed indicating that both TRAF3 and NEMO were present. 
The bottom three panels show a WB analysis of Flag and UCHL1 of non- immunoprecipitated 
lysate and a Ponceau S stained loading control for WB.  
(B) UCHL1, but not the control ubiquitin-specific protease 8 (USP8) mediates deubiquitination of 
TRAF3. HEK293T cells were co-transfected with Flag-TRAF3, HA-tagged wild-type ubiquitin (WT-
Ub), and with either empty vector, WT UCHL1 or USP8. TRAF3 was immunoprecipitated with Flag 
antibody and WB was done with HA or Flag antibodies (top panels). The bottom four panels show 
a WB analysis of Flag, UCHL1, and USP8 of non- immunoprecipitated lysate and a Ponceau S 
stained loading control for WB.  
(C) Deubiquitination but not degradation of TRAF3 by UCHL1. HEK293T cells were co-transfected 
with Flag-TRAF3, HA-tagged wild-type ubiquitin (WT-Ub), and with either empty vector or WT 
UCHL1. Cells were left untreated or treated with proteasome blocker MG132. TRAF3 was 
immunoprecipitated with Flag antibody and WB was done with HA or Flag antibodies (top two 
panels). 
(D) UCHL1 mainly removes K63-linked poly-ubiquitin chains of TRAF3. HEK293T cells expressing 
Flag-TRAF3, HA-tagged mutant ubiquitin either K63 Only or K48 Only, and WT UCHL1 were 
immunoprecipitated with Flag antibody and analyzed by HA or Flag antibodies (top two panels). 
(E) UCHL1 lowers TRAF3-TBK1 complex formation. HEK293T cells were co-transfected and 
TBK1 was immunoprecipitated using Flag antibody, and co-precipitating TRAF3 or TBK1 was 
detected by WB (top two panels).
 
synthesis (Figure 5) the interaction of UCHL1 with TRAF6 and NEMO was 
tested. Co-expression and immunoprecipitation experiments in HEK293T cells 
showed that UCHL1 bound to TRAF6 but not to NEMO (Figure 7A). In contrast 
to what we observed for TRAF3, UCHL1 displayed a modest effect on the poly-
ubiquitination of TRAF6 (Figure 8A). However, poly-ubiquitination of NEMO 
was reduced in UCHL1 overexpressing cells (Figure 8B, Figure S4) but not in 
USP8 overexpressing cells (Figure 8D). Inhibition of proteasome function by 
MG132 suggested that the reduced poly-ubiquitination of NEMO was the result 
of enhanced degradation of NEMO in cells overexpressing UCHL1 (Figure 
8C, compare lanes 2 and 4), albeit that the total protein levels of NEMO in 
these transfected cells remained unaffected. This is not unexpected as also in 
the endogenous setting (Figures 2 & 6) the degradation of NEMO could only 
be visualized when the hrHPV+ KCs where pretreated with cycloheximide to 
prevent new protein synthesis.
Collectively, these data support the notion that UCHL1 can suppress 
the PRR-signaling pathways necessary for type I IFN and pro-inflammatory 
cytokine production by the removal of the activating K63 ubiquitins from TRAF3 

































































































































































































Figure 8. Interaction of uCHL1 with the Prr downstream signaling molecules TrAF6 and 
NEMo. 
(A) UCHL1 overexpression results in a modest poly-ubiquitination of TRAF6. HEK293T cells were 
co-transfected with Flag-TRAF6, HA-tagged WT-Ub, and with either empty vector or WT UCHL1. 
TRAF6 was immunoprecipitated with Flag antibody and western Blotting (WB) was done with HA 
or Flag antibodies (top two panels). The bottom three panels show a WB analysis of UCHL1 and 
Flag of non-immunoprecipitated lysate and a Ponceau S stained loading control for WB. 
(B) The effect of UCHL1 on NEMO. HEK293T cells were co-transfected with Flag-NEMO, HA-
tagged WT-Ub, and with either empty vector or WT UCHL1. NEMO was immunoprecipitated with 
Flag antibody and WB was done with HA or Flag antibodies (top two panels). 
(C) The overexpression of UCHL1 mediates the degradation of NEMO. HEK293T cells were co-
transfected with Flag-NEMO, HA-tagged WT-Ub, and with either empty vector or WT UCHL1. 
Cells were left untreated or were treated with MG132, NEMO was immunoprecipitated with Flag 
antibody and WB was done with HA or Flag antibodies (top two panels). 
(D) USP8 does not deubiquitinate NEMO. HEK293T cells were co-transfected with Flag-NEMO, 
HA-tagged wild-type ubiquitin (WT-Ub) and UCHL1 or  USP8. NEMO was immunoprecipitated 
with Flag antibody and WB was done with HA antibodies (top panel). The bottom four panels show 
a WB analysis of Flag, UCHL1, and USP8 of non-immunoprecipitated lysate and a Ponceau S 











































We have employed a unique model for hrHPV infection to examine the 
potential mechanisms underlying the capacity of hrHPV to evade host immunity 
by suppression of the innate immune response [10]. We utilized primary KC 
cultures that were newly infected with HPV16 virions or primary KCs stably 
maintaining the episomal hrHPV genome to show that despite the expression 
of multiple PRRs the production of IFNβ and pro-inflammatory cytokines and 
chemokines is suppressed by hrHPV as a consequence of reduced PRR 
signaling. We provided firm evidence that this suppression depends on the 
hrHPV-induced upregulation of the cellular ubiquitin-modifying enzyme UCHL1 
in infected primary KCs. 
Finally, classical biochemical studies in HEK293T cells [11,21,22] performed 
to understand how UCHL1 mechanistically could suppress the production 
of type I interferons and pro-inflammatory cytokines revealed that UCHL1 
regulated the ubiquitination of the PRR-signaling pathway adaptor molecules 
TRAF3 and NEMO. UCHL1 removes activating K63-linked ubiquitin molecules 
from TRAF3 resulting in a lower amount of the downstream signaling complex 
TRAF3-TBK-1 to suppress the type I IFN pathway. This puts UCHL1 within the 
family of other deubiquinating enzymes that regulate the PRR pathways by 
selectively cleaving lysine-63 (K63)-linked ubiquitin chains from TRAFs (e.g. 
DUBA, OTUB1, OTUB2, A20) [21,22,23,24,25,26]. Furthermore, we showed 
that UCHL1 bound to TRAF6 and mediated the enhanced degradation of NEMO 
as a mechanism to suppress the proinflammatory cytokine NF-κB pathway. 
Notably, the ubiquitin-modifying enzyme A20, a known negative regulator of 
the TLR pathway, has two ubiquitin-editing domains allowing it to remove and 
to add ubiquitin chains (22, 26). UCHL1 has also been reported to have these 
two opposing functions (20). The ligase activity of UCHL1 may explain the 
ubiquitination of TRAF6 observed in our study. Although UCHL1 did not bind to 
NEMO, it is known that other deubiquitinating enzymes (e.g. CYLD, A20) bind 
to TRAFs in order to dock on the IKK complex and to associate with NEMO 
[21,27]. TRAF6-dependent poly-ubiquitination of NEMO is well known [28]. It 
is highly likely that UCH-L1 acts in a similar fashion and this would fit with 
TRAF6-NEMO interaction and our observations that NEMO is degraded.
Our data on the suppression of NF-κB signaling via the degradation of NEMO 
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by UCHL1 fits well with earlier observations concerning the overexpression 
of UCHL1 in vascular cells. Here UCHL1 attenuated TNF-a induced NF-κB 
signaling and this was associated with stabilization of IκBa and a decrease in 
its basal ubiquitination [29]. The activation of NF-κB signaling requires IκBa 
to become degraded following an interaction with the IκB kinase complex 
(IKK) which comprises NEMO. Hence, the degradation of NEMO may explain 
previous observations on UCHL1-associated stabilization of IκBa. 
UCHL1 is not found to be central in the network of genes affected by hrHPV, 
suggesting that it is not part of the cellular genes affected in order to assist 
in HPV genome replication and viral protein production [10]. This indicates 
that UCHL1 is not directly involved in viral propagation but rather recruited 
by hrHPV to suppress keratinocyte-mediated production of cytokines and 
chemokines that would result in the attraction and activation of an adaptive 
immune response, thereby enabling the virus to persist and propagate.
Many viruses utilize multifunctional viral proteins in order to evade NF-
κB- and IRF-mediated immune responses, to favor viral replication and/or 
to modulate cellular apoptosis and growth pathways [30]. The group of pox 
viruses have evolved to inhibit NF-κB-signaling by targeting one or more of 
the many different molecules of this signaling cascade [31]. The vaccinia virus 
B14 protein is known to inhibit NF-κB signaling by a variety of toll-like receptor 
agonists at the level of the IKK complex, of which NEMO is a member [32]. 
The vaccinia virus A64R protein inhibits TRIF-TRAF3-IRF signaling [33]. The 
pathogenic NY-1 hantavirus Gn protein inhibits TRAF3 signaling by blocking 
the formation of TBK1-TRAF3 complexes [34] whereas the LMP1 protein of 
Epstein-Barr virus directly binds to TRAF3 [35]. Furthermore, foot-and-mouth 
disease virus 3c protease cleaves NEMO [16] and cytomegalovirus M54 
protein induces the proteasome-independent degradation of NEMO [17]. In 
contrast, human papillomaviruses, with a rather limited coding capacity in their 
genomes, rely for many aspects of their life cycle on the utilization of cellular 
proteins [36] and this includes the recruitment of different cellular E3 ligases 
to mediate degradation of cellular proteins through the ubiquitin-proteasomal 
pathway [37].  UCHL1 is one of the most abundant proteins in the mammalian 
nervous system and is involved in regulating synaptic transmission at the 










































disease [20] and is also implicated in oncogenesis [39]. In hrHPV+ 
keratinocytes UCHL1 is expressed and redirected to adopt a new function that 
is to serve as a negative regulator of the PRR-signaling pathway. As such 
it mimics the ubiquitin-modifying enzyme A20 which is the natural negative 
regulator of the TLR pathway [22,26,40]. UCHL1 interferes with the adaptor 
molecules TRAF3, TRAF6 and NEMO which all function at junctions for the 
immune stimulating signals from different PRR and type I IFNR to activate NF-
κB- and IRF-mediated immune responses. Therefore, the utilization of UCHL1 
represents a truly effective use of a cellular protein as it may suppress the 
immunostimulatory signals initiated through recognition of HPV genomic DNA 
by TLR9 [5] and RIG-I  [11,12] as well as those obtained via the cell surface 
receptors for type I IFN  [41]. 
The high expression of UCHL1 in primary keratinocytes carrying infectious 
hrHPV [13,14] is generally lost after transformation of these keratinocytes to 
tumor cells. Although transformed keratinocytes expressing un-physiologically 
high levels of E6 and E7 via retroviral transduction still may express UCHL1, 
only a minority of spontaneously HPV-transformed cervical carcinoma’s and 
none of the well known HPV-induced cancer cell lines overexpress UCHL1 
[42], indicating that under normal conditions UCHL1 overexpression in HPV 
transformed cells is not a common event. The expression of the hrHPV 
oncoproteins E6 and E7 is required to maintain the transformed state of 
keratinocytes [2,43] suggesting that it is not E6 or E7, but one or more of 
the other viral proteins responsible for upregulation of UCHL1 (currently under 
investigation). Previous studies on the innate immune response to hrHPV 
relied on the overexpression of hrHPV E6 and/or E7 proteins, showing that 
the viral DNA-sensing TLR9 was altered [8] and that overexpressed HPV E6 
or E7 could bind to IRF3 [44] and/or the co-activator CPB [45]. Furthermore, 
overexpressed hrHPV E6 and/or E7 attenuated IκB kinase signaling [46], 
and interfered with the nuclear translocation of the interferon-stimulated 
gene factor 3 (ISGF3) transcription complex [47]. The fact that these studies 
were performed with only HPV E6- and E7 transfected or transformed cells 
may explain why the central role of UCHL1 in dampening immunity towards 
hrHPV+ keratinocytes was not discovered before. In addition, the loss of 
UCHL1 mediated suppression of the NF-κB pathway in hrHPV E6/E7-induced 
cancer cells fits well with the notion that solid tumors require the NF-κB-
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mediated expression of proteins that promote survival, proliferation, invasion 
and metastasis [48] which is acquired through the E6-mediated deactivation 
of CYLD [49], a negative regulator of TRAF2 and TRAF6-mediated activation 
of NF-κB [21,24].
All together, our data implicate UCHL1 as a negative regulator of the PRR 




Primary cultures of human epithelial keratinocytes were established from 
foreskin [50] and vaginal tissues and grown in serum-free medium (Defined 
KSFM, Invitrogen, Breda, The Netherlands). Keratinocyte lines stably 
maintaining the full episomal HPV genome following electroporation were 
grown in monolayer culture using E medium in the presence of mitomycin C 
treated J2 3T3 feeder cells [13,14] for two passages and were then adapted 
to Defined K-SFM for one passage before experimentation. None of the cell 
cultures were used after passage 15 and the non-transformed state of the cells 
used was confirmed by the expression of both E1 and E2 so that the cells used 
truly represent the preneoplastic state in which the HPV genomes remained 
episomal and were capable of the complete viral life cycle. Keratinocytes were 
terminally differentiated by placing them into serum-free medium containing 
1.75% methyl cellulose and 1.8 mM Ca2+ for 24 hours [50]. Cells were 
harvested by washing out the methyl cellulose three times. HEK293T cells were 
cultured in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal 
bovine serum, 2mM l-glutamine and 1% penicillin-streptomycin (Gibco-BRL, 
Invitrogen). Transient transfections were performed using calcium phosphate 
or Lipofectamine 2000 (Invitrogen).
HPV16 infection of non-infected keratinocytes. 
Primary basal layer human foreskin keratinocytes were seeded at 7.5x104 
cells per well of a 24-wells plate in K-SFM and then allowed to attach for 48 










































native HPV16 isolated from raft cultures at a MOI 100 for 24 hours. Cells were 
stimulated with or without 25 ug/ml poly(I:C) in K-SFM for 0 or 24 hours and 
harvested at the indicated time-points. 
Plasmid construction.
Full length human cDNA clones for UCHL1, TRAF3, TRAF6 and TBK1 
were obtained from Open Biosystems (Surrey, UK). The cDNA clones were 
PCR amplified and subcloned either into pcDNA3.1 expression vector or into 
Flag-tagged pcDNA3.1 vector. Full-length Flag-NEMO construct was kindly 
provided by Dr. C. Sasakawa, University of Tokyo, Japan [51]. HA-tagged wild-
type and mutant ubiquitin constructs were kindly provided by Dr. A. Iavarone, 
Columbia University, USA. 
RNA expression analyses.
Total RNA was isolated using TRIzol (Invitrogen) according to manufacturer’s 
instructions. RNA was purified using RNeasy Mini Protocol (Qiagen, Venlo, The 
Netherlands). Total RNA (0.2 µg) was reverse transcribed using SuperScript 
III reverse transcriptase (Invitrogen) and oligo dT primers (Promega, Madison, 
USA). TaqMan PCR was performed using TaqMan Universal PCR Master Mix 
and pre-designed, pre-optimized primers and probe mix for IL-8, MIP-1α, MIP-
3α, RANTES, IL-1β, IFNβ, UCHL1 and GAPDH (Applied Biosystems, Foster 
City, USA). Threshold cycle numbers (Ct) were determined using the 7900HT 
Fast Real-Time PCR System (Applied Biosystems) and the relative quantities 
of mRNA per sample were calculated using the ΔΔCt method as described by 
the manufacturer using GAPDH as the calibrator gene.
Stimulation of cells with TLr ligands and ELISA.
5x105 cells were plated in 1 ml in each well of 24-well flat bottom plate. Cells 
were left unstimulated or stimulated with Pam3CSK4 (5 μg/ml), Poly(I:C) (25 
μg/ml), LPS (3.33 μg/ml ), flagellin (150 ng/ml), R848 (1 μg/ml), CpG (1 μM) or 
TNFα (50 ng/ml) for 24 hours. Flagellin was a kind gift from Jean-Claude Sirard 
(Institut Pasteur, Lille, France). TLR ligands were purchased from Invivogen 
(San Diego, USA). The supernatants were harvested and IL-8, MIP-3α, and 
MIP-1α  concentrations were determined using corresponding Quantikine 
ELISA kits (R&D Systems, Oxon, UK). 
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Non-targeting RNAi oligos (ON-TARGETplus Non-targeting Pool, catalogue 
D-001810-10-20) and oligos targeting UCHL1 (ON-TARGETplus SMARTpool, 
catalogue L-004309-00) were purchased from Dharmacon (Chicago, IL). Cells 
were transfected with RNAi using N-TER Nanoparticle siRNA Transfection 
System (Sigma-Aldrich, St. Louis, MO) according to manufacturer’s instructions. 
24 hours after transfection, cells were stimulated with poly(I:C) (25 μg/ml) for 
another 24 hours and experiments were performed. 
The shRNA’s used were obtained from the MISSION TRC-library of 
Sigma-Aldrich (Zwijndrecht, The Netherlands). The MISSION shRNA 
clones are sequence-verified shRNA lentiviral plasmids (pLKO.1-puro) 
provided as frozen bacterial glycerol stocks (Luria Broth, carbenicillin 
at 100 µg/ml and 10% glycerol) in Escherichia coli for propagation and 
downstream purification of the shRNA clones. pLKO.1 contains the 
puromycin selection marker for transient or stable transfection. The 
construct against UCHL1 (NM_004181) was TRCN0000011079 (LV079): 
CCGGCAGTTCTGAAACAGTTTCTTTCTCGAGAAAGAAACTGTTTCA-
GAACTGTTTTT and the control was: SHC004 (MISSION TRC2-pLKO puro 
TurboGFP shRNA Control vector): CCGGCGTGATCTTCACCGACAAGA-
TCTCGAGATCTT GTCGGTGAAGATCACGTTTTT.
HPV16+ KCs were seeded 7.5x104 cells per well to a 12-wells plate in 
K-SFM and were allowed to attach over night. Medium was replaced by 
infection medium (K-SFM + 30% virus supernatant; MOI=5), containing either 
the lentivirus LV079 in IMDM 5% FCS or as control SHC004. HPV16+ KCs 
were infected over night after which infection medium was replaced by K-SFM 
containing 1000 ng/ml puromycin for 48 hours to select for successfully infected 
HPV16+ KCs. Then the medium was replaced by K-SFM without puromycin 
and cells were grown for 24 hours. To stimulate the PRR pathways lentivirus-
infected HPV16+ KCs were given K-SFM containing either  no poly(I:C) (two 
wells) or 25 ug/ml poly(I:C) and were cultured for 21 hours. Then one of the two 
non-stimulated wells received 25 ug/ml poly(I:C) and all cells were cultured for 
another 3 hours. Cells were harvested and total RNA was isolated.
Silencer Select siRNA against HPV16 E2 (AACACUACACCCAUAGUACAUtt) 
was designed using siRNA Target Finder software (Ambion, Invitrogen). Blast 










































human transcriptome. E2 and Negative control #2 (NC2) siRNA (sequence not 
provided by manufacturer) were purchased from Ambion. HPV16+ KCs were 
transfected with 50 nM siRNA E2 or NC2 using Lipofectamine 2000 (Invitrogen) 
according to the manufacturer’s instructions. 48 hours post-transfection cells 
received K-SFM containing no Poly(I:C) or 25 ug/ml Poly(I:C) and were cultured 
for 24 hours after which target gene expression was assayed by qRT-PCR.
Western blot analysis and immunoprecipitation. 
For Western blotting, polypeptides were resolved by SDS–polyacrylamide 
gel electrophoresis (SDS–PAGE) and transferred to a PVDF membrane (Bio-
Rad, Veenendaal, The Netherlands). Immunodetection was achieved with 
anti-Flag (1:2000, Sigma-Aldrich), anti-HA (1:1000, Covance), anti-TRAF3, 
anti-TRAF6 (both 1:500, Santa Cruz, CA), anti-ubiquitin lysine 48-specific 
(1:1000, Millipore, Amsterdam, The Netherlands), anti-poly-ubiquitin lysine 
63 specific (1:1000, Millipore), anti-TBK1 (1:400, Santa Cruz),  anti-NEMO 
(FL-419, Santa Cruz), anti-UCHL1 (1:1000 Millipore, 1:100 Abcam or 1:1000 
Santa Cruz), anti-USP8 (#8728, Cell Signaling Technology, Danvers, MA, 
USA), anti-phospho-p65 (Ser538; 1:1000, #3033 Cell Signaling Technology) 
and anti-phospho-IRF3 (Ser396; 1:2000, #4947, Cell Signaling Technology) or 
β-actin (1:10,000, Sigma-Aldrich) antibodies. The proteins were visualized by a 
chemoluminescence reagent (Thermo Scientific, Etten-Leur, The Netherlands). 
X-Ray films were scanned using a GS-800 calibrated densitometer and 
Quantity One software (Bio-Rad, Veenendaal, The Netherlands) to quantify 
the intensity of the bands as a measure of the amount of protein of interest in 
the blot. The relative amount was determined by calculating the ratio of each 
protein over that of the density measured for the household protein β-Actin. 
For immunoprecipitation, cells were collected after 48h and then lysed in 
NP40 buffer supplemented with a complete protease inhibitor cocktail (Roche, 
Almere, The Netherlands). After pre-clearing with protein A/G agarose beads 
for 1h at 4°C, whole-cell lysates were used for immunoprecipitation with either 
mouse or rabbit anti-Flag antibodies (Sigma-Aldrich), or rabbit anti-TRAF3 
or rabbit anti-TRAF6. One to two μg of the antibody was added to 1 ml of 
cell lysate, which was incubated at 4°C for 2-3h. After addition of protein A/G 
agarose beads, the incubation was continued for 1h. Immunoprecipitates 
were extensively washed with lysis buffer and eluted with SDS loading buffer 
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and boiled for 5 min. For immunoprecipitation under denaturing conditions, 
proteins were extracted using regular immunoprecipitation buffer plus 1% SDS 
and heated at 950C for 5 min. The samples were diluted (10-fold) in regular 
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Figure S1. Cytokine production by poly(I:C)-stimulated terminally differentiated 
keratinocytes. 
IL-8 and MIP3α expression levels in unstimulated or  poly(I:C)-stimulated uninfected KCs as 
examined by real-time PCR. KC were either left undifferentiated (undif) or terminally differentiated 


























































































































Figure S2. NEMO degradation depends on the expression of UCHL1. 
NEMO degradation is enhanced in HPV16+ KCs but not in non-infected KCs. Monolayer cultures 
were treated with different concentrations of cycloheximide (CHX) for 24 hours. Whole cell extracts 
were analyzed by WB using antibodies against NEMO and β-actin (control for protein content). 
Figure S3. restored cytokine production after knock down of uCHL1 by rNAi oligos. 
HPV16+ keratinocytes were transfected with non-targeting RNAi oligos and oligos targeting 
UCHL1. Cells were either left unstimulated, or were stimulated with poly(I:C) for 24 hrs. IL-8,and 
MIP3α mRNA expression was analyzed by qRT-PCR. Gene expression was normalized against 
GAPDH mRNA levels.
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Figure S4. TrAF3 and NEMo are deubiquitinated by uCHL1. 
HEK293T cells were co-transfected with HA-tagged wild-type ubiquitin (WT-Ub) only, with Flag-
TRAF3 and HA-tagged wild-type ubiquitin (WT-Ub), and with Flag-TRAF3 and HA-tagged wild-
type ubiquitin (WT-Ub) and UCHL1. A similar experiment was performed in which Flag-TRAF3 was 
replaced by Flag-NEMO (top panels). The bottom four panels show a WB analysis of Flag,Wt-Ub, 
and UCHL1 of non- immunoprecipitated lysate and a Ponceau S stained loading control for WB.  
Supplementary Figure 4, Karim et al. 2012
IP: Flag (TRAF3)




































































































Table S1. Enrichment of pathways between HPV-positive and uninfected keratinocytes as 
analyzed by Ingenuity Pathway Analysis (IPA).
Canonical pathway p-value
Purine Metabolism 1.15 x 10-5
Oxidative Phosphorylation 6.26 x 10-5
Protein ubiquitination Pathway 6.69 x 10-5
Graft-versus-Host Disease Signaling 5.35 x 10-4
LXR/RXR Activation 7.55 x 10-4
Mitochondrial Dysfunction 8.22 x 10-4
Nucleotide Excision Repair Pathway 1.56 x 10-3
Pyrimidine Metabolism 1.15 x 10-3
NRF2-mediated Oxidative Stress Response 1.15 x 10-3
Urea Cycle and Metabolism of Amino Groups 1.15 x 10-3
Inositol Metabolism 1.15 x 10-3
Glucocortocoid Receptor Signaling 8.41 x 10-3
IL-10 Signaling 1.08 x 10-2
Pentose Phosphate Pathway 1.34 x 10-2
Glutathione Metabolism 1.43 x 10-2
D-glutamine and D-glutamate Metabolism 1.46 x 10-2
Hypoxia Signaling 1.88 x 10-2
PPAR Signaling 1.94 x 10-2
Arginine and Purine Metabolism 2.02 x 10-2
Glutamate Metabolism 2.04 x 10-2
Role of Cytokine in Mediating Communication between Immune Cells 2.2 x 10-2
Aldosterone Signaling in Epithelial Cells 2.26 x 10-2
Cardiac Hypertrophy Signaling 2.61 x 10-2
Glycosphingolipid Biosynthesis- Neolactoseries 3.07 x 10-2
Role of BRCA1 in DNA Damage Response 3.36 x 10-2
Role of CHK Proteins in Cell Cycle Checkpoint Control 3.89 x 10-2

CD40-mediated amplification of local immunity 
by epithelial cells is impaired by HPV
Tummers B, Goedemans R, Jha V, Meyers C, Melief CJM,
van der Burg SH, Boer JM.












































The interaction between the transmembrane glycoprotein surface receptor 
CD40 expressed by skin epithelial cells (ECs) and its T cell-expressed ligand 
CD154 was suggested to exacerbate inflammatory skin diseases. However, 
the full spectrum of CD40-mediated effects by ECs underlying this observation 
is unknown. Therefore, changes in gene expression after CD40 ligation of ECs 
were studied by microarrays. CD40-mediated activation for 2 hours stimulated 
the expression of a coordinated network of immune-involved genes strongly 
interconnected by IL8 and TNF, while after 24 hours anti-proliferative and 
anti-apoptotic genes were upregulated. CD40 ligation was associated with 
the production of chemokines and the attraction of lymphocytes and myeloid 
cells from peripheral blood mononuclear cells (PBMCs). Thus, CD40-mediated 
activation of ECs resulted in a highly coordinated response of genes required 
for the local development and sustainment of adaptive immune responses. 
The importance of this process was confirmed by a study on the effects of 
human papilloma virus (HPV) infection to the EC’s response to CD40 ligation. 
HPV infection clearly attenuated the magnitude of the response to CD40 
ligation and the EC’s capacity to attract PBMCs. The fact that HPV attenuates 
CD40 signalling in ECs indicates the importance of the CD40-CD154 immune 
pathway in boosting cellular immunity within epithelia.
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CD40 is a 48 kDa transmembrane glycoprotein surface receptor also known 
as the tumour necrosis factor receptor superfamily member 5 (TNFRSF5). It is 
expressed at the cell surface of antigen presenting cells of the hematopoietic 
lineage, including B cells, dendritic cells (DCs), Langerhans cells and 
macrophages, and is also expressed by non-hematopoietic cells, such as 
endothelial cells (Hollenbaugh et al., 1995), fibroblasts (Fries et al., 1995; Yellin 
et al., 1995), smooth muscle cells and epithelial cells (Galy and Spits, 1992). 
The ligand for CD40 is the type II membrane protein CD40L (CD154), which 
is primarily expressed on activated CD4+ T helper cells. The CD40–CD154 
interaction plays a role in both cellular and humoral immune responses. Upon 
CD40 ligation, DCs mature and become activated to produce high levels of 
pro-inflammatory cytokines and chemokines, and upregulate MHC class II 
and co-stimulatory molecules such as CD80 and CD86. Together, these up-
regulated molecules facilitate effective priming of CD8+ T cells and stimulate 
activated CD8+ T cells to become cytotoxic effector cells (Ma and Clark, 
2009). In B cells, CD40 ligation induces immunoglobulin isotype switching 
and differentiation as well as inhibits apoptosis by upregulating anti-apoptotic 
genes like cIAPs, members of the BCL2 family and MYC (Kehry, 1996; Laman 
et al., 1996). Deregulation of CD40–CD154 interaction can lead to various 
clinical conditions (Peters et al., 2009), such as autoimmune diseases, multiple 
sclerosis, allograft rejections, intraepithelial pre-malignancies and inflammatory 
skin diseases such as psoriasis and subacute cutaneous lupus erythematosus 
(Caproni et al., 2007).
In the epidermis, CD40 is expressed at low levels by basal and para-basal 
layer epithelial cells (ECs). ECs upregulate CD40 expression when stimulated 
with IFNγ (Denfeld et al., 1996; Gaspari et al., 1996; Peguet-Navarro et al., 
1997), that normally is produced by effector cells of the innate immune system 
and by activated type 1 polarized (IFNγ-producing) CD40L-expressing CD4+ 
T-helper (Th1) cells that enter the skin (Swamy et al., 2010; van den Bogaard 
et al., 2013). Indeed, CD40 is highly expressed by ECs in T-cell infiltrated 
psoriatic lesions (Denfeld et al., 1996). A limited number of in vitro studies on 










































express ICAM-1 and secrete RANTES (CCL5), TNFα, IL-6, IL-8 and MCP-1 
(CCL2) (Companjen et al., 2002; Denfeld et al., 1996; Gaspari et al., 1996; 
Pasch et al., 2004; Peguet-Navarro et al., 1997). In addition, there is evidence 
that CD40-activated ECs stop proliferating and start differentiating (Concha 
et al., 2003; Grousson et al., 2000; Peguet-Navarro et al., 1997; Villarroel 
Dorrego et al., 2006). However, the full spectrum of effects mediated by CD40 
ligation on the response of ECs is still unknown.
The basal and parabasal layers ECs of squamous epithelia are a well-known 
target for different viruses (Andrei et al., 2010), including high-risk human 
papilloma virus (hrHPV). Chronic infections with hrHPV can last for many 
years, probably as a result of several sophisticated mechanisms employed 
by hrHPV to evade the hosts’ innate immune response (Karim et al., 2011; 
Karim et al., 2013; Reiser et al., 2011). Interestingly, an in vivo model for EC-
specific human-CD40 expression and activation showed that CD40 ligation 
on ECs enhanced DC migration and T cell priming in a mouse model (Fuller 
et al., 2002), suggesting that ECs boost the activity of cells from the adaptive 
immune system. HPV-specific cellular immunity, however, develops quite late 
and slowly during persistent HPV infections (van der Burg and Melief, 2011), 
posing the question if HPV may also impair pathways typically associated with 
activation of the adaptive immune response. 
To obtain a better understanding of the outcome between the interaction of 
epithelial cells and CD40 ligand-expressing CD4+ Th1 cells, we analysed the 
genome-wide expression profiles of CD40-stimulated undifferentiated primary 
ECs. We observed that ECs react in a very coordinated fashion to CD40 
ligation with the induction of mainly immune-related genes and the attraction 
of immune cells. The parallel analysis of hrHPV-infected primary ECs revealed 
that hrHPV did not grossly change the gene expression pattern but attenuated 
the magnitude of the CD40-stimulated immune response, resulting in an 
impaired immune cell attraction. These data strengthen the notion that the 
CD40-CD154 pathway plays an important role in protective epithelial immune 
responses.
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CD40 upregulation and functionality on epithelial cells
To study how ECs respond to CD40 ligation on a genome-wide scale, we 
mimicked the CD40 – CD154 interaction between ECs and IFNγ-secreting 
CD4+ T cells. Basal CD40 levels on cultured ECs are too low for efficient in 
vitro ligation with CD154, however ECs upregulate the expression of CD40 
when stimulated with IFNγ (Denfeld et al., 1996; Gaspari et al., 1996; Peguet-
Navarro et al., 1997). Therefore, we measured by flow cytometry the CD40 
expression on primary undifferentiated ECs stimulated with increasing 
concentrations of IFNγ for 72 hours. In line with previous reports, CD40 
expression was enhanced by IFNγ at all concentrations but became optimal at 
a concentration equal or more than 50 IU/ml IFNγ for the primary ECs obtained 
from 4 different healthy donors (Figure 1a and b). Therefore, this dose was 
used in our subsequent studies.
ECs were reported to secrete the pro-inflammatory chemokines IL8 (CXCL8) 
and RANTES (CCL5) upon CD40 ligation (Denfeld et al., 1996; Gaspari et al., 
1996; Pasch et al., 2004; Peguet-Navarro et al., 1997). Indeed, this was also 
observed for CD40 expressing ECs stimulated with CD154-expressing L-cells 
(CD40L) as compared to ECs cultured with control L-cells (Figure 1c and d), 
showing that our ECs expressed functionally active CD40. To determine the 
optimal time points for measuring the response of CD40-ligated ECs on a 
genome-wide scale, ECs were stimulated for up to 24 hours with CD40L and 
the peak gene expression of IL8 and RANTES was determined. The highest 
expression of IL8 was detected after 2 hours (Figure 1e), RANTES peaked 
after 24 hours of CD40 ligation (Figure 1f). We concluded that these two time-
points were most suited for studying early and late responses of ECs to CD40 
ligation.
Epithelial cells upregulate genes involved in immune signalling and 
proliferation after CD40 ligation
The effects of CD40 ligation on four freshly isolated uninfected primary 
EC cultures from healthy donors of foreskin, vaginal or cervical origin were 
studied by genome-wide expression profiling. These ECs are the natural 










































Figure 1. Epithelial cells produce cytokines and chemokines upon CD40 ligation
(a) CD40 upregulation on vaginal ECs upon stimulation with 0, 5, 10, 20, 50, 100 or 200 IU/ml IFNγ 
for 3 days. The height of the bars represent the CD40 mean fluorescence intensity as determined 
by flow cytometry. (b) Histogram of CD40 expression on vaginal ECs stimulated 3 days with 0 and 
50 IU/ml IFNγ. ELISA for IL8 (c) and RANTES (d) in cleared supernatants from IFNγ-pre-stimulated 
foreskin, vaginal and cervical EC cultures (n=5-12) co-cultured for 24 hours with Control or CD40L-
expressing L cells in presence of IFNγ. *** indicates p<0.0005. RT-qPCR of IL8 (e) and RANTES 
(f) expression by IFNγ-pre-stimulated vaginal ECs co-cultured with L-Control or L-CD40L cells in 
presence of IFNγ for 0, 1, 2, 3, 6, 12 or 24 hours. Gene expression was normalized using GAPDH 
as the calibrator gene. Fold changes over 0 hours co-culture were calculated and depicted. These 
data are representative for two to three independent experiments.
verified that the cells were activated via CD40 by confirming the increased 
expression of IL8 (2 hours) and RANTES (24 hours) (Supplemental figure S1) 
and subsequently subjected the samples to microarray analysis. Plots with 
microarray log2 intensities confirmed that IL8 and RANTES were upregulated 
after 2 and 24 hours, respectively (Supplemental figure S1) and confirmed the 
results obtained by quantitative PCR. 
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Using a False Discovery Rate (FDR) ≤0.05 the response to CD40 ligation 
in the four primary EC cultures was analyzed for genes that were at least two-
fold up- or down-regulated (log2-fold change filter (LogFC) ≥1) after 2 or 24 
hours of stimulation. The response obtained in EC cultures with control cells 
was used to correct the results obtained with CD40-ligated ECs for both the 
time of co-culture with L-cells and total cell density. In total 60 probes showed 
differential expression, representing 49 differentially expressed genes. Twenty-
four genes were upregulated after 2 hours and twenty-nine genes after 24 
hours, five genes were upregulated at both time points. One gene (MMP3) was 
significantly downregulated after 24 hours (Figure 2a, Supplemental table S1). 
By Ingenuity Pathways Analysis (IPA), we explored if these 49 differentially 
expressed genes were enriched for biological pathways and how they were 
connected. IPA enrichment analysis showed that the 24 genes differentially 
expressed after 2 hours CD40 ligation were mainly involved in ‘Cellular 
movement’, especially ‘Leukocyte migration’, ‘Cell-to-cell signalling and 
interaction’, and ‘Cell death and survival’. The highest upregulated gene was 
IL8, followed by CCL20, TNFAIP3, TNF, CXCL1, EFNA1 (TNFAIP4), IL36G 
and UBD, all having a LogFC≥2. At 24 hours post-stimulation the highest 
upregulated genes were CCL5 (RANTES), UBD, MMP9, C15orf48, SOD2, 
SerpinA3 and BIRC3 (cIAP2). The 30 genes differentially expressed at 
this time-point are involved in ‘Cellular movement’, ‘Cell death and survival 
pathways’, ‘Post-translational modification’, and ‘Protein degradation’. 
According to the IPA knowledge database 37 of these 49 differentially 
expressed genes formed a network (117 connections) including 23 out 
of the 24 genes differentially expressed after 2 hours, and 19 out of the 30 
genes differentially expressed after 24 hours (Figure 2b and c). The most 
interconnected genes within the center of the network were TNF and IL8, both 
upregulated only after 2 hours of CD40 ligation. These data indicated that 
CD40 stimulation of epithelial cells results in a very coordinated reaction; first 
highly connected immune-involved genes that are able to recruit leukocytes 
or regulate cytokine expression are upregulated, and subsequently genes 










































CD40 ligation amplifies immune cell attraction to epithelial cells. 
Many of the genes that were expressed by ECs after CD40 stimulation 
belonged to the ’Leukocyte migration‘ group, indicating that CD40-CD154 
interactions between T cells and ECs may serve primarily to boost the 
attraction of immune cells. Therefore, as a second functional assay to study 
the impact of CD40 ligation, we assessed the capacity of ECs to induce 
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Figure 2. CD40 stimulation stimulates a highly coordinated immune response by ECs 
(a) Venn diagram depicting the overlap between 49 signature genes (60 microarray probes) 
differentially expressed at 2 and/or 24 hours L-CD40L stimulation versus L-Control stimulation with 
adjusted p -value≤0.05 and absolute log2-fold change≥1. Networks with expression changes at 2 
(b) and 24 (c) hours were constructed of 49 connected CD40L signature genes using interaction 
data curated from literature and high-throughput screens by Ingenuity Pathways Analysis. The 
colours show the degree of upregulation (red) or downregulation (green) in the L-CD40L condition 
versus the L-Control condition. The genes meeting the adjusted p -value≤0.05 and absolute log2-
fold change≥1 thresholds, shown in the Venn diagram in (a), are indicated by blue borders.
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supernatants were isolated and used in a trans-well system with PBMCs 
seeded in the top wells. To confirm that CD40 ligation is associated with the 
production of chemokines belonging to the “Leukocyte migration” group, the 
production of the representative cytokines IL8 and RANTES were measured. 
Their increased secretions are representative for the production of several 
chemoattractants following CD40 stimulation (Figure 3a). Indeed, higher 
numbers of PBMCs migrated towards the supernatants from CD40-ligated ECs 
when compared to supernatants of control ECs (Figure 3b and c). Analysis 
of the fraction of lymphocytes and myeloid cells in the migrated PBMCs 
suggested that the myeloid fraction in the total pool of migrated PBMCs was 
slightly more increased (Figure 3b). These data indicate that CD40 stimulation 
of ECs mainly results in the secretion of pro-inflammatory cytokines that aid 
ECs in the attraction of PBMCs.
Figure 3. CD40 ligation induces immune cell migration towards epithelial cells
Example of a representative experiment of the (a) production of IL8 and RANTES in cleared 
supernatants of vaginal EC donors used for the migration assay by ELISA, and (b) PBMC 
migration towards these cleared supernatants from vaginal EC donors prepared for the migration 
assay. PBMC numbers were determined by flow cytometry in presence of FACS counting beads 
and subsequently gated on lymphocyte or monocyte fractions. Within the total cell numbers (total 
bar) the fractions of lymphocytes (white) and myeloid cells (black) are depicted. (c) Migration 
index of total PBMC towards indicated supernatants of ECs of  foreskin or vaginal origin of four 









































































































































Persistent infection with hrHPV attenuates the intensity of the CD40-
induced gene expression 
High-risk HPVs are known to deregulate the response of epithelial cells to 
TNF (Termini et al., 2008). In view of the cellular mediators shared between the 
TNF- and the CD40-pathway, we studied if a persistent infection with hrHPV 
influences the gene expression pattern of CD40-stimulated ECs by genome 
wide expression analysis. We confirmed the expression of CD40 after IFNγ 
stimulation at the cell surface of hrHPV-positive ECs as well as the expression 
of IL8 after 2 hours and RANTES after 24 hours of CD40 ligation (Supplemental 
figure S1a, b and c) and the secretion of these cytokines in the supernatant of 
hrHPV-infected ECs (Figure 5a). The gene expression profiles of four hrHPV-
positive primary EC cultures, stably harbouring HPV16 or HPV18 episomes, 
were compared with those of the four uninfected primary EC cultures. The 
expression of IL8 and RANTES of HPV-infected ECs after CD40-stimulation 
was verified by qPCR (Supplemental figure S1e). The log2 intensity plots of 
these genes as measured by microarray (Supplemental figure S1f), showed 
that the results obtained by both methods were comparable. 
We studied differential gene expression in HPV-positive epithelial cells after 
CD40 ligation. At 2 hours, HPV-positive ECs differentially expressed 13 genes, 
11 of which overlapped with the 24 genes differentially expressed in uninfected 
ECs (Figure 4a). At 24 hours, HPV-positive ECs differentially expressed 19 
genes, 10 of which overlapped with the 30 genes differentially expressed 
in uninfected ECs (Figure 4b). This was a first indication that HPV does not 
grossly alter the reaction to CD40. All differentially expressed genes, 65 in total, 
were analyzed by IPA and the resulting network (159 connections) was highly 
similar to the network of genes expressed by CD40-stimulated non-infected 
ECs (Supplemental figure S3, Supplemental table S1). There were no specific 
clusters of genes that were either up- or down-regulated in HPV-positive ECs 
but not in uninfected ECs (Supplemental figure S2), rather the expression 
intensities of the differentially expressed genes were attenuated in HPV-
positive ECs. Focusing on the immune-related genes (Figure 4c), revealed 
that the presence of hrHPV in ECs impaired the expression of twelve immune-
related genes after 2 hours of CD40 stimulation, whereas one gene (BDKRB1) 
was enhanced. After 24 hours of stimulation, hrHPV impaired the expression 
of eight genes and upregulated seven immune-related genes in ECs. A closer 
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look into the seven upregulated genes was carried out. Three genes, IL7R, 
LTB and SAA1, showed similar upregulation in the uninfected ECs but did 
not reach our significance and fold change thresholds (Supplemental figure 
S4). The remaining four genes, CXCL9, CXCL10, CXCL11 and RSAD2, were 
already strongly upregulated in uninfected ECs compared with HPV-positive 
ECs in response to the IFNγ pre-stimulation, and were not further increased 
by additional CD40 ligation (Supplemental figure S4). In HPV-positive ECs, 
CD40 ligation resulted in the upregulation of these genes to levels similar as in 
uninfected ECs (Supplemental figure S4). 
 
Figure 4. HPV infection results in an attenuated response of ECs to CD40 ligation
Venn diagrams showing the overlapping genes between ECs and HPV-positive ECs in their 
response to L-CD40L versus L-Control stimulation for 2 (a) and 24 (b) hours; significance thresholds 
as in Figure 2a, numbers in brackets represent unique genes. (c) Heat-map of differentially 
expressed immune-involved genes as determined by IPA. Expression ratios for each condition 
compared to the 0h time point per cell line were mean-centered and scaled over all conditions. 
The genes were hierarchically clustered using cosine similarity and average linking. Microarray 
intensities for CXCL9 (d), 10 (e) and 11 (f) represented in a box plot. (g) CXCL10 concentration 
as measured by ELISA in supernatants of 24 hours IFNγ-stimulated and L-Control or L-CD40L 
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hrHPV impairs CD40-ligation mediated immune cell attraction to epithelial 
cells. 
The T cell-attracting chemokines CXCL9, 10 and 11 are known to be 
induced by IFNγ in various cell types, including ECs (Kanda et al., 2007; Kanda 
and Watanabe, 2007; Kawaguchi et al., 2009; Ohta et al., 2008; Sauty et al., 
1999). Although CD40 stimulation salvaged the expression levels of CXCL9, 
CXCL10 and CXCL11 in HPV-positive ECs to similar levels found in non-
infected ECs (Figure 4d, e and f), ELISA assays showed that hrHPV-positive 
ECs still secreted lower levels of CXCL9 and CXCL10 than non-infected ECs 
(Figure 4g and not shown). On average the CD40-ligated HPV-positive ECs 
also produced lower amounts of IL8 and RANTES (Figure 5a) albeit that in 
some experiments the levels approached that of non-infected ECs. To obtain a 
broader view on the impact of HPV to CD40L-induced immune activation, also 
their capacity to attract PBMCs was tested. Notwithstanding the production 
of the earlier tested cytokines, no increased attraction of PBMCs to the 
supernatants of CD40L-stimulated HPV-positive ECs was observed (Figure 
5b and c). This indicates that also the production of other chemokines within 
the ‘Leukocyte migration’ group, those that are key in the attraction of PBMCs, 
must have been impaired in HPV-positive ECs. In independent experiments, 
the absolute numbers of migrated PBMCs differed per primary EC culture and 
PBMC donor used, however, the increase in PBMC attraction following CD40 
ligation was consistently and significantly higher in uninfected ECs (Figure 3c), 
but not in hrHPV+ ECs (Figure 5c). Together these data show that hrHPV does 
not grossly alter, but rather attenuates the intracellular response of epithelial 
cells to CD40 ligation, resulting in a hampered ability of the HPV-positive ECs 
to attract immune cells.
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Figure 5. HPV infection hampers the enhanced attraction of immune cells by CD40-
stimulated epithelial cells
(a) ELISA for IL8 and RANTES in cleared supernatants from IFNγ-pre-stimulated HPV-positive 
foreskin, vaginal and cervical EC cultures (n=5-12) co-cultured for 24 hours with Control or CD40L-
expressing L cells in presence of IFNγ. ** indicates p<0.005 using unpaired Welch corrected t-test. 
(b) Example of a representative experiment of the production of IL8 and RANTES in cleared 
supernatants of vaginal EC donors used for the migration assay by ELISA, and PBMC migration 
towards these cleared supernatants from vaginal EC donors prepared for the migration assay. (c) 
Migration index of total PBMC towards indicated HPV-positive foreskin, vaginal and cervical EC 




















































































































































































We studied the response of epithelial cells to CD40 ligation, a major immune 
trigger of B and T cell immunity, and a major cue for leukocyte migration 
towards the skin. Stimulation of ECs via CD40 resulted in a highly coordinated 
regulation of predominantly immune-related genes involved in the attraction, 
sustainment and amplification of adaptive immune responses as well as 
resulted in the attraction of immune cells. Interestingly, hrHPV infection did not 
qualitatively alter the gene expression profile of CD40-stimulated EC, instead 
the extent of the response was attenuated. The fact that HPV attenuates 
CD40 signalling in ECs indicates the importance of the CD40-CD154 immune 
pathway in boosting immunity in epithelia. 
Microarray expression studies showed that CD40 ligation of non-
hematopoietic cells, such as endothelial cells (Pluvinet et al., 2008), pancreatic 
cells (Klein et al., 2008), renal proximal tubule epithelial cells (Li and Nord, 
2005), smooth muscle cells (Stojakovic et al., 2007), microglia (Ait-Ghezala et 
al., 2005) and epithelial cells (this report), generally results in the upregulation 
of genes involved in immunity and inflammatory responses, cell fate and cell 
adhesion. The response of ECs to CD40 stimulation is alike that of muscle cells 
and pancreatic cells. Endothelial cells seem to have a broader response as 
they also upregulate genes involved in the viral immune surveillance system, 
e.g. the 2’-5’-oligoadenylate/RNase L system and guanylate-binding proteins 
(GBP1-4), potentially to keep the vasculature from harmful consequences 
and prevent the spread of systemic viral infection in the host (Pluvinet et al., 
2008). Epithelial cells are well equipped with viral sensors which can launch an 
antiviral response upon infection (Karim et al., 2011), and the CD40 pathway 
may help to establish efficient adaptive B and T cell immunity to expand the 
precision of protection after the initial innate immune cell response.
Interestingly, we found that late CD40-mediated responses in ECs involved 
the upregulation of the anti-apoptosis genes cIAP2 and BCL3 as well as the 
negative regulator of proliferation RARRES1. These observations may explain 
earlier findings that epithelial cells do not go into apoptosis but rather stop 
proliferating after CD40 ligation (Peguet-Navarro et al., 1997). We are currently 
exploring this further. The response of ECs to CD40 stimulation is paralleled by 
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B cells, which respond to CD40 ligation by preventing apoptosis through the 
upregulation of several anti-apoptotic genes, including cIAPs, MYC and BCL2 
members (Kehry, 1996; Laman et al., 1996). 
CD40 stimulation of dendritic cells (DCs) has been thoroughly studied as 
it plays a key role in the activation, maturation and T-cell priming capacity 
of DC. Upon CD40 stimulation DCs produce pro-inflammatory cytokines 
and chemokines, upregulate HLA class I and II as well as the co-stimulatory 
molecules CD86 and CD80 (Ma and Clark, 2009). This allows DC to convey 
the appropriate signals to T cells required for them to become effector cells. 
Candidate gene studies showed that ECs can express CD40, HLA class I and 
II, CD86, but not CD80 (Black et al., 2007; Ortiz-Sanchez et al., 2007; Romero-
Tlalolini et al., 2013) as well as the co-stimulatory molecules CD83 and ICAM-
1 and a number of cytokines after being exposed to IFNγ and CD40 activation 
(Companjen et al., 2002; Denfeld et al., 1996; Gaspari et al., 1996; Pasch et 
al., 2004; Peguet-Navarro et al., 1997). This may allow CD40-stimulated ECs 
to process and present antigen to effector/memory CD4+ and CD8+ T cells 
(Black et al., 2007) as well as to amplify immune responses. However, it is 
not likely that such activated ECs function as professional antigen-processing 
cells (APCs) as it was shown that CD40L-activated ECs fail to prime allogeneic 
T-cell reactions, underlining the difference of CD40 ligation on professional 
and non-professional APCs (Grousson et al., 2000). 
The pathogenesis of skin diseases such as psoriasis is based on an influx 
of immune cells into psoriatic lesions where cytokine levels are elevated. Our 
results sustain the notion that tissue-infiltrating T cells may exacerbate the 
disease via the production of IFNγ and the interaction with CD40 on ECs. The 
resulting cytokines may amplify the immune response via the attraction of more 
immune cells thereby forming a loop in EC stimulation and cytokine production. 
The involvement of ECs in the exacerbation of disease has been questioned 
as CD40 expression on epithelial cells in vivo can be weak (Ohta and Hamada, 
2004). However, we and others have shown that CD40 expression is rapidly 
upregulated (at least temporarily) under the influence of physiological doses of 
IFNγ and thus weak steady state expression does not preclude robust action 










































HPV attenuates the extent of the epithelial cells’ response to CD40 ligation, 
suggesting that HPV interferes with CD40 ligation-induced signal transduction 
and subsequent canonical and non-canonical NFκB activation (Gommerman 
and Summers deLuca, 2011; Hostager and Bishop, 2013; Ma and Clark, 2009). 
Several research groups have reported that hrHPV deregulates NFκB activation 
following the activation of pattern recognition receptors (PRRs) (Karim et al., 
2011; Reiser et al., 2011) or the TNF receptor (Termini et al., 2008). We and 
others have previously shown that hrHPV attenuates the PRR-induced (Karim 
et al., 2013) and TNFR-induced (Takami et al., 2007) NFκB pathway activation 
by upregulating UCHL1, a cellular deubiquitinase/E3 ligase. Therefore, the 
expression of UCHL1, or other non-identified modulators, may explain how 
HPV mediates the attenuation of CD40 ligation-induced gene expression. 
Surprisingly, PBMCs were more attracted to supernatants of non-CD40-
ligated HPV-positive ECs than to uninfected ECs, implying that supernatants 
of HPV-positive ECs contain higher cytokine levels than supernatants of 
uninfected ECs. However, not only in this study, but also in previous studies 
(Karim et al., 2011; Karim et al., 2013), we observed that hrHPV generally 
downregulates the basal expression and secretion of many pro-inflammatory 
cytokines. Recent literature has shown that metabolism intermediates can 
act as inflammatory signals (Tannahill et al., 2013), implying that a simple 
difference in cell density can affect basal immune cell attraction. Although 
both the HPV-positive and uninfected ECs have been treated exactly the 
same throughout the experiments, HPV-positive ECs proliferate faster than 
uninfected ECs, and as such the supernatants may contain higher metabolite 
levels to mediate CD40-independent PBMC attraction towards HPV-positive 
cells. In hrHPV+ ECs, despite the higher basal numbers of attracted PBMC, 
CD40 stimulation does not result in an increased number of PBMC attracted 
whereas in uninfected ECs this is the case.
In conclusion, epithelial cells show a coordinated response to CD40 ligation, 
mainly inducing the expression of genes involved in leukocyte migration, 
cell-to-cell signalling and interaction, as well as cell death and survival. 
HPV attenuates the extent of CD40-signalling, resulting in lower amounts of 
chemoattractants produced and a failure to enhance immune cell migration. 
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These data suggest that progression of inflammatory skin diseases may be 
driven by highly programmed immune activation scenario’s in epithelial cells, 










































MATErIALS & METHodS 
Ethics Statement
The use of discarded human foreskin, cervical and vaginal keratinocyte 
tissues to develop cell lines for these studies was approved by the Institutional 
Review Board at the Pennsylvania State University College of Medicine and 
by the Institutional Review Board at Pinnacle Health Hospitals. The Medical 
Ethical Committee of the Leiden University Medical Center approved the 
human tissue sections (healthy foreskin, healthy cervix, HPV16- or 18-positive 
cervical neoplasias) used for staining. All sections and cell lines were derived 
from discarded tissues and de-identified, therefore no informed consent was 
necessary.
Cell culture
Primary cultures of human epithelial cells (ECs) were established from 
foreskin, vaginal and cervical tissues as previously described (Karim et al., 
2011) and grown in keratinocyte serum-free medium (K-SFM; Medium 154 
supplemented with HKGS kit, Invitrogen, Breda, The Netherlands). The cells 
morphologically and biochemically resembled ECs in both monolayer and 
organotypic raft cultures, as indicated by keratin expression, hemidesmosome 
and desmosome structures, and ability to differentiate to full thickness 
epithelium (McLaughlin-Drubin et al., 2004; Meyers et al., 1997). Using the 
microarray data, the cells were verified to express high levels of keratin 
(KRT) 10, 14, 17, and 19, and low levels of KRT18 (Supplemental figure 
S5), a signature specific for keratinocytes (Bononi et al., 2012; Moll et al., 
2008). Epithelial cell lines stably maintaining the full episomal HPV genome 
following electroporation (HPV-positive ECs) were grown in monolayer culture 
using E medium in the presence of mitomycin C treated J2 3T3 feeder cells 
(McLaughlin-Drubin et al., 2004; Meyers et al., 1997) for two passages and 
were then adapted to K-SFM for one passage before experimentation. Since 
primary ECs have a limited life span and do not survive long enough to undergo 
a mock electroporation procedure similar to that used to obtain HPV-positive 
ECs, normal undifferentiated primary epithelial cells were used as control. J2 
3T3 mouse fibroblasts and L-cells were cultured in Dulbecco’s modified Eagle’s 
medium supplemented with 8% fetal bovine serum, 2mM l-glutamine and 1% 
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penicillin-streptomycin (complete DMEM medium) (Gibco-BRL, Invitrogen, 
Breda, The Netherlands). 
CD40 ligation on epithelial cells
Uninfected ECs or HPV-positive ECs were seeded at 1.5x105 cells/well in 
6-wells plates in K-SFM and allowed to attach for 24 hours, after which the cells 
received fresh K-SFM containing 50 IU/ml IFNγ (Immunotools, Friesoythe, 
Germany) for 72 hours. Control or CD40L-expressing L-cells were harvested, 
irradiated (4800 – 5200 rad) and resuspended in K-SFM containing 50 IU/
ml IFNγ. L-cells were co-cultured with ECs in a 1:1 ratio for indicated time 
points, after which the supernatant was collected, the L-cells were removed 
and the RNA of the ECs was harvested. CD40L expression and functionality of 
the L-cells were validated as was the percentage of residual L-cells after co-
culture (<1%; data not shown).
RNA expression analyses and ELISA
Total RNA was isolated using the NucleoSpin RNA II kit (Machery-Nagel, 
Leiden, The Netherlands) according to the manufacturer’s instructions. Total 
RNA (0.5 – 1.0 µg) was reverse transcribed using the SuperScript III First 
Strand synthesis system from Invitrogen. TaqMan PCR was performed using 
TaqMan Universal PCR Master Mix and pre-designed, pre-optimized primers 
and probe mix for RANTES (CCL5), IL8, and GAPDH (Applied Biosystems, 
Foster City, USA). Threshold cycle numbers (Ct) were determined using the 
CFX PCR System (BioRad, Veenendaal, The Netherlands) and the relative 
quantities of cDNA per sample were calculated using the ΔΔCt method using 
GAPDH as the calibrator gene. ELISA’s for CCL2, RANTES, IL8 and CXCL10 
were performed according to the manufacturer’s instruction (PeproTech, 
London, United Kingdom). Statistical differences in cytokine production were 
evaluated using a Welch-corrected t-test, correcting for possible unequal 
variances between the groups.
Gene expression profiling
Four primary EC cultures were used, HVK (vaginal), HCK (cervical), HFK_1 
and HFK_2 (both foreskin), as well as four EC cell lines stably maintaining 










































and HPV16 (foreskin). Cells were harvested at five conditions: 0 hrs, 2 hrs and 
24 hrs of 50 IU/ml IFNγ in combination with either L-Control or L-CD40L cells. 
Stimulated 2 hrs and 24 hrs samples were generated in duplo. Total RNA for 
these 72 samples was isolated as stated above. The microarray experiment 
was performed by ServiceXS according to their protocols (ServiceXS, Leiden, 
The Netherlands). Briefly, total RNA was analyzed by Lab-on-a-Chip. All RNA 
showed a RIN score of >9.5. Total RNA was reverse-transcribed, amplified and 
biotin labeled. cRNA was hybridized to Illumina Human HT-12 v4 BeadChips in 
a randomized fashion and scanned with the Illumina iScan. Samples passed 
quality control as assessed by Illumina GenomeStudio software. Values for 
missing bead types on the HumanHT-12 BeadChip were estimated using the 
k-Nearest Neighbor (k-NN) algorithm (Troyanskaya et al., 2001) in Illumina’s 
BeadStudio Gene Expression Module (v3.3+). 
Microarray data preprocessing 
The expression array data was analyzed using R2.14.1 and Bioconductor 
(R Development Core Team, 2008). The data were normalized using the 
Bioconductor package lumi version 2.6.0 (Du et al., 2008; Lin et al., 2008), 
resulting in log2-transformed normalized intensities. Quality control plots were 
generated using limma version 3.10.2 (Smyth, 2005) and mpm version 1.0-
22 (Wouters, 2011; Wouters et al., 2003). Uninfected and HPV-positive ECs 
correlated in separate blocks, and within these blocks the next level similarity 
was at the cell line level, and within cell line at the exposure level, indicating 
that the data behaved as expected (data not shown). All microarray data is 
MIAME compliant and the raw data has been deposited in the MIAME compliant 
database Gene Expression Omnibus with accession number GSE54181, as 
detailed on the MGED Society website http://www.mged.org/Workgroups/
MIAME/miame.html.
Analysis of differentially gene expression
Differentially expressed genes were identified using maanova version 
1.24.0 (Wu; Wu et al., 2003). We modelled the cell line effect as a random 
effect and indicated the technical replicates in the model. We calculated 
test statistics for testing the null hypotheses of no difference in expression 
between L-CD40L-stimulated and L-Control stimulated cells at 2 and 24 
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hours for uninfected epithelial cells as well as HPV-positive epithelial cells for 
each gene. We applied the Fs statistic, which uses a shrinkage estimator for 
gene-specific variance components based on the James-Stein estimator. To 
correct for multiple testing, false discovery rates (FDR) were calculated using 
the q-value method (Dabney; Storey, 2002). The ranking and selection of the 
genes is based on these adjusted p-values.
Functional genomics analyses
The networks were constructed using Ingenuity Pathways Analysis (IPA 
version 17199142; Ingenuity systems, Inc., www.ingenuity.com). The list of 
differentially expressed genes was used to generate the network. All edges 
are supported by at least one reference from the literature, from a textbook, or 
from canonical information stored in the Ingenuity Pathway Knowledge Base. 
Boxplot representations
Boxplots are drawn as a box, containing the 1st quartile up to the 3rd 
quartile of the data values. The median is represented as a line within the 
box. Whiskers represent the values of the outer 2 quartiles. These whiskers 
are however maximized at 1.5 times the size of the box (a.k.a. inter quartile 
distance). If 1 or more values outside of the whiskers are present, then this 
is indicated with a single mark ‘o’ next to the implicated whisker. Plots were 
generated using the webtool R2: microarray analysis and visualization platform 
(http://r2.amc.nl).
Migration assays
IFNγ pre-stimulated (HPV-positive) ECs were co-cultured with L-cells for 3 
hours after which the L-cells were removed. The ECs were cultured a subsequent 
24 hours with fresh K-SFM. Cleared (HPV-positive) EC supernatants were 
added to the lower compartment of a transwell plate (Corning). The upper 
compartment was filled with PBMCs, which were allowed to migrate for 16 
hours, after which the cells in the lower compartment were counted by flow 
cytometry in the presence of counting beads (Invitrogen) according to the 
manufacturer’s protocol. Myeloid cells and lymphocytes were differentiated 
by their respective size in the FSC/SCC plot (data not shown). To normalize 










































index was calculated of the total number of PBMCs migrated towards the 
indicated stimulation over the medium control. The statistical significance of 
differences in migration towards supernatants of EC cultures stimulated with 
CD40L or control L-cells was assessed using a paired t-test.
Flow cytometry
Expression of CD40 on epithelial cells was analyzed by flow cytometry 
using FITC-coupled Mouse-anti-human CD40 (BD Biosciences, Breda, The 
Netherlands). 50.000 cells/live gate were recorded using the BD FACS Calibur 
with Cellquest software (BD Bioscience) and data were analyzed using Flowjo 
(Treestar, Olten, Switzerland). 
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The interferon-related developmental regulator 
(IFRD1) is used by Human papillomavirus (HPV) 
to suppress NFκB activation
Tummers B, Goedemans R, Pelascini LPL, Jordanova ES, van Esch EMG, 
Meyers C, Melief CJM, Boer JM, van der Burg SH.












































High-risk human papillomaviruses (hrHPVs) infect keratinocytes and 
successfully evade host immunity despite the fact that keratinocytes are well 
equipped to respond to innate and adaptive immune signals. Using non-
infected and freshly established or persistent hrHPV-infected keratinocytes we 
show that hrHPV impairs the acetylation of NFκB/RelA K310 in keratinocytes. 
As a consequence, keratinocytes display a decreased pro-inflammatory 
cytokine production and immune cell attraction in response to stimuli of the 
innate or adaptive immune pathways. HPV accomplishes this by augmenting 
the expression of interferon-related developmental regulator 1 (IFRD1) in an 
EGFR-dependent manner. Restoration of NFκB/RelA acetylation by IFRD1 
shRNA, Cetuximab treatment or the HDAC1/3 inhibitor entinostat increases 
basal and induced cytokine expression. Similar observations are made in 
IFRD1-overexpressing HPV-induced cancer cells. Thus, our study reveals an 
EGFR-IFRD1 mediated viral immune evasion mechanism which can also be 
exploited by cancer cells. 
 101










































High-risk human papillomaviruses (hrHPVs) are absolutely species-specific 
small double-stranded DNA viruses that primarily target undifferentiated 
keratinocytes (KCs) of squamous epithelia via micro-wounds and abrasions. 
HrHPV infections can last up to two years despite viral activity in infected 
KCs, the expression of viral antigens and the presence of KC-expressed 
pattern recognition receptors (PRR)1-4 that should lead to activation of innate 
and adaptive immune responses. This indicates that hrHPV has evolved 
mechanisms to transiently evade innate and adaptive immune mechanisms. 
Ultimately, the majority of hrHPV infections are controlled by the immune 
system, in particular by type 1 (IFNγ and TNFα) cytokine producing T cells5. In 
case of immune failure, hrHPV causes cancer of the anogenital and/or head 
and neck regions6.
Upon infection, hrHPV alters the immune-related response of keratinocytes 
to various innate and adaptive immune stimuli resulting in impaired expression 
of interferon (IFN)-stimulated genes (ISG), interferon regulatory transcription 
factor (IRF)-induced genes, and NFκB-induced genes3,7-12, suggesting that HPV 
hampers STAT1 and NFκB activation. HPV-infected KCs display downregulated 
basal expression of STAT1 and lowered STAT1 protein levels explaining 
the impaired expression of ISGs13-16. Furthermore, soon after infection HPV 
upregulates the cellular deubiquitinase ubiquitin carboxy-terminal hydrolase 
L1 (UCHL1) to impair PRR-induced NFκB activation by upstream interference 
with TRAF3, TRAF6 and NEMO8. The upregulation of UCHL1 however can 
not explain how the virus manages to suppress the KCs response to adaptive 
immune signals12. In addition, repressing UCHL1 does not fully restore NFκB 
signaling via PRR8, suggesting that one or more additional mechanisms are in 
play to suppress NFκB signaling. 
In this study, we analyze NFκB activation and subsequent cytokine/
chemokine production following IFNγ and TNFα stimulation in uninfected and 
HPV-infected primary KCs. Our study reveals that RelA-acetylation, needed for 
NFκB transcriptional activity17, is impaired in hrHPV-infected KCs. The HPV-
induced overexpression of the cellular protein interferon-related developmental 










































HDAC1 and/or 3. The augmented expression of IFRD1 is the result of the 
HPV-mediated upregulation of EGFR. Blocking of IFRD1 protein expression 
by shRNA or via the anti-EGFR antibody Cetuximab restores NFκB/RelA-
mediated cytokine expression. Additional data suggest that IFRD1 may have 
a similar role in suppressing cytokine/chemokine production in HPV-positive 
cervical cancer cells. 
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HrHPV impairs the KCs cytokine response to IFNγ and TNFα
To evaluate if the KCs immune response following the exposure to IFNγ 
and/or TNFα is attenuated by hrHPV, we utilized a system that resembles 
the natural infection with hrHPV as closely as possible. Primary KCs stably 
maintaining the hrHPV genome as episomes (hrHPV+ KCs) display similar 
growth properties as non-transfected KC, and upon culture in organotypic raft 
cultures, mimic HPV infection in vivo as documented by genome amplification, 
late gene expression, and virus production during the differentiation dependent 
life cycle of HPV18-20.
The presence of HPV type 16 (HPV16) was clearly associated with an 
impaired capacity to respond to IFNγ and to TNFα as shown by the lower mRNA 
expression and production of the IFNγ and/or TNFα-induced pro-inflammatory 
cytokines CCL2, RANTES (CCL5), IL8 and the chemokines CXCL9, 10 and 
11 by KCs (Figure 1AB). Not only did the presence of HPV16 impair the 
production of cytokines, also the migration of peripheral blood mononuclear 
cells (PBMCs) to supernatants of IFNγ and TNFα-stimulated HPV16+ KCs 
was greatly impaired (Figure 1C). 
These data suggest that hrHPV, besides impairing the innate immune 
response of KCs8, also suppresses the KCs response to the adaptive immune 
signals provided by IFNγ and TNFα. 
The hrHPV-mediated deregulated expression of STAT113-16 may explain the 
impaired cytokine expression by hrHPV-positive KCs upon IFNγ stimulation 
but not the impaired response to TNFα (IL8) or to IFNγ and TNFα (RANTES). 
Previously, we showed that hrHPV hampers phosphorylation of the NFκB 
subunit RelA (p65) upon stimulation with the innate pattern recognition 
receptor (PRR) ligand Poly(I:C)8. As TNFα stimulation rapidly induces the 
phosphorylation of RelA17, we tested whether hrHPV also hampers rapid TNFα-
induced RelA phosphorylation by stimulating KCs and HPV16+ KCs for 0, 5, 
15 or 30 minutes with TNFα. Western blotting showed that RelA was rapidly 
phosphorylated similarly in KCs and HPV16+ KCs, peaking after 15 minutes of 
TNFα stimulation (Figure 1D), indicating that the impairment of TNFα-induced 










































after short-term TNFα stimulation. Activated NFκB translocates to the nucleus 
where it is modified to regulate its DNA binding ability and transcriptional activity. 
Acetylation of the RelA subunit at lysine 310 (K310) is crucial in this process17. 
Strikingly, acetylated RelA K310 protein levels were lower in the HPV16+ KCs 
than in uninfected KCs, both in the absence of stimulation and after short-term 
TNFα stimulation (Figure 1D). The lowered basal RelA K310 acetylation state 
was verified in three independent primary KC and two independent HPV16+ KC 
cultures (Figure 1E), indicating that HPV hampers the activity of NFκB already 
at steady-state levels. This was also reflected in a lowered basal cytokine gene 
expression in unstimulated HPV16+ KCs (Figure 1F). 












































































































































































































































































































(A) RT-qPCR of CCL2, RANTES, IL8 and CXCL9 expression by 24 hours control, IFNγ and/or 
TNFα-stimulated undifferentiated KCs or HPV16+ KCs. Gene expression was normalized using 
GAPDH as the calibrator gene. Fold changes over control-stimulated undifferentiated KCs were 
calculated and depicted. 
(B) ELISA for CCL2, RANTES, IL8 and CXCL9 in cleared supernatants of 24 hours control, IFNγ 
and/or TNFα-stimulated undifferentiated KCs or HPV16+ KCs.
(C) PBMCs migration towards cleared supernatants of 24 hours control, IFNγ and/or TNFα-
stimulated KCs or HPV16+ KCs. A representative example of 3 different donors is shown.
(D) RelA phosphorylation, acetylation and total levels in KCs and HPV16+ KCs stimulated with 
TNFα for 0, 5, 15 and 30 minutes.
(E) RelA acetylation and total levels at steady-state in three human primary keratinocyte (KC) 
donor pools originating from human foreskin keratinocytes (HFK), human vaginal keratinocytes 
(HVK) or human cervical keratinocytes (HCK) and two HPV16+ genome transfected primary KC 
pools foreskin (HFK16) or vaginal (HVK16) origin.
(F) RT-qPCR of CCL2, RANTES, IL8 and CXCL9 in HPV16+ KCs and KCs. Gene expression 
was normalized using GAPDH as the calibrator gene. Gene expression in HPV16+ KCs was 
standardized over KCs. 
All data are representative for at least three independent experiments. Error bars indicate SD. 
P-values were determined via Welch-corrected unpaired t tests. * p<0.05, ** p<0.01, *** p<0.001.
HrHPV upregulates IFRD1 to impair RelA K310 acetylation
Acetylation of RelA K310 can be regulated by the lysine acetyl transferases 
(KAT) PCAF (KAT2B), CBP (KAT3A), p300 (KAT3B), and TIP60 (KAT5) as well 
as the histone deacetylases (HDAC) 1 and 317. Since our results imply that 
hrHPV has a mechanism either to deacetylate or impair the acetylation of RelA, 
we screened our validated micro array data12 for genes involved in regulating 
RelA K310 acetylation. High-risk HPV did not significantly influence histone 
deacetylase (HDAC1 to 11) or sirtuin (SIRT1 to 7) expression (Figure 2A). The 
only significantly upregulated gene was the lysine acetyl transferase CREBBP 
(KAT3A), confirming previous observations stating that HPV upregulates 
CREBBP to enhance expression from episomal DNA21,22. However, as CREBBP 
acetylates RelA its upregulation can not explain the observed lower levels of 
RelA K310 acetylation in hrHPV-infected KCs under steady state conditions. 
Interestingly, the micro array data also showed the upregulation of Interferon-
related developmental regulator 1 (IFRD1) (Figure 2B), which previously was 
shown to complex HDAC123 and HDAC3 to RelA causing its deacetylation at 
lysine 310 in the mouse myoblast cell line C2C1224. We hypothesized that 
it may fulfill a similar role in human KCs. Therefore, RT-qPCR and western 
blotting was used to confirm that IFRD1 gene expression (Figure 2C left) 
and IFRD1 protein levels (Figure 2D left) were elevated in two independent 










































siRNA against HPV16 E2 in HPV16+ KCs resulted in the reduction of HPV16 
E1, E2, E6 and E7 expression (Supplementary Fig. S1), IFRD1 mRNA (Figure 
2C middle) and IFRD1 protein levels (Figure 2D middle), indicating that the 
augmented IFRD1 levels in hrHPV+ KCs are the result of the presence of 
hrHPV. Reciprocally, when undifferentiated KCs were infected with native 
HPV16 virions, IFRD1 mRNA (Figure 2C right) and IFRD1 protein (Figure 
2D right) levels were clearly enhanced after 2 days of infection. Furthermore, 
immunohistochemistry of HPV-positive vulvar lesions revealed the presence 
of IFRD1 in the nuclei of cells positive for HPV16 E2 (reflecting HPV-infected 
cells)25, but not in the nuclei of already transformed KCs (identified through p16 
staining25,26 or undifferentiated (E2 and p16 negative) healthy tissue (Figure 
2E).
We then asked if the hrHPV-induced increased levels of IFRD1 affected RelA 
K310 acetylation also in human undifferentiated KCs. Indeed, when lentivirus-
delivered siRNA against IFRD1 was used to lower IFRD1 protein expression 
a concomitant increase in the steady-state levels of acetylated RelA K310 in 
HPV16+ KCs was seen when compared to control knock-down HPV16+ KCs 
(Figure 2F; Supplementary Fig. S2A). Furthermore, a small increase in total 
RelA protein levels was observed. The gain in acetylated RelA K310 translated 
into a higher basal expression and secretion of cytokines in IFRD1 KD cells 
(Figure 2GHI), indicating that IFRD1 is involved in the deregulation of steady-
state inflammatory gene expression levels in HPV16+ KCs. The dampening 
effect of IFRD1 on the NFκB-regulated cytokine expression became even more 
apparent when the KCs were stimulated with both IFNγ and TNFα (Figure 2HI). 
The cytokine levels produced after stimulation were much higher in IFRD1 
KD HPV16+ KCs than in control KD HPV16+ KCs. Moreover, IFRD1 knock-
down augmented the ability of HPV16+ KCs to attract PBMCs (Figure 2J). The 
main results were recapitulated in HPV18-infected KCs (Supplementary Fig. 
S3), suggesting that IFRD1 may form a general mechanism exploited by any 
hrHPV type.
As the effect of IFRD1 occurred directly at the level of RelA, the influence 
of IFRD1 on the response of HPV16+ KCs to Poly(I:C) stimulation, previously 
shown by us to be impaired in hrHPV-infected KCs8, was also tested. Knock-
down of IFRD1 resulted in an enhanced expression of CCL2, RANTES, IL8 
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Figure 2: HrHPV upregulates IFRD1 to impair RelA K310 acetylation and basal cytokine 
expression
Microarray intensities for (A) all KATs, HDACs and SIRTs, and (B) IFRD1 in 4 independent KCs 
and 4 independent hrHPV+ KCs represented in a box plot. The box contains the 1st quartile up 




























































































Figure 2, Tummers et al. 
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(C) IFRD1 mRNA expression of one representative control primary KC culture and two HPV16+ 
KC culture (left panel), in HFK16 cells transfected with siControl or siHPV16 (middle panel) and in 
primary KCs that are either mock infected or infected with native HPV16 virions (right panel), as 
measured by RT-qPCR.
(D) IFRD1 protein expression in three human primary keratinocyte (KC) donor pools originating 
from human foreskin keratinocytes (HFK), human vaginal keratinocytes (HVK) or human cervical 
keratinocytes (HCK) and two HPV16+ genome transfected primary KC pools foreskin (HFK16) or 
vaginal (HVK16) origin (left panel) in HFK16 cells transfected with siControl or siHPV16 (middle 
panel) and in primary KCs that are either mock infected or infected with native HPV16 virions (right 
panel), as measured by western blot. 
(E) Immunohistochemical staining for IFRD1, HPV16 E2, p16 and negative antibody control 
of a vulvar intraepithelial neoplasia (VIN) lesion, one representative donor of two shown. 
Counterstaining was done using hematoxylin. Arrows indicate sites where E2 and nuclear IFRD1 
are expressed. Scale bar 500 μm. 
(F) IFRD1, RelA K310 acetylation and total RelA levels in 24 hours non- or IFNγ and TNFα-
stimulated control or IFRD1 knock-down (KD) HPV16+ KCs. 
(G) RT-qPCR of CCL2, RANTES, IL8 and CXCL9 expression in steady-state control or IFRD1 KD 
HPV16+ KCs.
(H) RT-qPCR of CCL2, RANTES, IL8 and CXCL9 expression in 24 hours non- or IFNγ and/or 
TNFα-stimulated control or IFRD1 KD HPV16+ KCs.
(I) ELISA for CCL2, RANTES, IL8 and CXCL9 in cleared supernatants of 24 hours non- or IFNγ 
and/or TNFα-stimulated control or IFRD1 KD HPV16+ KCs.
(J) PBMCs migration towards cleared supernatants of 24 hours non- or IFNγ and TNFα-stimulated 
control or IFRD1 KD HPV16+ KCs. A representative example of 3 different donors is shown.
These data are representative for at least three independent experiments. Error bars indicate SD. 
P-values were determined via Welch-corrected unpaired t tests. * p<0.05, ** p<0.01, *** p<0.001.
and CXCL9 following PRR stimulation with Poly(I:C) (Supplementary Fig. S4). 
Thus, hrHPV upregulates the expression of IFRD1 soon after infection, 
thereby effectively decreasing the basal levels of transcriptionally active RelA 
and as a consequence the levels of pro-inflammatory cytokines induced via 
various innate and adaptive immune-mediated NFκB stimulatory pathways. 
 
EGFR-signaling mediates the increased expression of IFRD1 
Growth factors, such as NGF, FGF or EGF, have previously been shown to 
induce the expression of Tis family genes, which also includes IFRD1, in rat 
neocortical astrocytes and chromaffin cell line PC12, mouse C243 and IEC-18, 
and mammary epithelial cells27. The hrHPV E5 protein is known to affect different 
aspects of EGF receptor (EGFR) signaling and expression28. Verification of 
EGFR expression in our model showed that EGFR mRNA expression (Figure 
3A) and membrane-bound protein expression (Figure 3B) were higher in 
hrHPV+ KCs than in non-infected KCs. When we transfected cDNA for E2 (as 
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control), E5 or a mix of several other HPV proteins, only E5 enhanced EGFR 
expression (Figure 3C). To test if EGFR signaling had a similar effect on IFRD1 
in human primary KCs, the clinically used anti-EGFR antibody Cetuximab was 
employed to block EGFR signaling. Indeed, IFRD1 expression decreased 
in HPV16+ KCs, but not in uninfected KCs, when treated with Cetuximab 
(Figure 3D). IFRD1 protein levels also decreased dose-dependently in both 
Cetuximab-treated non-infected KCs and HPV16+ KCs (Figure 3E). Notably, 
the isotype control antibody Rituximab (anti-CD20) had no effect (Figure 
3DE). Thus EGFR signaling does not only induce IFRD1 gene expression but 
also stabilizes IFRD1 protein levels. Relative density analysis revealed that 
in Cetuximab-treated HPV16+ KCs the protein levels of IFRD1 decreased 
while concomitantly the levels of RelA K310 acetylation increased in a dose-
dependent fashion. Total RelA levels were unaffected (Figure 3F). These results 
indicated that the HPV-induced expression of IFRD1 is mediated via the EGFR 
signaling pathway and implied that Cetuximab treatment may enhance the 
hrHPV+ KCs pro-inflammatory cytokine response to immune stimuli. Indeed, 
upon IFNγ and TNFα stimulation Cetuximab-treated HPV16+ KCs expressed 
higher levels of indicated cytokine genes than Rituximab-treated cells (Figure 
3G) as well as higher levels of secreted cytokines (Figure 3H). In uninfected 
KCs treatment with Cetuximab decreased the already low levels of IFRD1 
protein, and although this led to increased cytokine gene expression after 
IFNγ and TNFα-stimulation no additional increase in the already high levels 
of secreted cytokines was observed (Figure 3GH). The absence of cytokine 
production in Cetuximab-treated HPV16+ KC and uninfected KCs that were 
not stimulated with IFNγ and TNFα shows that binding of Cetuximab to EGFR 
per se does not result in the stimulation of cytokine production (Figure 3GH). 
As EGFR signaling involves the downstream partners PI3K, mTOR, MEK1, 
RAF and JNK, we selectively inhibited these proteins using small molecule 
inhibitors in HPV16+ KCs and observed that selective inhibition of mTOR 
(Rapamycin), MEK1 (PD98059) and RAF (GW5074) but not PI3K (LY94002) 
or JNK (SP60025) resulted in decreased expression of IFRD1 (Figure 3I). Thus 
EGFR-mediated upregulation of IFRD1 is fundamental to the impaired NFκB-























































































































































































































































































































































































































































































































Figure 3: Blocking EGFr-signaling decreases IFrd1 levels and rescues cytokine production 
by hrHPV+ KCs 
(A) Microarray intensities for EGFR in KCs (n=4) and hrHPV+ KCs (n=4) represented in a box plot.
(B) Histogram of EGFR surface protein expression on KCs and HPV16+ KCs as determined by 
flow cytometry.
(C) RT-qPCR of EGFR expression in KCs transfected with cDNA for E2, E5, E1+E2+E6+E7, or 
empty control.
(D) RT-qPCR of IFRD1 expression in KCs and HPV16+ KCs treated for 72 hours with 0, 0.1, 1 or 
10 µg ml-1 anti-EGFR or anti-CD20.
(E) IFRD1, RelA K310 acetylation and total RelA levels in KCs and HPV16+ KCs treated for 72 
hours with 0, 0.1, 1 or 10 µg ml-1 anti-EGFR or anti-CD20.
(F) Quantified protein levels of IFRD1, RelA K310 acetylation, and RelA over β-Actin in HPV16+ 
KCs treated for 72 hours with 0, 0.1, 1 or 10 µg ml-1 anti-EGFR (western blot 2D). The expression 
levels of the 0 µg/ml treated HPV+ KCs were set as 100%. 
(G) RT-qPCR of CCL2, RANTES, IL8 and CXCL9 expression in 24 hours non- or IFNγ and TNFα-
stimulated, anti-CD20 or anti-EGFR-treated HPV16+ KCs (left) and KCs (right).
(H) ELISA for CCL2, RANTES, IL8 and CXCL9 in cleared supernatants of 24 hours non- or IFNγ 
and TNFα-stimulated, anti-CD20 or anti-EGFR-treated HPV16+ KCs (left) and KCs (right). 
(I) RT-qPCR of IFRD1 expression in HPV16+ KCs treated with inhibitors of PI3K (LY94002, 25 
μM), mTOR (Rapamycin, 50 nM), MEK1 (PD98059, 50 μM), RAF (GW5074, 20 μM), and JNK 
(SP60025, 20 μM). Gene expression was normalized using GAPDH as the calibrator gene. Fold 
changes over Control were calculated and depicted.
These data are representative for at least three independent experiments, except for figure H 
which was performed once. Error bars indicate SD. P-values were determined via Welch-corrected 
unpaired t tests. * p<0.05, ** p<0.01, *** p<0.001.
HdAC1/3 inhibition stimulates cytokine production 
IFRD1-mediated RelA deacetylation required the recruitment of HDAC1 
and/or 3 to the RelA-IFRD1 complex in the mouse myoblast cell line C2C1224. 
To test if these HDACs played a similar role in human hrHPV+ KCs, the 
effect of HDAC inhibition was tested in HPV16+ KCs and non-infected KCs. 
A dose-titration of the HDAC1/3-specific inhibitor entinostat (MS-275), and the 
prototypic pan-HDAC inhibitors trichostatin A (TSA), sodium butyrate (NaBu) 
and the FDA-approved vorinostat (SAHA) was performed to study RelA K310 
acetylation. All pan-HDAC inhibitors increased RelA acetylation in KCs at the 
lowest concentration used (Figure 4A & Supplementary Fig. S2B) but at higher 
doses cells suffered from toxic effects as observed by microscopy. However, 
HPV16+ KCs did survive entinostat treatment, and clearly this HDAC1/3 inhibitor 
increased RelA K310 acetylation in HPV16+ KCs (Figure 4A & Supplementary 
Fig. S2B). This indicated that HDAC1 and/or 3 are indeed specifically involved 
in the deacetylation of RelA in hrHPV+ KCs. Entinostat treatment of HPV16+ 
KCs not only restored RelA K310 acetylation but also released the suppressive 
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Figure 4: Entinostat treatment reveals involvement of HdAC1/3 in relA deacetylation in 
HPV16+ KCs 
(A) RelA K310 acetylation and total RelA levels in KCs and HPV16+ KCs treated with decreasing 
doses of entinostat (40, 20, 10 and 2 µM), SAHA (10, 5 and 1 µM), TSA (5, 1 and 0.333 µM) or 
NaBu (10, 5 and 1 mM). 
RT-qPCR of CCL2, RANTES, IL8 and CXCL9 expression in steady-state (B) or 24 hours non- or 
IFNγ and TNFα-stimulated (C) control or entinostat (10 µM) pre-treated HPV16+ KCs.
(D) Total RelA levels and RelA K310 acetylation non- or entinostat-treated control or RelA knock-
down (KD) HPV16+ KCs. 
(E) RT-qPCR of CCL2, RANTES, IL8 and CXCL9 expression in 24 hours non- or IFNγ and TNFα-
stimulated non- or entinostat-treated control or RelA knock-down (KD) HPV16+ KCs. 
(F) RT-qPCR of EGFR expression in KCs and HPV16+ KCs treated with increasing doses of 
entinostat (0, 10 or 40 µM). Gene expression was normalized using GAPDH as the calibrator 
gene.
(G) IFRD1 in control or entinostat (10 µM) pre-treated HPV16+ KCs.
(H) RT-qPCR of IFRD1 and EGFR expression in control or IFRD1 KD HPV16+ KCs. Gene 
expression was normalized using GAPDH as the calibrator gene.
Histogram (I) and Geo mean (J) of EGFR expression on control or IFRD1 KD HPV16+ KCs as 
determined by flow cytometry. SEM of two independent experiments. 
These data are representative for at least two independent experiments. Error bars indicate SD. 
P-values were determined via Welch-corrected unpaired t tests. * p<0.05, ** p<0.01, *** p<0.001. 
higher basal expression for 3 out of 4 tested cytokines when compared to their 
untreated counterparts (Figure 4B). Moreover, when stimulated with IFNγ and 
TNFα both KCs and HP16V+ KCs displayed a higher expression of CCL2, IL8 
and CXCL9, although the expression of RANTES was abrogated (Figure 4C). 
To confirm the involvement of RelA in this process, RelA was knocked-down 
in HPV+ KCs (Figure 4D), after which the cells were treated with entinostat 
and stimulated with IFNy and TNFa. Indeed, RelA acetylation and cytokine 
production was increased in the control knock-down cells after stimulation 
with IFNy and TNFa when treated with entinostat (Figure 4DE). However, 
when RelA was knocked-down in HPV16+ KCs, the cytokine expression was 
abrogated despite treatment with entinostat (Figure 4E). 
Previously, it was shown that HDAC inhibition abrogates EGFR 
expression29,30, indicating that EGFR expression is dependent on acetylation 
events. Indeed, entinostat treatment dose-dependently abrogated EGFR 
expression in hrHPV+ KCs, but did not influence the expression in KCs (Figure 
4F). Furthermore, entinostat treatment resulted in a reduced level of IFRD1 
protein in hrHPV+ KCs (Figure 4G), which made us wonder if IFRD1 could 
regulate EGFR expression. Therefore, IFRD1 was knocked-down in hrHPV+ 










































of membrane-bound EGFR than control-treated hrHPV+ KCs (Figure 4IJ), 
indicating that IFRD1 can control EGFR expression. 
 
Figure 5: role of IFrd1 in hrHPV+ cervical cancer cells
(A) IFRD1, RelA acetylation and total RelA levels at steady-state in three KC donors and three 
HPV16-induced CxCa lines.














































































































































































































































































































































































































































































































































steady-state control or IFRD1 KD Caski cells.
(C) RT-qPCR of IFRD1, CCL2, RANTES, IL8 and CXCL9 expression in 24 hours non- or IFNγ and 
TNFα-stimulated control or IFRD1 KD Caski cells.
(D) Histogram of EGFR expression on three HPV16-induced CxCa lines.
(E) Geo mean of EGFR expression on KCs and CxCa as determined by flow cytometry. SEM of 
two independent experiments.
(F) RT-qPCR of CCL2, RANTES, IL8 and CXCL9 expression in 24 hours non- or IFNγ and TNFα-
stimulated anti-CD20 or anti-EGFR-treated Caski cells.
(G) IFRD1 and RelA K310 acetylation status in Caski cells treated for 72 hours with 0, 1 or 10 µg 
ml-1 anti-EGFR (Cetuximab) or anti-CD20 (Rituximab).
(H) RT-qPCR of IFRD1 expression in KCs and Caski cells treated for 72 hours with 0, 0.1, 1 or 10 
µg ml-1 anti-EGFR or anti-CD20.
(I) RT-qPCR of CCL2, RANTES, IL8 and CXCL9 expression in 24 hours non- or IFNγ and TNFα-
stimulated control (DMSO) or entinostat-treated Caski cells.
(J) Schematic representation of IFRD1-mediated RelA (de-)acetylation. I) In KCs, RelA acetylation 
is positively regulated by KATs, resulting in the production of pro-inflammatory cytokines. HDACs 
may suppress this process. II) In HPV+ KCs, elevated EGFR levels can induce the expression of 
IFRD1, which can mediate RelA deacetylation by forming a bridge between RelA and HDAC1 and/
or 3, hampering pro-inflammatory gene expression. III) Interfering with EGFR signaling (1 and 2) 
or HDAC function (3) may lower IFRD1 levels, restoring the RelA acetylation balance, augmenting 
pro-inflammatory gene expression. 
Error bars indicate SD. P-values were determined via Welch-corrected unpaired t tests. * p<0.05, 
** p<0.01, *** p<0.001.
IFRD1 hampers the response of cancer cells to IFNγ and TNFα
To evaluate if an increased expression of IFRD1 could also play a role in 
HPV16-induced squamous cell carcinoma, we analyzed the cell line Caski, as 
well as the two early passage cervical cancer cell lines, CSCC1 and CSCC731. 
IFRD1 protein expression differed between the cell lines (Figure 5A), but was 
increased in Caski and CSCC1 when compared to normal KCs. RelA K310 
acetylation was lower in all three cervical cancer cell lines than in uninfected 
KCs (Figure 5A & Supplementary Fig. S2C). For the Caski and CSCC1 lines 
this may be explained by the presence of upregulated IFRD1. However, 
the lack of RelA K310 acetylation in the CSCC7 line indicates that besides 
IFRD1 also other mechanisms can alter the acetylation of RelA K310 in these 
squamous cancer cells. 
Because IFRD1 was upregulated in the Caski and CSCC1 cells we studied the 
effects of IFRD1 using these cell lines. IFRD1 knock-down in the CSCC1 cells 
did not alter basal cytokine expression levels (Supplementary Fig. S5A), but 
IFRD1 knock-down in the Caski cells resulted in a direct increase of the basal 
expression levels of CCL2 and RANTES (Figure 5B). Furthermore, both cell 










































when IFRD1 was knocked-down as compared to their control knock-down 
counterparts (Figure 5C and Supplementary Fig. S5B). 
CSCC1 and Caski cells express EGFR (Figure 5D) at a level that is similar 
to that of uninfected KCs (Figure 5E). However the downstream signaling 
pathway is known to be constitutively higher in HPV-induced cancer cells32. As 
a consequence, the treatment of Caski and CSCC1 cancer cells with the anti-
EGFR antibody Cetuximab resulted in a higher production of IFNγ and TNFα-
induced cytokines than when the cancer cells were treated with the control 
anti-CD20 antibody Rituximab (Figure 5F and Supplementary Fig. S5C). The 
enhanced response to IFNγ and TNFα was associated with a concomitant 
decrease in IFRD1 protein levels (Figure 5G), but not mRNA expression (Figure 
5H), upon EGFR blockade. Similarly, treatment of Caski and CSCC1 cancer 
cells with entinostat resulted in a higher production of CCL2, IL8 and CXCL9 
by the cancer cells when stimulated with IFNγ and TNFα than DMSO carrier 
control treated cells (Figure 5I and Supplementary Fig. S5D). Congruent with 
our earlier observations, RANTES levels diminished after entinostat treatment. 
These results suggest that IFRD1 may also play a role in suppressing the 
response of cancer cells to immune stimuli such as IFNγ and TNFα. 
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Using a unique in vitro model we here show that hrHPV infection leads 
to the upregulated expression of endogenous IFRD1 to deregulate the K310 
acetylation of NFκB/RelA. As a result hrHPV-infected KCs display an impaired 
production of pro-inflammatory cytokines and chemokines, and a reduced 
capacity to attract immune cells. The increased expression of IFRD1 in hrHPV+ 
KCs is mediated by EGFR signaling via mTOR, RAF and/or MEK1. Knock-
down of IFRD1 with siRNA or indirectly via blockade of EGFR with the clinically 
used EGFR-specific antibody Cetuximab, resulted in decreased IFRD1 mRNA 
and protein levels, increased NFκB/RelA K310 acetylation and enhanced 
expression and production of pro-inflammatory cytokines and chemokines 
by hrHPV+ KCs. The use of entinostat indicated that HDAC1 and/or 3 are 
involved in lowering K310 acetylation of NFκB/RelA. These conclusions are 
schematically represented in figure 5J. 
EGFR activation on epithelial cells has been shown to result in a decreased 
production of CCL2, RANTES and CXCL10 and increased production of 
IL8. Inhibition of EGFR signaling with blocking antibodies or tyrosine kinase 
inhibitors can reverse the effect on these cytokines as well as result in an 
increased epithelial immune infiltrate in vivo33-35. Interestingly, virus-induced 
EGFR-activation has been implicated as novel mechanism for respiratory 
viruses to suppress antiviral host responses33. The exact underlying mechanism 
on EGFR-mediated immune suppression remained unclear, albeit that ERK1/2 
signaling was shown to be involved in regulating cytokine production and skin 
inflammation36. Using the EGFR blocking antibody Cetuximab in the absence 
of an additional EGFR stimulus such as TGFα we found similar effects on 
the cytokine production of HPV16+ KCs. In KCs the expression of EGFR and 
IFRD1 are tightly linked as EGFR inhibition reduced the expression and protein 
levels of IFRD1, via mTOR, RAF and/or MEK1, but not PI3K or JNK. This fits 
with the involvement of ERK1/2 in regulating cytokine production (Pastore et 
al., 2005) since RAF and MEK1 are just upstream of these kinases. Based 
on our data, the previously observed EGFR activation-induced suppression of 
cytokine production and immune cell infiltration of epithelia can be explained 










































data suggest that EGFR-driven overexpression of IFRD1 may also play a role 
in deregulating NFκB-signaling in HPV-induced tumor cells. Knock-down of 
IFRD1 results in an increased production of pro-inflammatory cytokines and 
chemokines by tumor cells when stimulated with IFNγ and TNFα. Furthermore, 
blocking of the EGFR by Cetuximab resulted in a decrease of IFRD1 protein 
levels as well as increased cytokine production. The HPV oncoproteins are 
also known to directly intervene with NFκB signaling. Studies with transfected 
or transformed cells – resembling protein expression in tumor cells – show 
that E6 and/or E7 proteins inhibit basal and TNFα-inducible NFκB activity37 by 
influencing NFκB localization38,39 and activation40-43.
Studies in immunosuppressed patients and healthy individuals show a key 
role for the adaptive immune response, in particular that of a strong type 1 
(IFNγ and TNFα)-associated HPV early antigen-specific T cells in the protection 
against progressive disease5. This notion is sustained by the clinical responses 
of patients treated with HPV-specific therapeutic vaccines5. Ample reasons, 
therefore, for HPV to also develop strategies preventing KCs to respond to 
these cytokines. Our data shows that HPV deploys multiple strategies to 
interfere with induced RelA-associated NFκB signaling. HPV utilizes the cellular 
deubiquitinase UCHL1 to interfere with TRAF3, TRAF6 and NEMO function8 
and here we show that HPV also upregulates the expression of endogenous 
IFRD1 to deregulate the K310 acetylation of NFκB. Furthermore, the E7 protein 
of hrHPV has been shown to bind HDAC1 and prevent acetylation of histones, 
thereby suppressing TLR9 signaling44, but E7 can also displace HDACs 
resulting in enhanced hypoxia-inducible factor 1α transcriptional activity45. It 
is not unusual for viruses to target NFκB activation46,47, and hampering RelA 
acetylation is a common strategy. For instance, the N-terminus of the orf virus 
(ORFV) protein 002 inhibits acetylation of RelA by blocking phosphorylation 
of RelA S276 and subsequent recruitment of acetylases p300 and CBP48, and 
the A238L protein of African swine fever virus (ASFV) hampers RelA K310 
acetylation by inhibiting RelA-p300 interaction49. We here postulate that hrHPV 
does not hamper KATs in acetylating RelA, but rather recruits a mediator to 
enhance HDAC-mediated RelA deacetylation. Together with our observation 
that HPV lowers basal cytokine expression in resting KCs due to the presence 
of IFRD1, we suggest that impairment of immune driven RelA-associated 
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NFκB-responsive gene expression is crucial for the virus to persist. This viral 
strategy has not been reported before, but as discussed above may also be 
employed by respiratory viruses that activate EGFR33. 
All together, our data indicate that HPV upregulates EGFR to drive IFRD1 
expression as a tool to decrease basal and adaptive-immune system driven 
cytokine expression. This may allow hrHPV to evade the host’s immune 
response. It is highly likely that this mechanism plays a role in other viral 












































The use of discarded human foreskin, cervical and vaginal keratinocyte 
tissues to develop cell lines for these studies was approved by the Institutional 
Review Board at the Pennsylvania State University College of Medicine and 
by the Institutional Review Board at Pinnacle Health Hospitals. The Medical 
Ethical Committee of the Leiden University Medical Center approved the 
human tissue sections (healthy foreskin, healthy cervix, HPV16- or 18-positive 
cervical neoplasias) used for staining. All sections and cell lines were derived 
from discarded tissues and de-identified, therefore no informed consent was 
necessary.
Cell culture
Primary cultures of human epithelial keratinocytes (KCs) were established 
from foreskin, vaginal, vulva and cervical tissues as previously described3 and 
grown in keratinocyte serum-free medium (K-SFM; Medium 154 supplemented 
with HKGS kit, Invitrogen, Breda, The Netherlands). KCs stably maintaining 
the full episomal HPV genome following electroporation (HPV-positive KCs) 
were grown in monolayer culture using E medium in the presence of mitomycin 
C (Sigma-Aldrich) treated J2 3T3 feeder cells19,20 for two passages and were 
then adapted to K-SFM for one passage before experimentation. J2 3T3 
mouse fibroblasts, Caski, CSCC1, CSCC7 and SiHa cell-lines were cultured 
in Iscove’s modified Dulbecco’s medium supplemented with 8% fetal bovine 
serum, 2 mM l-glutamine and 1% penicillin-streptomycin (complete IMDM 
medium) (Gibco-BRL, Invitrogen, Breda, The Netherlands). 
HPV16 infection of non-infected keratinocytes
Primary basal layer human foreskin keratinocytes were seeded 75.000 cells 
per well to 24-wells plates and allowed to attach for 48 hours. Cells received 
fresh medium (Mock infected) or medium containing native HPV16 isolated 
from raft cultures at MOI 100 for 24 hours. Cells were washed and harvested 
for either RT-qPCR or western blotting analysis.
IFrd1 and relA knock-down in HPV-positive KCs
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shRNA’s were obtained from the MISSION TRC-library of Sigma-Aldrich 
(Zwijndrecht, The Netherlands). The MISSION shRNA clones are sequence-
verified shRNA lentiviral plasmids (pLKO.1-puro) provided as frozen bacterial 
glycerol stocks (Luria Broth, carbenicillin at 100 µg/ml and 10% glycerol) in E. 
coli for propagation and downstream purification of the shRNA clones. pLKO.1 
contains the puromycin selection marker for transient or stable transfection. 
The construct against IFRD1 (NM_001550) was TRCN0000156194: 
CCGGCAGTTCTGAAACAGTTTCTTTCTCGAGAAAGAAACTGTTTCA-
GAACTGTTTTT, RelA (NM_021975) was TRCN0000014687: CCGGCCT-
GAGGCTATAACTCGCCTACTCGAGTAGGCGAGTTATAGCCTCAGGTTTTT, 
and the control was: SHC004 (MISSION TRC2-pLKO puro TurboGFP 
shRNA Control vector): CCGGCGTGATCTTCACCGACAAGATCTCGAGA-
TCTTGTCGGTGAAGATCACGTTTTT. HPV16-positive KCs at ~60% conflu-
ence were transduced with lentivirus at MOI 5-10 over night, after which me-
dium was replaced. At least 72 hours post-transduction cells were stimulated 
as indicated and target gene expression was assayed by RT-qPCR or western 
blotting.
HPV knock-down in HPV-positive KCs
Silencer Select siRNA against HPV16 E2 (AACACUACACCCAUAGUACAUtt) 
was designed using siRNA Target Finder software (Ambion, Invitrogen). Blast 
search revealed that the designed E2 siRNA does not match with the known 
human transcriptome. E2 and Negative control #2 (NC2) siRNA (sequence not 
provided by manufacturer) were purchased from Ambion. HPV16+ KCs were 
transfected with 50 nM siRNA E2 or NC2 using Lipofectamine 2000 (Invitrogen) 
according to the manufacturer’s instructions. 48 hours post-transfection cells 
were harvested or stimulated as indicated and target gene expression was 
assayed by RT-qPCR or western blotting.
Transfection of HPV genes into non-infected keratinocytes
Non-infected primary KCs were seeded 50.000 cells per well to 24-wells 
plates and allowed to attach over night. Cells were transfected with 500 ng DNA 
using Lipofectamine (invitrogen), according to the manufacturer’s instructions. 
Cells were maintained in E-medium. 72 hours post-transfection cells were 











































Subconfluent cells were cultured in respective complete growth medium in 
presence of Cetuximab (0.1, 1 or 10 µg ml-1; Merck serono), Rituximab (0.1, 
1 or 10 µg ml-1; Roche), rapamycin (50 nM; Calbiochem), PD98059 (50 µM; 
Sigma-Aldrich), GW5074 (20 µM; Sigma-Aldrich), LY94002 (25 µM; Sigma-
Aldrich) or SP60025 (20 µM; Sigma-Aldrich). Medium was changed every 2-3 
days. After at least 72 hours, cells were stimulated as indicated and target 
gene expression was assayed by RT-qPCR or western blotting.
HdAC inhibition
Subconfluent cells were cultured in presence of a dilution series of 
entinostat (MS-175; 40, 20, 10 and 2 µM; Selleckchem BioConnect), vorinostat 
(suberoylanilide hydroxamic acid (SAHA); 10, 5 and 1 µM; Sigma-Aldrich), 
trichostatin A (TSA; 5, 1 and 0.333 µM; Sigma-Aldrich) or Sodium Butyrate 
(NaBu; 10, 5 and 1 mM; Sigma-Aldrich) in respective complete growth medium 
over night. Medium was changed for respective complete growth medium, 
cells were stimulated as indicated and target gene expression was assayed by 
RT-qPCR or western blotting. Since treatment with 10 µM entinostat showed 
a good increase in RelA K310 acetylation without signs of toxicity, subsequent 
experiments were performed using this dose.
Migration assays
(HPV-positive) KCs were stimulated as indicated for 24 hours. Cleared 
(HPV-positive) KC supernatants were added to the lower compartment of a 
transwell plate (Corning). The upper compartment was filled with peripheral 
blood mononuclear cells (PBMCs) isolated from buffy coats (Sanquin). 
PBMCs were allowed to migrate for 16 hours, after which the cells in the lower 
compartment were counted by flow cytometry in the presence of counting 
beads (Invitrogen) according to the manufacturer’s instructions. Myeloid cells 
and lymphocytes were differentiated by their respective size in the FSC/SSC 
plot (data not shown). 
RNA expression analyses and ELISA
The microarray data12 is accessible in the Gene Expression Omnibus 
database (accession number GSE54181). Plots were generated using the 
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webtool R2: microarray analysis and visualization platform (http://r2.amc.nl). 
Total RNA was isolated using the NucleoSpin RNA II kit (Machery-Nagel, 
Leiden, The Netherlands) according to the manufacturer’s instructions. Total 
RNA (0.5 – 1.0 µg) was reverse transcribed using the SuperScript III First Strand 
synthesis system from Invitrogen. TaqMan PCR was performed using TaqMan 
Universal PCR Master Mix and pre-designed, pre-optimized primers and probe 
mix for CCL2, RANTES (CCL5), IL8 (CXCL8), CXCL9 and GAPDH (Applied 
Biosystems, Foster City, USA). Threshold cycle numbers (Ct) were determined 
using the CFX PCR System (BioRad, Veenendaal, The Netherlands) and the 
relative quantities of cDNA per sample were calculated using the ΔΔCt method 
using GAPDH as the calibrator gene. 
ELISA’s for CCL2, RANTES, IL8 and CXCL9 were performed according to 
the manufacturer’s instruction (PeproTech, London, United Kingdom). 
Flow cytometry
Expression of EGFR on keratinocytes was analyzed by flow cytometry using 
PE-coupled Mouse-anti-human EGFR (1:20, BD Biosciences, Breda, The 
Netherlands). Per live gate, 50.000 cells were recorded using the BD FACS 
Calibur with Cellquest software (BD Bioscience) and data were analyzed using 
Flowjo (Treestar, Olten, Switzerland). 
Western blot analysis 
For Western blotting, polypeptides were resolved by SDS–polyacrylamide 
gel electrophoresis (SDS–PAGE) and transferred to a nitrocellulose membrane 
(Bio-Rad, Veenendaal, The Netherlands). Immunodetection was achieved with 
anti-p65 (1:1000, sc-372, Santa Cruz), anti-phospho-p65 (Ser536; 1:1000, 
#3033 Cell Signaling Technology (CST)), anti-acetyl-p65 (Lys310; 1:1000, 
#3045 CST), anti-IFRD1 (1:400, T2576 Sigma-Aldrich), β-actin (1:10,000, 
Sigma-Aldrich) primary antibodies, and HRP-coupled anti-mouse (1:5000; 
CST) and HRP-coupled anti-rabbit (1:5000, CST) secondary antibodies. 
Chemoluminescence reagent (Bio-Rad) was used as substrate and signal was 
scanned using the Chemidoc and accompanying Software (Bio-Rad) to quantify 
the intensity of the bands as a measure of the amount of protein of interest in 
the blot. The relative amount was determined by calculating the ratio of each 











































4 µm formalin fixed, paraffin embedded tissue sections from two random 
VIN cases were deparaffinised and rehydrated using graded concentrations 
of ethanol to distilled water. Endogenous peroxidise activity was blocked 
with 0.03% H2O2/MeOH for 20 minutes. Antigen retrieval was performed in 
boiling EDTA buffer (pH 9.0) for 12 minutes. After 2 hours of cooling down 
to RT, slides were washed twice in distilled water and twice in phosphate-
buffered saline (PBS). Subsequently, incubation was performed overnight at 
room temperature with the primary IFRD1 antibody (T2576 Sigma-Aldrich; 
1:500 in PBS containing 1% bovine serum albumin); p16 (CINTEC, diluted 
1:5) and E2 (1:50) (provided by Dr. F. Thierry). Second, sections were 
incubated with BrightVision polyhorseradish peroxidase anti-mouse/rabbit/
rat IgG (Immunologic BV, Duiven, The Netherlands) for 30 minutes at room 
temperature. Washing between incubations was performed 3 times for 5 minutes 
in PBS. Immune complexes were visualized by applying a 0.05M tris-HCl 
buffer (pH 7.6) containing 0.05% of 3,3′-diamino-benzidine-tetrahydrochloride 
and 0.0018% of H2O2. After 10 minutes, the reaction was stopped by rinsing 
with demineralised water. Finally, the tissue sections were counterstained with 
Mayer’s haematoxylin before addition of a cover slip.
Statistical analysis
Statistical analysis were performed using GraphPad InStat version 3.00. 
P-values were determined via Welch-corrected unpaired t tests. * p<0.05, ** 
p<0.01, *** p<0.001.
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Figure S1: HPV16 E gene expression after HPV16 knock-down in HPV16+ KCs
E1, E2, E6 and E7 expression in HFK16 cells transfected with siControl or siHPV16.
Error bars indicate SD. P-values were determined via Welch-corrected unpaired t tests. ** p<0.01, 
*** p<0.001
Supplem ntary Figure 1: HPV16 E gene xpression after HPV16 knock-down in HPV16+ KCs
E1, E2, E6 and E7 expression in HFK16 cells transfected with siControl or siHPV16. 
Error bars indicate SD. P-values were determined via Welch-corrected unpaired t tests. ** p<0.01, *** p<0.001
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Figure S2: Western blot quantifications of RelA acetylation
(A) Quantified protein levels of RelA K310 acetylation and RelA over β-Actin in 24 hours non- or 
IFNγ and TNFα-stimulated control or
IFRD1 knock-down (KD) HPV16+ KCs. The expression levels of the control-treated HPV16+ KCs 
were set as 100%.
(B) Quantified protein levels of RelA K310 acetylation over β-Actin in KCs and HPV16+ KCs 
treated with decreasing doses of
entinostat (40, 20, 10 and 2 μM), SAHA (10, 5 and 1 μM), TSA (5, 1 and 0.333 μM) or NaBu (10, 5 
and 1 mM) (western blot Figure 4A).
The expression levels of the control-treated HPV16+ KCs were set as 100%.
(C) Quantified protein levels of RelA K310 acetylation and RelA over β-Actin in in three KC donors 
and three HPV16-induced CxCa lines.




Suppl mentary Figur  2: Western blot quantifica ions of relA acetylation
(A) Quantified protein levels of RelA K310 acetylation and RelA over β-Actin in 24 hours non- or IFNγ and TNFα-stimulated control or 
IFRD1 knock-down (KD) HPV16+ KCs. The expression levels of the control-treated HPV16+ KCs were set as 100%.
(B) Quantified protein levels of RelA K310 acetylation over β-Actin in KCs and HPV16+ KCs treated with decreasing doses of 
entinostat (40, 20, 10 and 2 µM), SAHA (10, 5 and 1 µM), TSA (5, 1 and 0.333 µM) or NaBu (10, 5 and 1 mM) (western blot Figure 4A). 
The expression levels of the control-treated HPV16+ KCs were set as 100%.
(C) Quantified protein levels of RelA K310 acetylation and RelA over β-Actin in in three KC donors and three HPV16-induced CxCa lines. 
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Figure S3: RelA acetylation, IFRD1 expression and IFRD1 knock-down effects in HPV18+ 
KCs
(A) RelA phosphorylation, acetylation and total levels in KCs and HPV18+ KCs stimulated with 
TNFα for 0, 5, 15 and 30 minutes.
(B) IFRD1 levels in three KC donor pools, two HPV16+ KC lines and one HPV18+ KC line.
(C) RelA acetylation levels in control or IFRD1 knock-down HPV18+ KCs.
(D) RT-qPCR of RANTES expression in 24 hours non- or IFNγ and TNFα-stimulated control or 
IFRD1 knock-down HPV18+ KCs.
(E) ELISA for RANTES, CXCL9 and CXCL11 in cleared supernatants of 24 hours non- or IFNγ and 
TNFα-stimulated control or IFRD1
knock-down HPV18+ KCs.
Supplementary Figure 3: RelA acetylation, IFRD1 expression and IFRD1 knock-down effects in HPV18+ KCs
(A) RelA phosphorylation, acetylation and total levels in KCs and HPV18+ KCs stimulated with TNFα for 0, 5, 15 and 30 minutes.
(B) IFRD1 levels in three KC donor pools, two HPV16+ KC lines and one HPV18+ KC line.
(C) RelA acetylation levels in control or IFRD1 knock-down HPV18+ KCs. 
(d) T-qPCR of RANTES expression in 24 hours n n- or IFNγ and TNFα-stimulated control or IFRD1 knock-down HPV18+ KCs.
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Figure S4: IFRD1 impairs Poly(I:C)-induced cytokine expression
RT-qPCR of CCL2, RANTES, IL8 and CXCL9 expression in 24 hours non- or Poly(I:C)-stimulated 
control or IFRD1 knock-down HPV16+ KCs.
These data are representative for at least two independent experiments. Error bars indicate SD.
P-values were determined via Welch-corrected unpaired t tests. * p<0.05, ** p<0.01, *** p<0.001.
Supplementary Figure 4: IFRD1 impairs Poly(I:C)-induced cytokine expression
RT-qPCR of CCL2, RANTES, IL8 and CXCL9 expression in 24 hours non- or Poly(I:C)-stimulated control or IFRD1 knock-down HPV16+ KCs.
These data are representative for at least two independent experiments. Error bars indicate SD. 



























































































































Figure S5: The effects of IFrd1 knock-down, anti-EGFr and entinostat on CSCC1
(A) RT-qPCR of IFRD1, CCL2, 
RANTES, IL8 and CXCL9 
expression in steady-state control 
or IFRD1 knock-down CSCC1 cells.
(B) RT-qPCR of CCL2, RANTES 
and IL8 expression in 24 hours 
non- or IFNγ and TNFα-stimulated 
control or IFRD1 knock-down 
CSCC1 cells.
(C) RT-qPCR of CCL2, RANTES 
and CXCL9 expression in 24 hours 
non- or IFNγ and TNFα-stimulated 
anti-CD20 or anti-EGFR-treated 
CSCC1 cells.
(D) RT-qPCR of CCL2, RANTES 
and CXCL9 expression in 24 hours 
non- or IFNγ and TNFα-stimulated 
DMSO (control) or entinostat-
treated CSCC1 cells.
These data are representative for at 
least two independent experiments. 
Error bars indicate SD. P-values 
were determined via Welch-
corrected unpaired t tests.
* p<0.05, ** p<0.01, *** p<0.001.
Supplementary Figure 5: The effects of IFrd1 knock-down, anti-EGFr and entinostat on CSCC1
(A) RT-qPCR of IFRD1, CCL2, RANTES, IL8 and CXCL9 expression in steady-state control or IFRD1 knock-down CSCC1 cells.
(B) RT-qPCR of CCL2, RANTES and IL8 expression in 24 hours non- or IFNγ and TNFα-stimulated control or IFRD1 knock-down CSCC1 cells.
(C) RT-qPCR of CCL2, RANTES and CXCL9 expression in 24 hours non- or IFNγ and TNFα-stimulated anti-CD20 or anti-EGFR-treated CSCC1 cells.
(d) RT-qPCR of CCL2, RANTES and CXCL9 expression in 24 hours non- or IFNγ and TNFα-stimulated DMSO (control) or entinostat-treated CSCC1 cells.
These data are representative for at least two independent experiments. Error bars indicate SD. P-values were determined via Welch-corrected unpaired t tests.































































































































































































































































Supplementary Figure 6: Full Western Blot data















































































Figure 4d RelA-AcrelA β-actin
Figure 5G β-actinIFrd1
Figure 5B IFrd1 β-actin
Supplementary Figure 6: Full Western Blot data Continued
RelA-AcRelA-p relA β-actinFigure 5A
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Figure 3A RelA-AcRelA-p relA β-actin
Supplementary
Figure 3C RelA-Ac β-actin
Figure S6: Full Western Blot data Continued 
The full blots for all Western blot pictures. Above the blot the used target is indicated. The black 
boxes represent the depicted parts of the blot.
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Human papillomavirus (HPV) downregulates the 
expression of IFITM1 to resist the anti-
proliferative effects of IFNγ and TNFα
Bart Tummers, Edith M.G. van Esch, Wenbo Ma, Renske Goedemans, 
Laetitia P.L. Pelascini, Roser Vilarrasa-Blasi, Sofia Torreggiani, Craig Meyers, 












































Basal keratinocytes (KCs) are responsible for renewal of the epithelium 
and are the target cells for high risk human papilloma viruses (hrHPVs) which 
may cause KCs to become transformed. The immune system has developed 
means to counteract infections through several mechanisms, including the 
suppression of viral spread through the proliferation of infected cells via the 
production of the effector cytokines IFNγ and TNFα. These two cytokines are 
known to synergize in the suppression of KC proliferation. Using an unique 
system for freshly established or persistent hrHPV infection, we show that 
hrHPV renders KCs resistant to the growth inhibitory effects of these cytokines. 
Furthermore, a comparative analysis of marker expression for senescence 
(GLB1), apoptosis (BAX and BCL2) and proliferation (RARRES1 and PCNA) 
showed that hrHPV specifically resists the induction of an anti-proliferative 
state induced by IFNγ in KCs. hrHPV accomplished this by targeting the 
expression of the anti-proliferative gene IFITM1, the expression of which 
was down-regulated already at 48 hours after hrHPV infection. Knock-down 
of IFITM1 in uninfected KCs confirmed its role in providing resistance to the 
anti-proliferative effects of IFNγ and TNF, whereas the analysis of IFITM1, 
RARRES1 and PCNA in cells isolated from clinical samples of HPV-positive 
and – negative (pre-)malignant vulvar cells underlined the relevance of our 
finding. Thus, our study revealed that hrHPV targets IFITM1 in order to evade 
the anti-proliferative effects of IFNγ and TNFα.
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A persistent infection with high-risk human papillomavirus (hrHPV) may 
cause cancer. In order to combat viruses the immune system has developed 
several mechanisms to counteract infections. One such a mechanism is the 
production of two cytokines, called interferon-gamma and tumor necrosis 
factor-alpha, which can prevent the proliferation of infected cells and as such 
can suppress viral spread. However, hrHPV has developed ways to evade the 
host’s immune response for sustained periods of time. We showed that hrHPV 
accomplishes this by downregulating the expression of a negative regulator 
of cell growth called interferon-induced transmembrane protein 1 (IFITM1). 
When the cytokines of the immune system activate IFITM1 in non-infected 
cells a cellular program is started that stops cell proliferation. Downregulation 
of IFITM1, allows hrHPV infected cells to evade the anti-proliferative effects of 
the immune system on hrHPV-infected cells, thus promoting viral spread and 











































High-risk human papillomaviruses (hrHPVs) infect undifferentiated 
keratinocytes (KCs) of squamous epithelia. Persistent infections may lead to 
cancers of the anogenital region as well as of the head and neck [1]. Studies 
in healthy individuals, immunosuppressed patients and in patients with 
spontaneously or vaccine-induced regressions revealed an important role for 
a strong type 1 (IFNγ and TNFα)-associated HPV early antigen-specific T cell 
response in the control of HPV [2]. 
IFNγ is a pleiotropic cytokine that affects immune regulation, immune 
surveillance, inflammation, tumor suppression, and has antiviral as well as 
anti-proliferative properties. Binding of IFNγ to its receptor (IFNγR) leads 
to JAK1/2-mediated STAT1 phosphorylation, dimerization and nuclear 
translocation, resulting in interferon-stimulated gene expression [3]. TNFα also 
regulates immune and cell death mechanisms. It activates NFκB and MAP 
kinase pathways and induces the formation of cell death complexes [4]. hrHPV 
attenuates immune signalling of the STAT1 [5-8], IRF and NFκB pathways [9-
15], resulting in suppressed innate and adaptive antiviral responses.
IFNγ and TNFα are known to synergize in the suppression of KC 
proliferation [16]. IFNγ induces growth arrest and differentiation [17,18]. TNFα 
also induces growth arrest but there are conflicting data concerning its capacity 
to induce cell death of primary KCs [16,19]. In unstimulated KCs, HPV can 
regulate cell growth via its early (E) proteins. E6 and E7 promote proliferation 
by directly modulating p53 and p21, however, their expression is regulated 
by E2, which can also induce apoptosis. E5 can both protect and induce 
apoptosis. E1^E4 expression results in growth arrest [20,21]. Previously, 
it was shown that retrovirus-mediated expression of E6 and/or E7 in KCs 
resulted in downregulation of IFNγ responsive genes and the upregulation of 
genes associated with cellular proliferation [7,22]. However, the ability of HPV-
infected KCs to resist the effects of IFNγ and/or TNFα on proliferation as well 
as the underlying mechanisms are not well understood.
In this study, we analyzed the influence of HPV on the IFNγ and TNFα-
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mediated cell growth inhibition of KCs by functional and biochemical analyses. 
Here we show that hrHPV presence renders KCs more resistant to the anti-
proliferative effects of IFNγ and TNFα, via the downregulation of IFITM1. Ex-
vivo analysis of KCs isolated from clinically obtained control tissue and HPV-











































HPV hampers the anti-proliferative state of KCs upon IFNγ and/or TNFα 
treatment
We previously reported that hrHPV suppresses the IFNγ and TNFα-induced 
immune response of KCs. Since IFNγ and TNFα are also known to synergize in 
the suppression of KC proliferation by inducing growth arrest and differentiation 
[16-19], we studied the influence of HPV herein. First, our previously reported 
validated microarray, in which uninfected KCs of four different donors and four 
different hrHPV-infected KCs were pre-stimulated with IFNγ for 72 hours, and 
subsequently treated with control or IFNγ for another 24 hours [15], was re-
analysed for gene expression of markers indicative for apoptosis, senescence, 
or proliferation (Figure 1A). Genes indicative for apoptosis (BAX, BCL2) 
and senescence (GLB1, RGN) were not differentially expressed, whereas 
genes indicative for anti-proliferation (RARRES1, SAMD9L, TOB1) were 
downregulated and pro-proliferative genes (MCM2, MKI67, MT1A, PCNA) 
upregulated in hrHPV+ KCs compared to KCs after stimulation. 
To validate the microarray data and investigate the additive role of TNFα, 
KCs and HPV+ KCs were harvested after 24 hours of IFNγ and TNFα 
stimulation and the gene expression of markers indicative for apoptosis, 
senescence, or proliferation were determined by RT-qPCR (Figure 1B). In 
this setting, uninfected KCs displayed a slight increase in the expression 
of the senescence marker beta-Galactosidase (GLB1), a strong reduction 
in the expression of the anti-apoptosis marker BCL2 while the expression 
level of BAX was marginally affected (Figure 1B). Importantly, this analysis 
confirmed the anti-proliferative state of IFNγ- and TNFα-stimulated KCs since 
the expression level of RARRES1, a marker for anti-proliferation [23,24], was 
highly upregulated and in parallel, the level of the proliferation marker PCNA 
was decreased. 
In hrHPV-positive KCs, the expression levels of BCL2, GLB1 and BAX 
mirrored that of non-infected KCs, albeit that the basal level of the anti-
apoptotic gene BCL2 was lower in hrHPV+ KCs. Analysis of the genes 
involved in proliferation revealed that the basal levels of PCNA were higher in 
hrHPV-positive KCs than in uninfected KCs. In contrast to non-infected KCs 
stimulated with IFNγ and/or TNFα, the hrHPV+ KCs displayed only a marginal 
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Figure 1: hrHPV resists IFNγ and TNFα-induced growth inhibition
(A) Microarray intensities for BAX, BCL2, GLB1, RGN, RARRES1, SAMD9L, TOB1, MCM2, 
MKI67, MT1A and PCNA in 72 hours IFNγ (50 IU/ml) pre-treated four independent KCs and four 
independent hrHPV+ KCs, stimulated with IFNγ (50 IU/ml) for 0 or 24 hours, represented in a box 
plot. The box contains the 1st quartile up to the 3rd quartile, the median is represented as a line, 
whiskers represent the values of the outer 2 quartiles. * p<0.05, ** p<0.01, *** p<0.001.
(B) RT-qPCR of BCL2, BAX, GLB1, RARRES1 and PCNA in 24 hours Control, IFNγ (50 or 250 
IU/ml) or IFNγ and TNFα (50 IU/ml IFNγ + 50 ng/ml TNFα or 250 IU/ml IFNγ + 250 ng/ml TNFα)-
treated KCs and HPV16+ KCs. Gene expression was normalized using GAPDH as the calibrator 






























































































































































































































































































































































(C) Microscopy pictures (4x magnification) of 72 hours IFNγ (0, 50, 250 or 1000 IU/ml) and/or 
TNFα (0, 50 or 250 ng/ml)-treated KCs and HPV16+ KCs. 
(D) Microscopy pictures (4x, 10x and 20x magnifications) of 72 hours IFNγ-treated KCs and 
HPV16+ KCs.
Representative results of three independent experiments.
increase in RARRES1 expression and the levels of PCNA were only reduced 
to the levels observed in uninfected KCs upon stimulation with a combination 
of the highest doses of IFNγ and TNFα. 
To confirm that hrHPV-positive KCs are indeed less sensitive to the IFNγ 
and/or TNFα-induced arrest in proliferation, uninfected KCs and hrHPV-positive 
KCs, seeded into 96 well plates, were treated for four days with increasing 
doses of IFNγ and/or TNFα. Cell confluence was monitored by phase-contrast 
microscopy as a measure of proliferation since we and others [25] had observed 
that KC proliferation can not be quantified via usual proliferation assays (data 
not shown). As expected, the growth of uninfected KCs was greatly affected 
by increasing doses of IFNγ. In contrast, hrHPV-positive KCs were much 
more resistant (Figure 1C). TNFα in itself appeared not to affect the growth 
of uninfected or HPV-infected KCs, but when combined with IFNγ augmented 
the reduction in cell density (Figure 1C). We observed that the remaining KCs 
after treatment displayed a senescence-like morphology [26] following IFNγ 
stimulation (Figure 1D), fitting well with the upregulated expression of GLB1 
in the uninfected KCs. All together, these data confirm that IFNγ or IFNγ and 
TNFα affect the growth of uninfected KCs by arresting their proliferation and 
skewing them to a senesced, pro-apoptotic state. Moreover, our data clearly 
indicate that hrHPV alters the IFNγ and TNFα-regulated proliferative pathway 
in KCs by resisting the induction a proliferative arrest. 
HPV downregulates the expression of IFITM1
The interferon-induced transmembrane protein 1 (IFITM1) plays an 
essential role in the anti-proliferative action of IFNγ [27], making it a potential 
target for hrHPV. Indeed, re-analysis of the data from one of our earlier 
validated microarrays, in which the basal expression of genes measured in 
different uninfected and hrHPV infected KCs was compared [28], showed 
that IFITM1 expression is downregulated in HPV-positive KCs (Figure 2A). 
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Figure 2: HPV downregulates IFITM1 expression
(A) Microarray intensities for IFITM1 in four independent KCs and four independent hrHPV+ KCs 
represented in a box plot. The box contains the 1st quartile up to the 3rd quartile, the median is 
represented as a line, whiskers represent the values of the outer 2 quartiles. * p<0.05.
(B) RT-qPCR of IFITM1 expression in two independent KCs and two independent HPV16+ KCs 
cultures.
(C) Western blot of IFITM1 protein levels in three independent KC, four independent HPV16+ KC, 
and one HPV18+ KC cultures. 
RT-qPCR of IFITM1 expression in KCs infected with mock or HPV16 for 1 or 2 days, as indicated 
(D), and siControl and siHPV16 E2-transfected HPV16+ KCs (E).
(F) RT-qPCR of IFITM1 expression in 24 hours IFNγ (50 IU/ml) and/or TNFα (50 ng/ml)-stimulated 
KCs and HPV16+ KCs. Fold changes over control-stimulated undifferentiated KCs were calculated 
and depicted. 
(G) RT-qPCR of IFITM1 expression in 24 hours IFNγ (50 IU/ml) and/or TNFα (50 ng/ml)-stimulated 
HPV16+ KCs. Fold changes over control-stimulated HPV16+ KCs were calculated and depicted.
(H) IFITM1 protein levels in KC and HPV18+ KC stimulated with IFNγ (0, 100 or 1000 IU/ml).
(I) STAT1 protein levels in three independent KC, four independent HPV16+ KC, and one HPV18+ 
KC cultures. 
(J) STAT1 and phosphorylated STAT1 protein levels in KCs and HPV16+ KCs stimulated with IFNγ 


























































































































































































































































































































































Representative results of at least two independent experiments.
This was confirmed by RT-qPCR (Figure 2B) and western blot (Figure 2C) in 
different independent hrHPV-positive primary KC cultures. To show that the 
expression of IFITM1 was genuinely altered by the presence of hrHPV in KCs, 
undifferentiated KCs were infected with native HPV16 virions resulting in a 
reduced expression of IFITM1 two days after infection (Figure 2D). Reciprocally, 
the knock-down of total HPV16 early gene expression by introduction of siRNA 
against HPV16 E2 in HPV-positive KCs [14], resulted in the upregulation of 
IFITM1 (Figure 2E). 
IFNγ induces de novo synthesis of IFITM1 for which STAT1 is required 
[29-32]. Indeed, IFNγ stimulation of uninfected KCs resulted in approximately 
4-fold increase in IFITM1 after 24 hours (Figure 2F). Strikingly, IFNγ stimulation 
of hrHPV+ KCs resulted in a much stronger relative increase of IFITM1 levels 
(Figure 2G), albeit that these levels still remained lower than those measured 
in uninfected KCs (Figure 2F). IFITM1 protein levels in IFNγ-stimulated KCs 
and hrHPV+ KCs confirmed the gene expression data (Figure 2H). These 
data indicated that hrHPV predominantly regulates the expression of IFITM1 
at the basal level but less at the level of IFNγ-mediated induction of IFITM1 
gene expression. It has been reported that HPV can lower STAT1 mRNA and 
protein levels in KCs [5-8], and this was also detected in the hrHPV+ KCs 
analyzed at the protein level (Figure 2I). Interestingly, the HPV+ KCs with the 
highest basal IFITM1 protein expression (Figure 2C) also showed the highest 
STAT1 levels (Figure 2I). Concomitant with the induction of IFITM1 expression, 
IFNγ stimulation also stimulated the phosphorylation of STAT1 (Figure 2J). 
Together this indicates that HPV represses the basal levels of STAT1 but 
does not interfere with STAT1 signalling in our persistently hrHPV infected 
KCs. Furthermore, it explains why IFNγ is able to stimulate the expression of 
IFITM1. TNFα did not influence IFITM1 expression (Figure 2F-G).
IFITM1 downregulation helps to overcome the anti-proliferative effects of 
IFNγ and TNFα
To study the effects of IFITM1 on KC proliferation in a setting where all 
additional influences of HPV are ruled out [20,21], IFITM1 was knocked-
down in uninfected KCs (Figure 3A). The KCs were stimulated with IFNγ 
or a combination of IFNγ and TNFα. IFITM1 knock-down KCs displayed a 
less pronounced downregulation of BCL2 and PCNA upon IFNγ stimulation 
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(Figure 3B). The expression of RARRES1 was lower at the basal level when 
IFITM1 was knocked-down and its IFNγ-induced expression was only affected 
when KCs were stimulated with a low but not with a higher concentration of 
IFNγ. Importantly, IFITM1 knock-down KCs were more resistant to the anti-
proliferative effects of IFNγ and the combination of IFNγ and TNFα than control 
shRNA and non-transduced KCs (Figure 3C). 
Thus, HPV is able to resist IFNγ-mediated arrest of proliferation by lowering 
the basal levels of IFITM1.
Figure 3: IFITM1 downregulation helps to overcome the anti-proliferative effects of IFNγ 
and TNFα
(A) RT-qPCR of IFITM1 expression in control and IFITM1 knock-down KCs. 
(B) RT-qPCR of BCL2, BAX, GLB1, RARRES1 and PCNA in 24 hours Control, IFNγ (50 or 250 
IU/ml) or IFNγ and TNFα (50 IU/ml IFNγ + 50 ng/ml TNFα or 250 IU/ml IFNγ + 250 ng/ml TNFα)-
treated control and IFITM1 knock-down KCs.
(C) Microscopy pictures (4x magnification) of 72 hours IFNγ (0, 50, 250 or 1000 IU/ml) and/or 
TNFα (0, 50 or 250 ng/ml)-treated control and IFITM1 knock-down KCs.














































































































































































































































































IFITM1 expression is down in HPV-induced premalignant and malignant 
vulvar cells. 
In order to study the relevancy of these results we analysed the five genetic 
markers for apoptosis, senescence and proliferation in cells isolated from 
clinical biopsies taken from women suffering from different stages of HPV-
induced (pre)malignancies. The isolated cells were treated with 0 or 100 IU/
ml IFNγ for 24 hours and gene expression was analyzed by RT-qPCR. Basal 
IFITM1 expression was lower in the cells isolated from a HPV16-induced 
vulvar intraepithelial neoplasia (VIN) and a HPV16-induced vulvar carcinoma 
when compared to that in the KCs obtained from control tissue or an HPV-
negative vulvar carcinoma (Figure 4A). The levels of GLB1 and BAX were 
similar between control and HPV16+ vulvar cells, both at the basal level as 
after IFNγ stimulation. The expression of BCL2 was lower in the HPV16+ 
vulvar cells than in controls, but similar to control KCs, the HPV16+ cells 
displayed a decreased BCL2 expression upon stimulation with IFNγ (Figure 
4B), albeit that control KCs show a stronger decrease. The levels of PCNA 
and RARRES1 were similar in control cells and HPV16+ vulvar cells, however 
upon stimulation with IFNγ only the control cells showed a strong decrease in 
PCNA expression and a stronger increase in RARRES1 when compared to 
the HPV16+ vulvar cells (Figure 4B). Interestingly, the cells isolated from an 
HPV-negative vulvar carcinoma reacted more or less similar as control cells, 
pointing out the HPV-specific component in these analyses. These results 
indicate that also in situ hrHPV+ cells display a reduced expression of IFITM1 
and a concomitant resistance to IFNγ-induced arrest of proliferation. 
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Figure 4: IFITM1 expression is decreased in HPV-induced VIN lesions
(A) RT-qPCR of IFITM1 expression in KCs derived from clinical biopts. 
(B) RT-qPCR of BCL2, BAX, GLB1, RARRES1 and PCNA in 24 hours control or IFNγ (100 IU/





















































































































































































































































































Using a unique in vitro model we here show that hrHPV infection renders 
KCs resistant to IFNγ and TNFα-induced arrest of cell growth. Analysis of 
the expression of markers representative for senescence, apoptosis and 
proliferation of KCs showed that HPV specifically counteracts the arrest in 
cell proliferation of KCs when stimulated by IFNγ. The resistance of hrHPV+ 
cells to an IFNγ-mediated proliferative arrest was associated with a strong 
downregulation in the basal expression of the negative regulator of cell growth 
IFITM1 and an impaired IFNγ-mediated increase in the expression of the anti-
proliferative RARRES1 gene. Notably, this basal and IFNγ-stimulated gene 
profile was also found ex vivo, in cells isolated from biopsies of HPV-induced 
(pre-)malignant vulvar lesions.
The IFNγ-induced increase in expression of both IFITM1 and RARRES1 
depends on STAT1, which is downregulated by HPV E6 and E7 proteins [5-7]. 
Basal IFITM1 expression is downregulated in HPV+ KCs, but RARRES1 is not, 
which might be explained by the fact that the basal expression of RARRES1 in 
uninfected KCs is already low. Our data confirm the hrHPV-mediated decrease 
in STAT1 protein levels but also show that hrHPV does not hamper IFNγ-
induced STAT1 activation, as reflected by STAT1 phosphorylation and increase 
in RARRES1 and IFITM1 expression in HPV+ KCs. Still, as total STAT1 levels 
are lower in HPV+ KCs, the amount of available STAT1 to phosphorylate 
and signal is lower in hrHPV+ KCs potentially explaining why the increase 
in RARRES1 and IFITM1 expression does not reach the levels observed in 
uninfected KCs. This is also demonstrated in our study showing that the effect 
of IFITM1 knock-down on proliferation of uninfected KCs does not resemble 
the influence of hrHPV on KCs. Whilst the effect of IFITM1 in uninfected KCs 
is apparent and anti-proliferative as indicated by the retained expression of 
PCNA and RARRES1 in KCs stimulated with a low dose of IFNγ when IFITM1 
was knocked-down, clearly the downregulation of STAT1 as well as the positive 
growth signals as delivered by hrHPV [20,21] are missing in these cells. Hence 
differences in IFNγ-stimulated arrest of proliferation are less noticeable. Thus, 
whereas the decreased basal level of IFITM1 is already providing resistance 
to the IFNγ-stimulated arrest of proliferation, the downregulation of STAT1 is 
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likely to exaggerate this effect.
The downregulation of IFITM1 clearly is advantageous to hrHPV as it allows 
infected KCs to expand. Mechanistically, IFITM1 inhibits the phosphorylation 
of ERK and thus regulates mitogen-activated protein (MAP) kinase signalling 
[27]. Furthermore, IFITM1 mediates the dephosphorylation of p53 at Thr55 
resulting in increased p53 stability and transcriptional activity, as indicated by 
the upregulated expression of p21. Consequently, arrest occurs in cell cycle 
progression at the G1 phase and, hence, a halt in proliferation [27]. This is 
also reflected by the retained PCNA expression when IFITM1 was knocked-
down in low dose IFNγ-stimulated KCs. Conceivably, the effect of hrHPV on 
IFITM1 in infected KCs extents to HPV-induced cancer cells as we found that 
cells isolated from an HPV16-induced vulvar tumor, but not cells isolated from 
a non-HPV induced vulvar tumor, displayed a strongly decreased level of 
IFITM1 and a highly impaired response to IFNγ stimulation with respect to the 
expression of RARRES1 and PCNA. 
In conclusion, hrHPV allows infected KCs to resist the IFNγ-induced anti-
proliferative state by regulating the expression of (anti-)proliferative genes 
through regulation of STAT1 and IFITM1. This identifies IFITM1 as one the 
proteins within the IFNγ-signalling pathway that is targeted by hrHPV to evade 
the anti-proliferative effects of the immune system on hrHPV-infected cells, thus 













































The use of discarded human foreskin, cervical and vaginal keratinocyte 
tissues to develop cell lines for these studies was approved by the Institutional 
Review Board at the Pennsylvania State University College of Medicine and 
by the Institutional Review Board at Pinnacle Health Hospitals. The Leiden 
University Medical Ethic Committee approved our study on prospective 
collection of healthy control tissue and for keratinocyte isolation patients were 
enrolled in the Circle study, which investigates cellular immunity against HPV-
induced neoplasia. All human samples were anonymized. 
Cell culture
Primary cultures of human epithelial keratinocytes (KCs) were established 
from foreskin, vaginal, vulva and cervical tissues as previously described 
[28] and grown in keratinocyte serum-free medium (K-SFM; Medium 154 
supplemented with HKGS kit, Invitrogen, Breda, The Netherlands). KCs 
stably maintaining the full episomal HPV genome following electroporation 
(HPV-positive KCs) were grown in monolayer culture using E medium in 
the presence of mitomycin C (Sigma-Aldrich) treated J2 3T3 feeder cells 
[33,34] for two passages and were then adapted to K-SFM for one passage 
before experimentation. J2 3T3 mouse fibroblasts were cultured in Iscove’s 
modified Dulbecco’s medium supplemented with 8% fetal bovine serum, 2 mM 
l-glutamine and 1% penicillin-streptomycin (complete IMDM medium) (Gibco-
BRL, Invitrogen, Breda, The Netherlands). 
HPV16 knock-down in HPV16-positive KCs and infection of 
undifferentiated keratinocytes
HPV16-positive KCs were transfected with 50 nM Control or HPV16 E2 
siRNA for at least 72 hours as previously described [14]. Primary basal layer 
human foreskin keratinocytes were infected with native HPV16 at MOI 100 as 
previously described [14]. Cells were washed and harvested and target gene 
expression was assayed by RT-qPCR.
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IFITM1 knock-down in undifferentiated KCs
shRNA’s were obtained from the MISSION TRC-library of Sigma-Aldrich 
(Zwijndrecht, The Netherlands). The MISSION shRNA clones are sequence-
verified shRNA lentiviral plasmids (pLKO.1-puro) provided as frozen bacte-
rial glycerol stocks (Luria Broth, carbenicillin at 100 µg/ml and 10% glycerol) 
in E. coli for propagation and downstream purification of the shRNA clones. 
pLKO.1 contains the puromycin selection marker for transient or stable trans-
fection. The construct against IFITM1 (NM_003641) was TRCN0000057499: 
CCGGCCTCATGACCATTGGATTCAT CTCGAGATGAATCCAATGGTCAT-
GAGGTTTTTG and the control was: SHC004 (MISSION TRC2-pLKO puro 
TurboGFP shRNA Control vector): CCGGCGTGATCTTCACCGACAAGA-
TCTCGAGATCTTGTCGGTGAAGATCACGT TTTT. KCs at ~60% confluency 
were transduced with lentivirus at MOI 5-10 over night, after which medium was 
replaced. At least 72 hours post-transduction cells were harvested, washed 
and plated as indicated and allowed to attach overnight. Cell were stimulated 
as indicated and assayed accordingly.
Proliferation assay
KC, HPV+ KCs, control shRNA-expressing KCs, or IFITM1 shRNA-
expressing KCs were seeded 5,000 cell/well in 96-well plates and allowed to 
attach over night. Cells were cultured in presence of indicated concentrations of 
IFNγ (Immunotools, Friesoythe, Germany) and/or TNFα (Invivogen, Toulouse, 
France) in 150 μl for 96 hours. 15 μl/well MTT (3-(4,5-dimethylthiazol-2-yl)-2,3-
diphenyl-2H-tetrazolum bromide) stock solution (5 mg/ml in 0.1 M PBS) was 
added for 3 hours. When the purple formazan precipitate was clearly visible 
under the microscope, bright light pictures were made using an Olympus IX51 
inverse fluorescence microscope (Olympus, Zoeterwoude, The Netherlands) 
and ColorView II Peltier-cooled charge-coupled device camera (Olympus), 
and archived using Cell^F software (Olympus).
RNA expression analyses 
All microarray data is accessible in the Gene Expression Omnibus 
database. The microarray data of Karim et al. [28] (accession number 
GSE21260) compared four independent KC cultures with four independent 










































(accession number GSE54181) compared four independent KC cultures with 
four independent HPV+ KCs cultures that were pre-stimulated with IFNγ for 72 
hours after which they were treated with IFNγ in the presence of Control L-cells 
for 24 hours. Plots were generated using the webtool R2: microarray analysis 
and visualization platform (http://r2.amc.nl). 
KC, HPV+ KCs, control shRNA-expressing KCs, or IFITM1 shRNA-
expressing KCs were seeded 150,000 cell/well in 12-well plates and allowed to 
attach over night. Cells were cultured in presence of indicated concentrations 
of IFNγ and/or TNFα in 1 ml for 24 hours. Total RNA was isolated using the 
NucleoSpin RNA II kit (Machery-Nagel, Leiden, The Netherlands) according 
to the manufacturer’s instructions. Total RNA (0.5 – 1.0 µg) was reverse 
transcribed using the SuperScript III First Strand synthesis system from 
Invitrogen. TaqMan PCR was performed using TaqMan Universal PCR Master 
Mix and pre-designed, pre-optimized primers and probe mix for IFITM1, BAX, 
BCL2, GLB1, RARRES1, PCNA and GAPDH (Applied Biosystems, Foster City, 
USA). Threshold cycle numbers (Ct) were determined using the CFX PCR 
System (BioRad, Veenendaal, The Netherlands) and the relative quantities of 
cDNA per sample were calculated using the ΔΔCt method using GAPDH as 
the calibrator gene. The error bars indicate standard deviations of triple PCR 
measurements. 
Western blot analysis 
Polypeptides were resolved by SDS–polyacrylamide gel electrophoresis 
(SDS–PAGE) and transferred to a nitrocellulose membrane (Bio-Rad, 
Veenendaal, The Netherlands). Immunodetection was achieved with anti-
IFITM1 (1:1000, PA5-20989, Thermo Scientific) anti-STAT1 (1:1000, #9172, 
Cell Signaling Technology (CST)), anti-phospho-STAT1 (Tyr701, 1:1000, 
#9167, CST), b-actin (1:10,000, Sigma-Aldrich) primary antibodies, and HRP-
coupled anti-mouse (1:5000, CST) and HRP-coupled anti-rabbit (1:5000, CST) 
secondary antibodies. Chemoluminescence reagent (Bio-Rad) was used as 
substrate and signal was scanned using the Chemidoc and accompanying 
Software (Bio-Rad).
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Keratinocytes are well equipped to recognize and react to invading 
pathogens, and hrHPV is no exception to this. However, hrHPV initiates 
several immune evasion mechanisms soon after infecting the KC. The virus 
interferes with the innate immune response by affecting several signaling 
pathways that otherwise would prompt anti-viral mechanisms in the host 
cell. Furthermore, hrHPV interferes with the production of cytokines that are 
involved in the attraction of immune cells to the infected epithelium. In addition, 
the virus hides itself from the immune system by suppressing the antigen 
presentation machinery normally allowing infected cells to be recognized by 
adaptive immune cells and, if this is not successful, hrHPV still employs means 
to hamper the response of KC’s to signals from the effector molecules used by 
adaptive immune cells to exert their antiviral function. In this thesis we show that 
hrHPV attenuates innate immune signaling (Chapter 2) and CD40-mediated 
(Chapter 3) and IFNγ and/or TNFα-induced (Chapter 4) adaptive immune 
signaling. For this hrHPV exploits the cellular proteins UCHL1 (Chapter 2) and 
IFRD1 (Chapter 4) that act on multiple points in the IRF and NFκB signaling 
pathways. Moreover, hrHPV downregulates cellular IFITM1 to resist the growth 
inhibitory effects of IFNγ and/or TNFα (Chapter 5). Taken together, our data 
provide important new insights on how the small hrHPV can persist in the face 
of host immunity. 
HPV exploits cellular proteins to alter canonical NFκB signaling
The canonical NFκB pathway is attacked by hrHPV at multiple positions 
in the signaling cascade downstream of immune receptors. This indicates 
that suppression of the NFκB pathway forms a very important target for the 
virus and implies that this pathway normally would allow the host to resist 
viral infection. There are several early proteins involved in this process (see 
Chapter 1). The observations made in this thesis using hrHPV episome-baring 
KCs revealed that hrHPV exploits the cellular proteins UCHL1 and IFRD1 to 
interfere with NFκB signaling. 
We showed that HPV-induced UCHL1 attenuates PRR-induced type I IFN 






































IRF pathway by interacting with and deubiquitinating K63-linked polyubiquitin 
chains from TRAF3, resulting in reduced TBK1 – TRAF3 interaction, IRF3 
phosphorylation and IFNβ expression (Figure 1). PRR-induced NFκB signaling 
was also attenuated through binding of UCHL1 to TRAF6, thereby influencing 
the Ub status of TRAF6 (Figure 2). Furthermore, UCHL1 exacerbated NEMO 
degradation and UCHL1 can prevent IκBα ubiquitination [1]. 
That UCHL1 binds and affects the ubiquitination status of TRAF3 and 6 
implies that UCHL1 may influence other TRAF proteins as well. Indeed, co-
immunoprecipitation (co-IP) experiments of UCHL1 and TRAF1-6 in HEK293T 
cells showed that UCHL1 can bind to all TRAFs (Tummers, Unpublished data) 
and might therefore be a regulator of TRAF ubiquitination and thus function. 
Furthermore, our co-IP experiments showed that UCHL1 binds to RIP1. In line 
with this, UCHL1 may influence adaptive immunity-induced canonical and non-
canonical NFκB signaling, since the TRAF proteins and RIP1 mediate these 
pathways [2]. Indeed, knock-down of UCHL1 in HPV-episome expressing KCs 
enhanced pro-inflammatory cytokine expression upon IFNγ and/or TNFα or 
CD40L (Tummers, Unpublished data). Furthermore, although the two proteins 
do not co-immunoprecipitate, UCHL1 mediated the degradation of NEMO 
(Chapter 2). How UCHL1 does this is currently unknown, but, as TRAF6 
facilitates the phosphorylation of the IKK complex by TAB1-TAB2-TAK1, one 
could speculate that UCHL1 is in close enough proximity to NEMO to facilitate 
its degradation, suggesting that UCHL1 may have a variety of cellular protein 
targets. 
EGFR activation on epithelial cells has been shown to result in a decreased 
production of pro-inflammatory cytokines [3-5]. HrHPV upregulates EGFR gene 
and surface expression via the E5, E6 and E7 proteins (Chapter 4 and [6]), and 
enhances EGFR signaling via E5 and E6 [7-9]. Blocking the EGFR on our 
HPV+ KCs using the clinically used anti-EGFR antibody cetuximab augmented 
the production of IFNγ and TNFα-induced production of pro-inflammatory 
cytokines, indicating that by elevating EGFR levels and signaling HPV may 
hamper cytokine production (Chapter 4). Via EGFR signaling through mTOR, 
RAF and/or MEK1, HPV increased the expression of IFRD1, which mediates 
RelA K310 deacetylation by HDAC1/3 [10] and, thereby, attenuates the 











































experiments in HPV+ KCs indeed showed that basal RelA acetylation was 
restored and basal signaling and signaling induced by Poly(I:C), TNFα and the 
combination of IFNγ and TNFα resulted in higher cytokine expression levels in 
cells in which IFRD1 was knocked-down (Chapter 4). Interestingly, after IFNγ 
stimulation alone cytokine expression levels were also higher in IFRD1 knock-
down HPV+ KCs, suggesting that IFRD1 may also affect the transcriptional 
activity of STAT1 and/or IRF1. If IFRD1 can regulate transcriptional activity of 
transcription factors other than NFκB, HPV could deregulate a whole network 










































Figure 1: The effects of hrHPV on IRF signaling
Schematic representation of the effects of hrHPV on IRF signaling. All TLRs, except TLR3, activate IRF7 via 
signaling through MyD88, the IRAK complex, TRAF3 and IKKα. TLR3 and 4 signal via TRIF, cytosolic RNA 
sensors through MAVS and cytosolic DNA sensors via STING activate IRF3 through TRAF3, TBK1 and IKK
ε. Activated IRFs dimerize, translocate to the nucleus and initiate gene transcription. HPV utilizes its own 
encoded E proteins (red) as well as exploits the cellular protein UCHL1 (red) to interfere with these signaling 
pathways. Green circles on TRAF3 indicate K63-linked poly-ubiquitin chains.
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Interestingly, E2 may promote canonical NFκB signaling [11-13]. It may 
form an E2-NFκB-p300/CBP transcriptional repressor complex on the LCR of 
the episome and as such regulates episome transcription which is required 
for the virus to sustain a low profile. However, as luciferase assays show that 
the E2 protein renders NFκB more active [13], the virus thus may prompt E2-
mediated NFκB-induced pro-inflammatory cytokine production and immune cell 
attraction. This indicates that the virus needs additional mechanisms in order 
to regulate the episome while keeping pro-inflammatory cytokine expression 
in check during infection. The combined expression of E2, UCHL1 and IFRD1 
during an infection might form a perfect cocktail to allow hrHPV to regulate its 
episome while suppressing KCs pro-inflammatory cytokine production. 
HPV allows signaling to the non-canonical NFκB pathway
IFNγ and TNFα are known to synergistically affect gene expression, and 
also in KCs pro-inflammatory cytokine expression is synergistically higher than 
expression induced by IFNγ or TNFα alone (Chapter 4). Still, hrHPV attenuates 
IFNγ and/or TNFα-induced pro-inflammatory cytokine expression and the 
attraction of PBMCs to KCs that have been stimulated with the combination 
of IFNγ and TNFα. Furthermore, exposure of hrHPV-infected KCs to IFNγ and 
TNFα fails to induce cellular programs associated with a block of proliferation 
as seen in uninfected KCs (Chapter 5). The IFN pathways seems to be 
centrally attacked through downregulation of STAT1 levels which is observed 
in hrHPV episome-baring KCs when compared to uninfected KCs [14-16]. 
Downregulation of STAT1 results in attenuated ISG expression, albeit that 
signaling downstream of the IFNAR and IFNγR still functions (Chapter 5 and 
[15]). Thus, the attenuated type I IFN-induced ISG expression in HPV+ KCs 
must be due to the basal lowered STAT1 levels. In contrast, in experiments 
where E6 is overexpressed, E6 was shown to bind TYK2 and to interfere with 
STAT1 and STAT2 phosphorylation [17], implying that also STAT1 signaling 
is hampered by E6. If E6 plays a similar role in early infection remains to be 
determined. Importantly, IFNγ and TNFα stimulation induced processing of the 
non-canonical NFκB precursor p100 into p52 in hrHPV-infected cells but not 
uninfected KCs (Tummers, Unpublished data), indicating that hrHPV skews 











































canonical NFκB pathway. Potentially, this is caused by E7 as this oncoprotein 
was shown to increase SCF-βTrCP protein levels [18] and in this way might 
accelerate p100 processing [19]. Although unexplored at this point, it is highly 
likely that this forms another pathway allowing hrHPV-infected cells to resist 
control of infection by the immune system and the anti-proliferative effects of 
IFNγ and TNFα (Chapter 5).
Figure 2: The effects of hrHPV on NFκB signaling
Schematic representation of the effects of hrHPV on NFκB signaling. The canonical NFκB1 
pathway is activated by PRRs and CD40 through TRAF6 and TNFR1 through RIP1. Poly-
ubiquitination of TRAF6 and RIP1 recruits the TAB1-TAB2-TAK1 and IKK complexes resulting in 
the phosphorylation of IKKβ by TAK1. IKKβ phosphorylates IκBα, which is then ubiquitinated by 
SCF-βTrCP and subsequently degraded, and thereby releases the NFκB1 complex to translocate 
to the nucleus. CD40 and TNFR2 initiate non-canonical NFκB2 signaling by recruitment of 
TRAF2/5, cIAP1/2 and TRAF3 to the respective receptor, leading to TRAF3 degradation. This 
Figure 2: The effects of hrHPV on NFκB signaling
Schematic representation of the effects of hrHPV on NFκB signaling. The canonical NFκB1 pathway is 
activated by PRRs and CD40 through TRAF6 and TNFR1 through RIP1. Poly-ubiquitination of TRAF6 and 
RIP1 recruits the T B1-TAB2-TAK  and IKK complexes resulting in the phosphorylati n of IKKβ by TAK1. 
IKKβ phosphorylates IκBα, which is then ubiquitinated by SCF-βTrCP and subsequently degraded, and 
thereby releases the NFκB1 complex to translocate to the nucleus. CD40 and TNFR2 initiate non-canonical 
NFκB2 signaling by recruitment of TRAF2/5, cIAP1/2 and TRAF3 to the respective receptor, leading to 
TRAF3 degradation. This causes NIK to accumulate and activate IKKα to phosphorylate p100. This induces 
SCF-βTrCP to ubiquitinate p100, leading to the proteosomal processing of p100 into p52, and the subse-
quent nuclear translocation of NFκB2. In the nucleus NFκB binds to the DNA and is aided by coactivators 
to initiate gene transcription. HPV utilizes its own encoded E proteins (red) as well as exploits the cellular 
proteins (red) UCHL1 and IFRD1 to interfere with NFκB1 signaling at multiple positions in the pathway. 
Green circles indicate K63-linked poly-ubiquitin chains, blue circles indicate linear poly-ubiquitin chains. 

















































































































causes NIK to accumulate and activate IKKα to phosphorylate p100. This induces SCF-βTrCP to 
ubiquitinate p100, leading to the proteosomal processing of p100 into p52, and the subsequent 
nuclear translocation of NFκB2. In the nucleus NFκB binds to the DNA and is aided by coactivators 
to initiate gene transcription. HPV utilizes its own encoded E proteins (red) as well as exploits the 
cellular proteins (red) UCHL1 and IFRD1 to interfere with NFκB1 signaling at multiple positions 
in the pathway. Green circles indicate K63-linked poly-ubiquitin chains, red circles indicate K48-
linked poly-ubiquitin chains, and blue circles indicate linear poly-ubiquitin chains. Dashed lines 
indicate hypothetical effects.
Epithelial cells express CD40 on their cell surface [20] and ligation of CD40 
induces both canonical and non-canonical NFκB signaling, similar to TNFR1 
and 2, respectively [21]. We showed that ligation of CD40 on epithelial cells 
results in a very coordinated response by KCs, dominated by the expression of 
genes involved in leukocyte migration, cell-to-cell signaling and interaction, as 
well as cell death and survival. The presence of HPV does not affect the gene 
expression profile of CD40 stimulated KCs, but it does attenuate the extent 
of the response and reduces the attraction of PBMCs (Chapter 3), indicating 
that the virus also attenuates CD40-induced signaling. Based on our previous 
studies it is likely that the CD40 – NFκB1 axis of CD40 signaling is affected via 
the interaction of UCHL1 and TRAF6, the effects of E7 on the IKK complex, 
and that of IFRD1 on NFκB1 transcriptional activation. Speculatively, at the 
non-canonical side signaling could be hampered by abrogation of UCHL1-
mediated TRAF2 and/or 5- or E7-mediated IKKα functioning. However, UCHL1-
mediated TRAF3 hampering could also lead to constitutive NIK accumulation 
and subsequent pathway activation (Figure 2). It remains to be determined if 
hrHPV prefers to skew KCs towards non-canonical NFκB activation after CD40 
ligation. 
NFκB signaling in hrHPV transformed cells
In contrast to hrHPV-infected cells, higher intraepithelial neoplastic lesions 
and HPV-positive cancers often show overactive canonical NFκB gene 
expression [22]. Indeed, overexpression experiments showed that E6 and/or 
E7 can also have pro-NFκB signaling effects and can increase NFκB target 
gene expression [16]. Mechanistically, E6 targets the NFκB repressor NFX1-91 
for degradation [23] and under hypoxic conditions hampers CYLD, a negative 
regulator of NFκB signaling [24]. E6 also upregulates gene expression of the 
NFκB signaling components p50, NIK and TRAIP [16]. E7 upregulates SCF-











































and p100 processing [19]. The transformed cell may benefit from E6/E7-
enhanced NFκB signaling by maintaining a proliferative, anti-apoptotic state, 
although also pro-inflammatory cytokine expression is increased. Notably, 
cell type and growth rate are important determinants whether HPV E6 or E6/
E7 stimulate or inhibit NFκB activation [25], and since viral gene expression 
considerably differs between hrHPV-infected KCs and hrHPV-transformed 
cells, data obtained from viral protein overexpression experiments should be 
carefully interpreted with respect to what their effects are in infection or cancer.
How HPV regulates cellular gene expression remains unclear
How HPV differentially expresses the genes studied in this thesis is still 
under investigation, but the episomal nature of the viral genome and it’s 
translation into polycistronic mRNA make it difficult to study the functions 
of the individual E proteins in the context of a primary infection. We have 
overexpressed the individual early genes, their combinations and all combined 
in basal KCs, HaCat cells and primary fibroblasts, but, although the early genes 
were expressed, we could not detect differential expression of UCHL1, IFRD1 
or IFITM1 in any of these overexpression experiments (Tummers, Unpublished 
data). Since plasmid-based overexpression of the early genes does not 
count for the effects of the episome itself, the presence of the viral episome 
in regulating cellular gene expression must be important. Transcription of the 
episome produces a polycistronic mRNA strand that completely disintegrates 
with current siRNA techniques directed at a single early gene. siRNA directed 
against E6, E7 (Tummers, Unpublished data) or E2 abolishes expression of 
the other early genes and abrogates the HPV-induced differential expression of 
UCHL1 (Chapter 2), IFRD1 (Chapter 4), and IFITM1 (Chapter 5), indicating that 
episome presence is indeed necessary in regulating cellular gene expression. 
Since single early genes cannot be knocked-down in our model, generating 
KCs harboring episomes with specific mutations in a gene, rendering the gene 
functionally inactive without influencing the other genes or polycistronic mRNA 
strand, could be a way to study specific early genes. This could give important 
insights into the function of an early gene in the context of early infection, but 






































Genetic predisposition to developing HPV-induced malignancies
Most HPV infections resolve spontaneously, although HPV invests heavily in 
suppressing host immunity. This indicates that external factors, such as genetic 
and environmental factors may contribute to the establishment of a persistent 
infection and progression to cancer. Genetic predisposition to cervical tumors 
was found [26] and several combinations of single nucleotide polymorphisms 
(SNPs) were associated with an increased risk to cancer. SNPs in genes of the 
antigen processing machinery, such as HLA-A, LMP7, TAP2 and ERAP1 [27], 
and in the FANCA and IRF3 genes [28] were linked to persistent HPV infection 
and formation of cancer. SNPs in the TLR and NFκB pathways were also 
studied [29]. Of the thirty-two candidate genes involved in these pathways, 
including TLR3, NFκB1, NFκB2, RelA, RelB, TRAF3 and TRAF6, only a SNP 
in the 5’ UTR of the lymphotoxin alpha (LTA; TNF superfamily member 1) was 
significantly associated with increased risks of cervical and vulvar cancers [29]. 
Based on the interactions between the different proteins in the downstream 
signaling pathways and their outcomes with respect to activation, splicing, 
degradation and translocation it might well be that combinations of SNPs, of 
multiple genes associated with the IRF and NFκB pathways, rather than single 
SNPs, may confer protection or susceptibility towards persistence of HPV 
infection.
Final comment
Being a small virus, HPV relies on just 6 encoded early proteins, and some 
splice variants thereof, to interfere with normal KC physiology. Although the 
early proteins have a variety of cellular protein targets, it is remarkable that the 
virus only needs so few encoded genes to persist. Our work showed that HPV, 
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Het humaan papillomavirus (HPV) onderdrukt signalen in cellen om te 
ontsnappen aan het immuunsysteem. 
Humaan papillomavirus (HPV) is een klein DNA virus dat epitheelcellen van 
mucosa en de huid - keratinocyten - infecteert. Er zijn momenteel ongeveer 
200 HPV types bekend. De meeste types zijn ongevaarlijk en veroorzaken 
bijvoorbeeld wratten op handen, voeten of genitaliën. Sommige types, echter 
veroorzaken kanker in het hoofd-hals gebied en de genitaliën. Het bekendst 
is baarmoederhalskanker. Deze laatste types worden de hoog-risico HPVs 
(hrHPVs) genoemd. Infecties met hrHPV komen over de gehele wereld 
voor en ongeveer 80% van alle mensen is ooit met een hrHPV geïnfecteerd 
geraakt. Het is dan ook de meest voorkomende seksueel overdraagbare 
aandoening. Het virus kan zich lang weren tegen het afweersysteem maar na 
een periode van een tot twee jaar verdwijnen de meeste infecties spontaan. 
Bij iets minder dan 1% van de infecties komt het virus niet onder controle van 
het afweersysteem. Dan ontstaan er afwijkingen aan het epitheel die, wanneer 
niet tijdig behandeld, kunnen uitmonden in kanker. Wereldwijd zijn de hrHPV 
typen verantwoordelijk voor ongeveer 530.000 nieuwe kankergevallen en 
275.000 doden per jaar. 
Het afweersysteem kan virus-geïnfecteerde cellen herkennen en opruimen 
wanneer het eerst geattendeerd wordt op de aanwezigheid van een infectie. 
Om het afweersysteem te alarmeren zijn de cellen in het lichaam uitgerust met 
sensoren - receptoren - die de aanwezigheid van een virus kunnen herkennen. 
Als een cel geïnfecteerd raakt reageren de receptoren op specifieke structuren 
van het virus waardoor allerlei signaleringsroutes op gang komen die leiden tot 
de aanmaak van verschillende eiwitten in de geïnfecteerde cel. Deze eiwitten 
kunnen de infectie onderdrukken door onder andere a) de cel in een staat van 
verdediging te brengen, b) de virus productie te voorkomen, en c) afweercellen 
- lymfocyten - aan te trekken. Wanneer de aangetrokken lymfocyten het virus 
herkennen reageren ze door eiwitten te produceren die nog meer afweercellen 
kunnen aantrekken (cytokines) en eiwitten die verschillende uitwerkingen 
hebben op de geïnfecteerde cel. Zo kunnen eiwitten zoals interferon gamma 
(IFNγ) en tumor necrosis factor alpha (TNFα) ervoor zorgen dat de geïnfecteerde 









































Om zich te weren tegen een aanval van het afweersysteem hebben 
virussen verschillende methodes ontwikkeld die ingrijpen op verschillende 
fases van de aanval. Door de expressie van de sensoren te onderdrukken, de 
signaleringsroutes te blokkeren, of de productie van cytokines te onderdrukken 
proberen virussen te voorkomen dat het afweersysteem reageert. Daarnaast 
kunnen virussen proberen te voorkomen dat de geïnfecteerde cellen worden 
herkend door gealarmeerde lymfocyten of dat de geïnfecteerde cel adequaat 
kan reageren op de door lymfocyten uitgescheiden eiwitten die de cel 
instrueren om te stoppen met groeien of om dood te gaan. Vanuit eerdere 
studies weten we dat het afweersysteem pas laat op gang komt tegen HPV en 
ook dat het virus nog lang resistent is tegen een aanval. Dit duidt erop dat HPV 
ook methodes heeft om zichzelf in ieder geval een tijdje te beschermen tegen 
aanvallen van het afweersysteem. Hoe HPV in staat is om het afweersysteem 
om de tuin te leiden is in dit proefschrift bestudeerd voor de twee meest 
voorkomende hoog-risico types, HPV16 en 18. 
Voorheen was al aangetoond dat bepaalde viruseiwitten van HPV 
verschillende signaleringsroutes in de keratinocyt onderdrukken of de 
interactie tussen geïnfecteerde cel en afweercel verhinderen (hoofdstuk 1). 
In dit proefschrift tonen we aan dat hrHPVs ook cellulaire eiwitten uitbuit om te 
ontsnappen aan het immuunsysteem. 
In hoofdstuk 2 wordt aangetoond dat een infectie met hrHPV leidt tot de 
verhoogde expressie van het cellulaire eiwit UCHL1. Dit eiwit hindert verdere 
activering van de IRF3 en NF-κB signaleringsroutes als deze worden aangezet 
door binding van virale structuren aan de virussensoren TLR3, RIG-I en Mda5. 
Signalering van deze receptoren naar de kern verloopt onder meer door de 
ubiquitinering van enkele signaal eiwitten. UCHL1 verhindert de ubiquitinering 
van de eiwitten TRAF3 en TRAF6 en beïnvloedt de expressie van NEMO. 
Hierdoor verloopt de signalering minder efficiënt met als resultaat dat de 
geïnfecteerde keratinocyt minder cytokines uitscheidt die het afweersysteem 
kunnen alarmeren en activeren. 
Hoofdstuk 3 laat zien dat een infectie met een hrHPV leidt tot de verhoogde 
expressie van het cellulaire eiwit IFRD1. Dit cellulaire eiwit blijkt de activatie 
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van NF-κB te onderdrukken als deze wordt aangezet via de virussensor 
TLR3, of via de IFNγ en/of TNFα receptoren. IFRD1 vormt een brug tussen 
het NF-κB complex en een de-acetylase (HDAC3) waardoor de acetylatie van 
NF-κB, welke belangrijk is voor het functioneren van dit eiwit complex, kan 
verhinderen. Ook hierdoor verloopt de signalering minder efficiënt waardoor 
de geïnfecteerde cel minder eiwitten maakt die het afweersysteem kunnen 
aantrekken en activeren.
Het was eerder bekend dat hrHPV de expressie van de epidermal growth 
factor receptor (EGFR) verhoogt en EGFR signalering versterkt. Deze 
signalering verhoogt ook de expressie van IFDR1, waardoor er een link kan 
worden gemaakt tussen de remming van de aanmaak van afweersysteem 
aantrekkende eiwitten en de expressie van EGFR. In de kliniek worden 
momenteel tests gedaan met stoffen die de werking van de EGFR en diens 
signalering kunnen remmen en met stoffen die de werking van HDAC3 kunnen 
tegengaan. Als geïnfecteerde keratinocyten behandeld worden met deze 
stoffen gaan deze meer afweersysteem aantrekkende cytokines produceren. 
Deze resultaten zijn therapeutisch zeer interessant, maar er is nog veel 
meer onderzoek nodig om te bepalen of deze stoffen ook daadwerkelijk de 
afweerreactie tegen HPV infecties en HPV-geïnduceerde kankers stimuleren.
In hoofdstuk 4 laten we het gen expressie profiel zien van keratinocyten 
wanneer signalering door de receptor CD40 wordt aangezet. CD40 is een 
receptor van de keratinocyt dat het molecuul CD154 (CD40L) herkent dat 
aanwezig is op bepaalde afweercellen. Snel na het activeren van CD40 worden 
er door de keratinocyt cytokines geproduceerd die ervoor kunnen zorgen dat 
de afweercellen geactiveerd en naar het geïnfecteerde gebied gerekruteerd 
worden. In een latere fase van CD40 activatie worden er cellulaire programma’s 
aangezet die ertoe leiden dat de cel stopt met groeien. HrHPV verandert dit gen 
expressie profiel op zich niet, maar onderdrukt de intensiteit van de expressie. 
Dit leidt ertoe dat de CD40-geinduceerde aanmaak van cytokines onderdrukt 
is en dat lokale versterking van de afweerreactie minder goed plaatsvindt. 
De eiwitten IFNγ en TNFα worden gemaakt door de lymfocyten van het 
afweersysteem. Deze cytokines hebben verscheidene effecten op de cellen die 








































en de dood van cellen veroorzaken. In hoofdstuk 5 is de invloed van hrHPV 
op de reactie van keratinocyten na stimulatie met IFNγ en TNFα bepaald. Niet-
geïnfecteerde keratinocyten stopten met groeien. Dit bleek minder het geval 
te zijn met hrHPV geïnfecteerde cellen, deze groeiden veel gemakkelijker 
door. HPV onderdrukte onder andere de expressie van de genen IFITM1 en 
RARRES1 die bij de normale regulatie van celgroei betrokken zijn. 
Het is duidelijk dat HPV er veel aan doet om te ontsnappen aan het 
immuunsysteem. HPV onderdrukt verschillende signaleringsroutes die ervoor 
zorgen dat de geïnfecteerde cel tegen het virus op kan treden. Met name de 
activatie van het NF-κB complex blijkt te worden aangepakt op verschillende 
niveaus in de verschillende routes die allemaal tot NF-κB activatie leiden. 
Hierdoor verhindert HPV dat de geïnfecteerde keratinocyt eiwitten aanmaakt 
die het afweersysteem kunnen alarmeren en activeren wanneer de cel het 
virus herkent. HPV zorgt er ook voor dat de afweercellen die toch worden 
aangetrokken de geïnfecteerde cellen moeilijk kunnen herkennen. Zelfs als de 
afweercellen op de geïnfecteerde cel reageren beïnvloedt HPV de reactie van 
zijn gastheercel door signaleringsroutes te onderdrukken die ervoor zorgen 
dat de cel stopt met groeien.
In het kort wordt in dit proefschrift aangetoond dat hrHPV cellulaire eiwitten 
exploiteert om tijdelijk te kunnen ontsnappen aan het immuunsysteem. 
 
 181





























































































































CCL2 Chemokine (c-c motif) ligand 2
CD40 Cluster of differentiation 40
CXCL9 Chemokine (c-x-c motif) ligand 9
E protein Early protein
EC Epithelial cell
EGFr Epidermal growth factor receptor
hrHPV High-risk Human papillomavirus




IFrd1 Interferon-related developmental regulator 1
IKK Inhibitor of nuclear factor kappa-B kinase
IL8 Interleukin 8
IrF Interferon regulatory factor
ISG Interferon-stimulated gene
KC Keratinocyte
MIP3α Macrophage inflammatory protein 3α 
NEMo NF-kappa-B essential modulator
MHC Major histocompatibility complex
NFκB Nuclear factor of kappa-light-chain-enhancer of activated B cells
Prr Pattern-recognition receptor 
rANTES Regulated on activation, normal T cell expressed and secreted
TLr Toll-like receptor
TNFα Tumor necrosis factor α
TNFr Tumor necrosis factor receptor
TrAF TNF receptor associated factor
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